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Abstract
S100A8 in development
SlOO proteins are a family of binding EF-hand proteins. S100A8 is a 
cytosolic protein expressed in myeloid cells and epithelia where it forms a 
stable heterodimer with another SlOO protein family member, S100A9. The 
S100A9 null mouse is viable and has no gross defect whereas the S100A8 null 
mouse is embryonic lethal. It was originally proposed that the S100A8 null 
mouse is lethal at E 9.0 in development due to lack of expression at E 6.5 in 
ectoplacental cone cells. This thesis shows that the S100A8 null phenotype is 
more complex than originally thought. S100A8 has a role in preimplantation 
development, which is previously unstudied. A small number of S100A8 null 
embryos survive to blastocyst but none survive implantation showing fatal 
compromise of S100A8 null embryos early in development. This thesis 
presents evidence that this lethality presents between fertilisation and E 2.5 of 
development. S100A8 also has a role in the murine decidua after implantation 
possibly key to normal murine development. S100A8 mRNA is highly 
expressed in maternal decidua yet S100A8 protein is not highly expressed. 
Foetal yolk sac cells do not express S100A8 mRNA yet they do stain 
positively for S100A8 protein. This thesis proposes that S100A8 protein is 
generated in the murine decidua and exported to the foetus where 
haematopoietic cells present the protein. The S100A8 protein has been shown 
to be expressed and stable independently of its myeloid partner, S100A9. 
These observations explain the discrepancy between the two SlOO null mouse 
phenotypes and add new insight to the S100A8 null phenotype.
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CHAPTER 1
1 Introduction
1.1 SlOO Proteins
The SlOO proteins are a subfamily of the EF-hand Ca^ "^  binding proteins. 
They are named SlOO due to their solubility in 100% ammonium sulphate 
at neutral pH. The first members of the family were discovered in the 
SlOO fraction of bovine brain homogenate and were originally named 
SI00A and SIOOB (Moore 1965). There are now approximately 20 SlOO 
family members and they will be referred to throughout this thesis using 
their updated nomenclature (Marenholz, Lovering et al, 2006).
The SlOO family are low weight (8-13kD), acidic proteins, which mostly 
form either homo or heterodimers (Marenholz, Heizmann et al. 2004) 
(Donato 2001). They contain two EF hand motifs, a classical 12-residue 
C-terminal EF hand and an atypical 14-residue N terminal EF hand, which 
is specific to the SlOO protein family. The EF hands are flanked by 
hydrophobic termini and connected by a central hinge region as shown in 
fig 1.1.
13
Exon 1 Exon 2 Exon 3
DNA
mRNA
— n-ii i—I I
I r
Protein
Hinge
Helix I Loop 1 Helix 2 Helix 3 Loop 2 Helix 4
SlOO EF-hand Classical EF-hand
B
WT Allele
E l E2 H E3
Null Allele
E1 N e o  I E2
Figure 1.1 SlOO gene, mRNA and protein structure with SlOO gene  
insertion strategy. Diagram of typical SlOO family gene structure and the 
mRNA produced from the gene (A) Sequences expressed in the protein are 
shaded grey while untranslated regions are white. 3) Typical protein struc­
ture of SI OOprotein. EF hands are represented by coloured boxes (alpha 
helices) and calcium binding loops in yellow. Areas with no secondary 
structure are shown as black lines.Typical insertion strategy used to  silence 
SlOO genes in this thesis (B) Neo insert (Green) sits within the sequence of 
Exon 2 just after the start codon (Blue).
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1.1.1 Protein structure
The protein structure of 13 SlOO family members have been solved in at 
least one species and all show 4 alpha helices (H) containing two EF-hand 
motifs. Internal hydrophobic
interactions are responsible for maintaining the alignment of the helices 
with each monomer. Dimers are held together by predominantly 
hydrophobic interactions between HI and H4 of each monomer, which 
arrange in an anti-parallel orientation.
1.1.2 Ca?* binding and conformational change
All SlOO proteins bind with the exception of SI OOA 10. The structures 
of apo and Ca^  ^ bound SlOO proteins have been solved for many SlOO 
proteins and show conformational change on binding Ca^* (Drohat, 
Amburgey et al. 1996; Drohat, Baldisseri et al. 1998; Otterbein, 
Kordowska et al. 2002). The two different EF hands within an SlOO 
family protein often have different Ca^  ^ binding affinities with the C - 
terminal hand having the higher affinity (Gribenko and Makhatadze 1998). 
Ca^ "^  binding causes global shape changes and leads to the exposure of a 
hydrophobic binding patch. Typically helices 1,2 and 4 remain largely 
unchanged while helix 3 reorients from being parallel to helix 4 to almost 
perpendicular to it. The hinge region moves from the interior of the protein 
to the exterior. This reorientation exposes the hydrophobic patch formed 
largely from the hinge region, Helix 3 and 4 and the C-terminal region. 
This conformation is often called the open conformation. In an open SlOO 
homodimer two patches are formed which are symmetric whereas with an 
SlOO heterodimer the patches are asymmetric.
15
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This induced conformational change is strong evidence of a Ca^  ^
sensor role in SlOO proteins. Also because of their lack of identified 
functional domains, it is generally believed that SlOO proteins act through 
protein-protein interactions mediated by the hydrophobic patches they 
display in open conformation (Heizmann and Cox 1998). The in vitro Ca^  ^
binding affinity of most SlOO proteins (pM to mM) lies outside the 
physiological range of Ca^  ^within the cell (100 nM to 1 pM) (Heizmann 
and Cox 1998) yet it is thought that in vivo SlOO proteins can be 
influenced by other factors including binding partners, Zn^* and highly 
localised Ca^  ^ concentrations. It should also be noted that some SlOO 
proteins have lost the ability to bind Ca^  ^either in one EF hand as is seen 
with S100A7 (Brodersen, Nyborg et al. 1999) and SlOOAll (Rety, 
Osterloh et al. 2000), or both EF hands as with SIOOAIO (Rety, Sopkova 
et al. 1999). However this does not stop the adoption of the open, “Ca^  ^
bound” conformation. S100A7 can still switch to the open conformation 
and SIOOAIO is constitutively in the open, “Ca^ "^  bound” conformation 
despite not binding Ca^ .^
1.1.3 Target interaction
The SlOO hydrophobic patch is shallow and flat and target binding is 
highly specific. The binding region is largely helical and formed of basic 
and hydrophobic residues. The target sequence is typically acidic and 
hydrophobic in nature. Crystals of several SlOO proteins with peptides 
(Rety, Sopkova et al. 1999; Rety, Osterloh et al. 2000; Rustandi, 
Baldisseri et al. 2000) bound have shown that there is no single orientation 
of peptide binding within the hydrophobic patch. Peptides such as p53 and 
NDR, crystallised separately with SIOOB, bind almost perpendicular to 
each other within the same hydrophobic patch (Bhattacharya, Bunick et al.
16
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2004). It is possible that with proteins a broad attachment is possible in the 
binding site. Close inspection shows that the binding sites of SlOO proteins 
and known target peptides show complementary electrostatic residues 
bringing hydrophobic residues into close proximity (Bhattacharya, Bunick 
et al. 2004). The variation of SlOO protein sequence within the 
hydrophobic patch should therefore explain the variety of target proteins 
capable of binding.
1.1.4 and
Some SlOO proteins are also capable of binding Zn^  ^ and Cu^  ^ at a site 
distinct from the Ca^ * binding sites. Zn^  ^ has been shown to bind to 
S100A2, A3, A5, A6, A7, A9, A12 and B (Heizmann and Cox 1998) and 
binding can increase or decrease Ca^  ^affinity. Several SlOO proteins have 
Zn^  ^ binding motifs and tertiary structures give rise to clusters of Zn^  ^
binding motifs strongly suggesting a distinct binding site (Clohessy and 
Golden 1996). Zn^  ^ binding sites in SlOO proteins are frequently found 
near the dimer interface and it is thought that Zn^  ^binding may stabilise 
dimer formation. It must be remembered though that Zn^  ^is present in the 
cell at low concentrations (<0.1 nM) so SlOO protein interactions with 
Zn^  ^ may be dependent on localisation to high Zn^  ^ vesicles or the 
extracellular milieu. Cu^  ^ also binds to several SlOO proteins and can be 
displaced by Zn^  ^ suggesting mutual binding sites (Nishikawa, Lee et al. 
1997).
1.1.5 Gene evolution and structure
SlOO proteins evolved comparatively recently and have so far been found 
only in vertebrates. No SlOO like gene has been found in worms, flies or 
protozoa despite the fact that they do contain other EF hand genes like
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calmodulin and troponin. Despite their recent emergence SlOO proteins are 
the largest sub family of the EF hand group suggesting rapid expansion of 
SlOO genes from a single ancestor (Zimmer, Chessher et al. 1996). There 
are currently 20 recognised human SlOO proteins, which vary in homology 
between 22% and 57% at the gene level. Across species individual SlOO 
genes show a high degree of homology with above 75% identity within 
mammalian genes and even Xenopus show higher than 50% homology. At 
the amino acid level there is also a high degree of homology for individual 
SlOO genes across species. Homology at this level can be as high as 50% 
in mammals (Zimmer, Chessher et al. 1996).
There is a high conservation both of gene structure and chromosomal 
arrangement between human, rat and mouse. There are SlOO gene clusters 
on human chromosome 1 (Schafer, Wicki et al. 1995), mouse chromosome 
3 (Ridinger, Ilg et al. 1998) and rat chromosome 2 with both gene 
direction and position being highly conserved leading to the numerical 
nomenclature of most SlOO proteins (Schafer, Wicki et al. 1995). There 
are also SKX) genes not located to these main clusters such as SIOOB, 
SIOOG, SI OOP and SIOOZ in human and mouse. These genes are assigned 
a letter in the nomenclature to reflect that they would not fit into the 
numerical system from the main cluster. Within the clusters there are also 
discrepancies in arrangement. Human SlOOAl and S100A13 are found 
together yet in mice they are separated. This is, however, consistent with 
known chromosomal rearrangements in this area in mouse (Ridinger, Ilg et 
al. 1998). In human there are 4 main subgroups by homology (Marenholz, 
Heizmann et al. 2(X)4), which appear to be evolutionarily linked 
suggesting multiple gene duplication events. Of interest is the SIOOAS, 
S100A9 and S1(X)A12 group, which are clustered within 30Kb although 
not all subgroups are clustered together.
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The exon-intron structure of SlOO genes is also highly conserved with a 
distinctive 3 exon 2 intron template as shown in fig 1.1. The first exon 
contains the 5’ UTR region, the second exon contains the N-terminal EF 
hand and the third exon contains the C-terminal EF hand and the 3’UTR. 
The only exception to this is SIOOAS, which contains 4 exons and 3 
introns. Exon 1 contains 5’UTR in SIOOAS and is similar to a typical exon 
1. Exon 2 is similar to exon 1 with S’ UTR dominating with a start site and 
13 residues of particularly long N-terminal sequence contained at the 3’ 
end. Exon 3 contains the majority of the protein and exon 4 contains the 
C-terminus and 3’ UTR. The promoter, intron. S’ and 3’ UTR regions 
show little homology between SlOO genes although first intron length is 
highly conserved. The lack of homology in these regions indicates that co­
regulation is unlikely and that the SlOO genes are regulated differentially. 
This is consistent with their individual patterns of expression.
1.2 Expression
SlOO proteins are characterised by their cell and tissue specific expression, 
which is summarised in table 1.1.1. Some SlOO proteins are widely 
expressed such as SI00A4 and S100A6, whereas others are highly 
restricted e.g. SI OOP. Some cells contain multiple SlOO proteins, for 
example, murine glial cells contain SIOOB, SlOOAl, S100A6 and SI00A4 
(Nishiyama, Takemura et al. 2002). SlOO expression can be inducible or 
can be regulated during processes such as cell differentiation and cell 
cycle progression (Kligman and Hilt 1988; Zimmer and Landar 1995). The 
varied expression pattern confirms the highly specialised nature of the 
SlOO proteins and reinforces the idea that their functions are varied
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1.2.1 General functions
There are many proposed functions for the SlOO proteins and they are 
summarised in table 1.1.1 Some SlOO proteins have yet to have a function 
proposed for them indicating that work on the family is far from even or 
comprehensive. Common themes to emerge from the family include Ca^  ^
modulation, chemo-attraction, anti-microbial activity, cytoskeletal 
interaction and cell differentiation. Some of the functions described are 
intracellular and some are extracellular. SlOO proteins lack export signals 
but it is thought that they may be secreted via a novel pathway (Rammes, 
Roth et al. 1997). It should be noted that most of the evidence for SlOO 
functions come from in vitro studies and the exact physiological role of 
most SlOO proteins is unclear.
1.2.2 SlOO proteins in disease
SlOO proteins have been associated with a number of disease states such 
as cancer, heart disease, inflammatory disorders and neurodegeneration. In 
many of these disease states it is still unknown whether unusual SlOO 
expression is a cause or effect of the underlying condition.
1.2.3 SlOO proteins in cancer
In cancer SlOO proteins like SIOOB, S100A2, SI00A4, S100A7 and 
S100A6 have shown dramatic changes in expression (Emberley, Murphy 
et al. 2004). S100A4 is probably the most characterised SlOO protein in 
cancer and was originally named metastasin-1 due to its high expression in 
metastatic cell lines (Ebralidze, Tulchinsky et al. 1989; Ebralidze, 
Tul'chinskii et al. 1989). Elevated S100A4 levels in many forms of cancer
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SlOO
Protein
Ortholog 
in mouse
Expression
pattern
(Normal)
Proposed Functions 
from literature
References
SlOOAl Yes Heart, skeletal 
muscle and 
brain
Involved in cardiac Ca^  ^
signalling
Most 2004, 
Treves 1997
S100A2 Yes Some epithelial 
cells and 
kératinocytes
Regulates cytoskeletal 
interactions, tumour 
suppressor, 
chemoattractant for 
Eosinophils
Komada 1996, 
Gimona 1997, 
Wicki 1997
SI 00 A3 Yes Skin specific None
SI 00 A4 Yes Ubiquitous Involved in cell 
migration, promotes 
metastisis, interacts with 
p53, myosin IIA and 
annexin II
Kim 2003, 
Garret 2005
SIOOAS Yes Kidney, Brain Cu^* homeostasis Schafer 2000
S100A6 Yes Ubiquitous Regulates cell cycle, 
required for 
proliferation
Ferrari 1987, 
Breen 2003
S100A7 Yes Skin, tongue Chemoattractant for 
CD4 T-cells, interacts 
with cell survival 
mechanisms, 
antimicrobial activity
Jinquan 1996, 
Emberley 2005, 
Glaser 2005
SIOOAS Yes Myeloid cells, 
some epithelial 
cells
Inflammatory response, 
AA binding, chemo- 
attractant/repellent, 
antimicrobial, oxidative 
protection, development 
(see cross ref)
Lackman 1992, 
Harrison 1999, 
Sroussi 2006, 
Passey 1999
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S100A9 Yes Myeloid cells, 
some epithelial 
cells
Inflammatory response, 
AA binding, chemo- 
attractant/repellent, 
antimicrobial, oxidative 
protection (see cross ref)
Lackman 1992, 
Harrison 1999, 
Sroussi 2006
SIOOAIO Yes Connective 
tissue, epithelia
Interacts with annexin II Waismann 1995
SlOOAll Yes Haematopoietic
cells,
reproductive
cells
Interacts with annexin I Seemann 1996
S100A12 No Lymphocytes,
monocytes
Interacts with RAGE Hoffmann 1999
S100A13 Yes Heart and 
skeletal muscle
Involved in release of 
FGF-Iand IL-a, 
angiogenic role
Mouta Carreira 
1998, 
Landriscina 
2006, Sivaraja 
2006
S100A14 Yes Colon, thymus, 
kidney, liver and 
lung
Upregulated in cancer Pietas 2002
S100A16 Yes Unknown Upregulated in cancer Marenholz 2004
SIOOB Yes Brain Neuronal Ca^  ^
signalling, Neurite 
growth and apoptosis
Huttunen 2000, 
Xiong 2000
SI OOP Yes Placenta Associated with 
metastasis
Missiaglia 2004, 
Wang 2006
SIOOZ Putative
sequence
Leukocytes and 
spleen
Upregulated with other 
SlOO proteins in 
Kawasaki disease
Ebihara 2005
Table 1.1 Putative functions of SlOO family proteins. Adapted from 
references cited. Expression pattern taken from Swiss-Prot database.
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are associated with poor prognosis and a metastatic phenotype (Rudland, 
Platt-Higgins et al. 2000). It is thought that SI00A4 may inhibit the 
phosphorylation of p53 by protein kinase C (Sherbet and Lakshmi 1998; 
Grigorian, Andresen et al. 2001) preventing apoptotic cell death. It is not 
however thought that SI00A4 plays a role in the initiation of cancer but 
rather in progression (Garrett, Varney et al. 2006) as overexpression of 
SI00A4 does not cause cancer but can promote tumour progression once 
initiated (Davies, Rudland et al. 1996). S100A4 is believed to promote 
cancer cell motility through interactions with Myosin IIA (cytoskeletal 
remodelling) (Ford, Silver et al. 1997) and Annexin II (extracellular 
matrix remodelling) (Sherbet and Lakshmi 1998).
S100A7 is expressed in many tumour types and there are many suggested 
roles. S100A7 has been shown to regulate pro-survival NF-xB pathways 
through interaction with Jab-1 (Emberley, Niu et al. 2005) and is so 
strongly associated with the hyperproliferative condition psoriasis that it 
was originally named psoriasin (Madsen, Rasmussen et al. 1991). It is also 
thought that S100A7 could act in the response to cellular stress and 
anoikis, a form of apoptosis, to promote cell survival (Emberley, Niu et al. 
2005). S100A6 is believed to play an as yet unknown role in regulating the 
cell cycle (Tonini, Casalaro et al. 1991; Breen and Tang 2003) and is 
found at elevated levels in breast, pancreatic and lung cancers. S100A2 is 
thought to act as a tumour suppressor and is down regulated in carcinomas 
due to gene silencing (Wicki, Franz et al. 1997). S100A2 expression is 
normal in primary tumours but down regulated in métastasés (Boni, Burg 
et al. 1997; Boni, Heizmann et al. 1997). Forced re-expression of S100A2 
in carcinoma cell lines had an effect that was the opposite of SI00A4: 
inhibition of cell motility through cytoskeletal rearrangements (Nagy, 
Brenner et al. 2001). Rearrangement of chromosome lq21 in humans is 
frequently observed in tumour cells (Ilg, Schafer et al. 1996) suggesting 
that SlOO proteins could be involved in the development of cancer or
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could be induced as a result of chromosome rearrangement as most are 
localised to this chromosome. The evidence so far seems to point to the 
former of those two possibilities. SIOOAS and S100A9 are covered in 
section 1.2.
Consistent with its expression in the myocardium, SlOOAl is associated 
with heart disease. Levels of SlOOAl in the myocardium seem to correlate 
with heart performance as they are increased in hypertrophy (Ehlermann, 
Remppis et al. 2000) and lower during heart failure (Remppis, Greten et 
al. 1996). Elevated levels of SIOOB are found in patients with a variety of 
neurological conditions including Down’s syndrome (von Eggeling, 
Freytag et al. 1993), Alzheimer’s and multiple sclerosis (Schmidt 1998) 
although in Down’s syndrome it is believed that trisomy 21 affects SIOOB 
levels as the gene is situated on chromosome 21. It is thought that normal 
levels of SIOOB in the brain promote neuron survival and growth whereas 
high extracellular levels caused by trauma have an apoptotic effect and can 
cause neurodegeneration (Rothermundt, Peters et al. 2003).
S100A7, SIOOAS, S100A9 and SI OOA 12 are associated with 
inflammation. High serum levels of SIOOAS, S100A9 and SlOOAl2 are 
associated with inflammatory diseases such as cystic fibrosis, rheumatoid 
arthritis and chronic bronchitis (Chilosi, Mombello et al. 1990; Roth, 
Teigelkamp et al. 1992), which is covered in more detail in section 1.3.
1.2.4 SlOO mouse models
Knockout and transgenic mice have been generated for SlOOAl, SIOOB, 
SI00A4, SIOOAS and S100A9. All SlOO null mice are viable and show no 
gross abnormalities except SIOOAS null, which shows embryonic lethality
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(Passey, Williams et al. 1999). More detail on the S100A9 and S100A8 
null mice will follow in section 1.4.
SlOOAl null mice show reduced response to beta-adrenergic stimulation 
consistent with reduced Ca^  ^sensitivity. They also show reduced ability of 
the myocardium to compensate in a model of haemodynamic stress (Du, 
Cole et al. 2002). SIOOB null mice have been shown to display enhanced 
Ca^ "^  transients in cultured astrocytes (Xiong, O'Hanlon et al. 2000). 
However the cultures are prepared from 6-day SIOOB null mice and could 
not be seen in adult SIOOB null astrocytes in vivo (Nishiyama, Takemura 
et al. 2002). S 100A4 null mice show decreased susceptibility to 
spontaneous tumour formation (Grum-Schwensen, Klingelhofer et al.
2005). Crosses of SI00A4 null mice with spontaneous tumour forming 
mouse lines have shown that loss of SI00A4 can reduce tumour 
progression and metastasis. However, transgenic mice, which over-express 
SI00A4 in breast, show no increase in tumour formation (Garrett, Varney 
et al. 2006). This reinforces the idea that SI00A4 is not involved in the 
initiation step in cancer but in tumour progression and metastasis. 
SlOOAl 1 null mice show no abnormalities and are viable and fertile. Even 
in Sertoli cells where SlOOAl 1 is highly expressed no defect can be found. 
One lesson that can be learned from the SI00 null mice is that attributed in 
vitro functions are not always impaired when the protein is lacking. This 
suggests that either compensatory mechanisms apply or that many in vitro 
functions are not reproducible in vivo.
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1.3 S100A8 and S100A9
1.3.1 S100A8/A9
These two SlOO proteins were first identified in a number of separate 
investigations and given a correspondingly varied nomenclature. They 
were identified as the cystic fibrosis antigen, the human leukocyte antigen 
LI (Dale, Fagerhol et al. 1983) heavy and light chains, migration 
inhibitory factor related proteins (MRPs) (Burmeister, Tarcsay et al. 1986) 
8 and 14 (Hogg, Allen et al. 1989) and calprotectin (Steinbakk, Naess- 
Andresen et al. 1990). It was eventually found by cloning cDNA that this 
ensemble of antigens and proteins were in fact a heterodimer of two SlOO 
proteins (Andersson, Sletten et al. 1988), which were named S100A8 and 
S100A9 in the reorganisation of SlOO nomenclature (Schafer, Wicki et al. 
1995). S100A8 is one of the smallest SlOO proteins at lO.SkD whereas 
S100A9 is the largest SlOO protein at 13.2kD.
SlOO proteins typically form homodimers so the S100A8 and S100A9 
heterodimer (S100A8/A9) was of interest. Immunoaffinity 
chromatography studies have shown that the 1:1 ratio of the heterodimer is 
the most favourable combination although higher order multimers and 
homodimers of S100A8 and S1(X)A9 were found (Edgeworth, Gorman et 
al. 1991). A yeast 2-hybrid study confirmed the favoured status of the 1:1 
heterodimer and showed that homodimers of the two proteins only 
occurred in the murine proteins (Propper, Huang et al. 1999). It has been 
shown that higher order multimers could exist in vivo (Teigelkamp, 
Bhardwaj et al. 1991). Homodimers of S100A8 and S100A9 have been 
shown to lack the complementary interface displayed by the heterodimer 
(Hunter and Chazin 1998). It should be noted that relatively few functions
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have been proposed for homodimers of these SlOO proteins whereas many 
functions have been proposed for the heterodimer.
1,3.2 Structure
S100A8 and S100A9 have been crystallised separately (Ishikawa, 
Nakagawa et al. 2000; Itou, Yao et al. 2002) and as a heterotetramer 
(Komdoerfer IP, Brueckner F et al. 2004) and they display structures 
typical of SlOO proteins with an N-terminal “SlOO” EF hand and C- 
terminal “classical” EF hand as shown in fig 1.2. In S100A8 the C- 
terminal EF hand has an aspartic acid (Asp) in place of the SlOO 
conserved glutamic acid (Glu). As Asp has a shorter side chain it was 
thought that this might impair Ca^  ^binding. It has been shown, however, 
that a water molecule bridges the space between Asp 33 and Ca^ *.
S100A9 has an unusually long C-terminal extension making it the largest 
SlOO protein. This C-terminus also shows low electron density during 
crystallisation suggesting it is flexible, which is consistent with a sequence 
rich in hydrophilic residues and no predicted secondary structure. Amino 
acids 89-108 in S100A9 show exact homology to Neutrophil Immobilising 
Factor (NIF-1) (Freemont, Hogg et al. 1989). This factor has been shown 
to inhibit the movement of neutrophils and monocytes but the relevance of 
this homology is in doubt as it has been shown that many of the residues 
on this section are involved in dimer formation and thus inaccessible (Itou, 
Yao et al. 2002). Amino acids 90-112 in S100A9 also show high 
homology with a sequence in high molecular weight kininogen (HMWK) 
(Hessian, Wilkinson et al. 1995).
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Fig 1.2 S100A8 and S100A9 protein heterodimer. Cartoon representa­
tion of S100A8 (Red) and S100A9 (Blue) heterodimer. Significant features 
are labelled. Figure adapted from structure entry:
http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?form=6&db= 
t&Dopt=s&uid=35490 with help from S.Griffiths, Molecular Enzymology 
Laboratory CRUK.
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S100A9 has been shown in human to possess isoforms due to alternative 
start sites (Edgeworth, Gorman et al. 1991). No expression or functional 
difference has been shown for these isoforms. Human S100A9 has a 
phosphorylation site at the penultimate residue. Threonine 113 
(Edgeworth, Freemont et al. 1989). Phosphorylation rises after stimulation 
of human myeloid cells with ionophores, fMLP or PMA (Edgeworth, 
Freemont et al. 1989; Guignard, Mauel et al. 1996). Murine S100A9 does 
not possess the phosphorylation site of human S100A9 (Lagasse and 
Weissman 1992).
1,3.3 Expression
S100A8/A9 is expressed normally in myeloid and epithelial cells. Like 
most SlOO proteins cell type specific expression is seen and it is not 
ubiquitously expressed. In human SI00A8/A9 comprises 45% of cytosolic 
neutrophil protein and in monocytes it comprises 1% of cytosolic protein 
(Edgeworth, Gorman et al. 1991). The expression seems dependant on 
differentiation status, as tissue macrophages do not normally express 
S100A8/A9 and murine monocytes have been shown to lose expression 
when they differentiate to macrophages (Lagasse and Weissman 1992; 
Goebeler, Roth et al. 1995). Immature myeloid cell lines such as HL-60 
and U937 express low levels of S100A8/A9. When HL-60 cells are 
differentiated to monocytes however expression increases (Hogg, Allen et 
al. 1989). Also murine myeloid cells that express S100A8/A9 do so 
concurrently with Mac-1 and Gr-1 suggesting expression is confined to 
mature myeloid cells (Lagasse and Weissman 1992). The proteins are not 
expressed in other leukocytes, eosinophils or platelets.
A subset of normal squamous epithelia expresses S100A8/A9 including 
the tongue, oesophagus and cervix (Wilkinson, Busuttil et al. 1988). Some
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epithelial cell lines also express the proteins and this is often linked to 
their differentiation ability. Cultured normal kératinocytes express the 
proteins whereas normal epidermis does not. Also expression is seen in the 
medulla of the hair shaft where expression overlaps with involucrin, 
suggesting terminally differentiated hair follicle cells (Saintigny, Schmidt 
et al. 1992; Thorey, Roth et al. 2001).
1.3.4 Expression in disease
Expression profiles for S100A8/A9 expand dramatically during certain 
disease conditions. The plasma of patients with cystic fibrosis shows 
elevated levels of S100A8/A9 (approximate 5-10 fold higher than control) 
(Roth, Teigelkamp et al. 1992). In conditions of chronic inflammation 
such as rheumatoid arthritis and pneumonia S100A8/A9 is expressed in 
macrophages as well as myeloid cells (Odink, Cerletti et al. 1987; Zwadlo, 
Bruggen et al. 1988). It is believed that these macrophages are derived 
from monocytes that did not shed their heterodimer expression upon 
differentiation. S100A8/A9 is also found in kératinocytes during psoriasis 
(Kelly, Jones et al. 1989), eczema and lupus (Wilkinson, Busuttil et al. 
1988). Expression is largely in the spinous and granular layers of the 
epidermis although some basal expression can be seen. Squamous cell 
carcinomas also show high levels of the proteins (Schafer, Sachse et al. 
1991).
S100A8/A9 expression is also upregulated in conditions of the epidermis 
like psoriasis and wound healing (Thorey, Roth et al. 2001; Broome, Ryan 
et al. 2003). It is thought that the proteins may play a role in stress-induced 
pathways and act to influence the immune response to these conditions 
(Eckert, Broome et al. 2004). A lot of the evidence in disease states seems 
to point towards association of S100A8/A9 with inflammation.
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hyperproliferative conditions and rapid differentiation although no direct 
link has yet been conclusively proven.
Another condition associated with S100A8/A9 is a form of zincaemia 
where 5 patients (2 related) display infection, inflammation and metabolic 
problems (Sampson, Fagerhol et al. 2002). The patients have high plasma 
levels of S100A8/A9 (1,5-6.5 g/L compared with normal < Img/L) and it 
is thought that this may be chelating Zn^  ^ and causing the symptoms, 
which are consistent with low Zn^ "", although it is not known how the 
disease originates.
1.3.5 Cellular localisation
In resting myeloid cells S100A8/A9 is expressed in the cytosol 
(Edgeworth, Gorman et al. 1991). Stimulation with Ca^  ^ ionophores or 
zymosan has been shown to cause relocalisation to the membrane and also 
to intermediate filaments (van den Bos, Roth et al. 1996). Association with 
microtubules has been proposed as a potential mechanism of S100A8/A9 
secretion (Rammes, Roth et al. 1997). It has been suggested that secretion 
of S100A8/A9 follows a novel path that is susceptible to microtubule 
disrupting agents. Recently it has been proposed that S100A8/S100A9 is 
found in primary and secondary granule fractions in neutrophils (Stroncek, 
Shankar et al. 2005) although this conflicts with previous reports of 
myeloid cell localisation (Edgeworth, Gorman et al. 1991). Several of the 
functions proposed for S100A8/A9 rely on secretion of the proteins and so 
any potential mechanism for this process would be of interest.
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1.4 Proposed functions of S100A8/A9
1.4.1 Inflammation
The S100A8/A9 heterodimer has long been associated with inflammation 
and inflammatory conditions. It is highly expressed in immune cells like 
neutrophils, which are the first cells to arrive at a site of inflammation. It is 
also expressed in monocytes and has been shown in macrophages during 
acute and chronic inflammation (Odink, Cerletti et al. 1987; Zwadlo, 
Bruggen et al. 1988). Plasma levels of the proteins are raised in 
inflammatoiy disease and in Inflammatory Bowel Syndrome levels of 
SI00A8/A9 in faeces are used as a non-invasive diagnostic. It is also 
believed that the proteins could have a role in monocyte activation 
(Hessian, Edgeworth et al. 1993). Activating stimuli cause S100A8/A9 in 
monocytes to relocate to the plasma membrane, cell surface and 
cytoskeleton (Lemarchand, Vaglio et a l 1992; Roth, Burwinkel et al. 
1993; Burwinkel, Roth et al. 1994). The proteins have been located on the 
endothelium of venules near sites of inflammation (Hogg, Allen et al. 
1989; Robinson, Tessier et al. 2002). This lead to the theory that 
S100A8/A9 could have a role in leukocyte trafficking and extravasation 
although no further evidence has confirmed this theory to date. A recent 
report has proposed that S100A8/A9 are involved in the inflammatory 
cascade during sepsis (Vogl, Tenbrock et al. 2007). The proposed model is 
S100A8 binding to the TLR-4/MD2 and inducing downstream TNF-a 
signalling.
It has been proposed that S1(X)A8 and the S100A8/A9 heterodimer are 
chemotactic in both mouse and human. Murine S100A8 is proposed to 
attract both human and mouse neutrophils and mouse macrophages in 
vitro and in vivo (Lackmann, Cornish et ai. 1992; Lackmann, Rajasekariah
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et al. 1993; De very, King et al. 1994). There is disagreement about 
whether the human proteins are chemotactic. One group shows human 
neutrophil chemotaxis in response to S100A8 and S100A8/A9, but the 
level at which they show the effect in vitro (10 M) is lower than the 
likely normal level in vivo (Roth, Vogl et al. 2003; Ryckman, Vandal et al. 
2003). Also our group has shown that mice insensitive to endotoxin 
(C3H/HeJ) do not respond to recombinant S100A8/A9. Even when the 
group of Ryckman et al 2003 supplied the recombinant protein, the result 
could not be reproduced in the endotoxin insensitive mice. There is 
concern that chemotaxis could be induced by endotoxin present in 
recombinant samples, which seems the most likely conclusion. It should 
also be remembered that human and murine S100A8 show low homology 
(58%) for a cross species SlOO protein comparison. This could suggest 
that human and murine S100A8 could have differing roles.
It has also been proposed that human S100A8 alone could be a chemo- 
repellent and anti-inflammatory agent. One study showed S100A8 to act 
as a repellent to neutrophils and that this effect could be blocked by 
oxidation of S100A8. Oxidation resistant mutants repelled neutrophils in 
an in vivo model in rat (Sroussi, Berline et al. 2006). This effect has 
recently been reproduced for S100A9 (Sroussi, Berline et al. 2007). 
Another study showed the S100A8/A9 complex reducing the 
concentration of inflammatory markers, IL-6 and nitric oxide, in an in vivo 
model of inflammation (Ikemoto, Murayama et al. 2007). This effect was 
reversed with injection of anti S100A8/A9 complex IgG, It is possible that 
if the two SlOO proteins have a role in inflammation that this role could be 
dependent upon the inflammatory status and that the SlOO proteins could 
act as either attractant or repellent as a secondary effect. No study has yet 
looked into this possibility and so it remains speculative.
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Other SlOO proteins have also been linked to inflammation with S100A7 
thought to act as a chemoattractant. It is believed to recruit CD4 T cells 
and neutrophils but not CD8 T cells or monocytes. Despite the many links 
to inflammation no coherent picture has emerged as to the exact role the 
SlOO proteins play in vivo, an impression that is confirmed by work in the 
null models.
1.4,2 Fatty acid binding
Arachidonic acid (AA) is a polyunsaturated fatty acid that has been shown 
to bind to the S100A8/A9 heterodimer with high affinity in a Ca^" 
dependent manner (Kerkhoff, Klempt et al. 1999). Monomers and 
homodimers of either S100A8 or S100A9 do not bind A A. The interaction 
is inhibited by other unsaturated fatty acids but not by saturated ones 
(Kerkhoff, Klempt et al. 1999). Additionally HL-60 cells stimulated with 
Ca^Tonophores or phorbol ester release both S100A8/A9 and A A. It has 
been proposed that S100A8/A9 binding of AA is part of a trans-cellular 
process of leukotriene synthesis (Kannan 2003). It is believed that 
S100A8/A9 is responsible for Ca^  ^ mediated AA transport from the cell. 
This leads to leukotriene synthesis and neutrophil degranulation in an 
extracellular nucleotide triggered mechanism (Kannan 03). This process is 
believed to exacerbate inflammation and correlates with the high 
S100A8/A9 expression at inflammatory sites. It is believed that 
S100A8/A9 is the major fatty acid binding complex in neutrophils, which 
would provide a role for S1(X)A8/A9 in that cell type and explain the high 
levels of expression.
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1.4.3 Antimicrobial
One of the original names for the S100A8/A9 complex was calprotectin, 
reflecting evidence that it had antimicrobial properties. At low 
concentrations (4-128 |ig/ml) it inhibits the growth of Candida species and 
Cryptococcus.neoformans. At higher concentrations (64-256 pg/ml) it 
inhibits the growth of bacteria such as Escherichia.coli, 
Staphylococcus .aureus, and Klebsiela (Santhanagopalan 95). The 
antimicrobial effect is independent of Ca^  ^ yet is dependent on Zn^ .^ 
Candida grown in Zn^  ^enriched conditions proved resistant to S100A8/A9 
growth inhibition. Polyhistidine, a Zn^ "^  chelator, also inhibited microbial 
growth in a Zn^  ^ dependent fashion. Microbes require Zn^  ^ for vital 
enzymes such as DNA and RNA polymerases and S100A8/A9 may exert 
its anti microbial activity by chelating Zn^ .^ It has been shown that 
S100A8/A9 levels in abscess fluid are higher than the level required for 
microbe inhibition suggesting this may indeed be an in vivo role (Sohnle, 
Collins-Lech et al. 1991). As many of the functions proposed for 
S100A8/A9 occur in areas of inflammation a secondary characteristic of 
anti-microbial activity would definitely prove beneficial.
1.4.4 Protection from oxidative damage
It has been proposed that S100A8, when oxidised can form homodimers 
linked by disulphide bonds. It is suggested that S100A8 oxidation could be 
a protection mechanism preventing reactive oxygen species from 
damaging tissues (Harrison, Raftery et al. 1999), The evidence is that 
exposure to hypochlorite causes S100A8 homodimers to appear which are 
92 Da heavier than expected. These homodimers have been seen both in 
vitro and in lung lavage fluid from endotoxin-induced pulmonary injury 
(Harrison, Raftery et al, 1999),
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1.4.5 Other functions
The C terminal domain of S100A9 shows homology to high molecular 
weight kininogen (HMWK), which is capable of interacting with anionic 
surfaces in the blood clotting process. S100A9 and also S100A9 
complexed with S100A8 caused delayed onset of plasma coagulation in in 
vitro studies (Hessian, Wilkinson et al. 1995). It has been proposed that 
the A8/A9 complex may have a role preventing fibrin formation at sites of 
leukocyte migration.
It has also been proposed that A8/A9 is an inducer of cytostasis and 
apoptosis. The complex has been shown to inhibit growth of leukocytes, 
bone marrow cells and certain cell lines. It has been shown to induce 
apoptosis in normal fibroblasts and a human leukaemia cell line. However 
this effect is reversed by Zn^  ^showing that the effect may be similar to the 
antimicrobial effect proposed for the A8/A9 complex (Yui, Mikami et al. 
1995; Yui, Mikami et al. 1995; Yui, Mikami et al. 1997).
S100A8/A9 has been shown to enhance activation of NADPH oxidase in 
neutrophils. It is thought to associate with a subunit called p67phox and 
Rac via S100A8. It is believed to both activate NADPH oxidase and 
deliver arachidonic acid to the complex, which could be the activating 
agent (Doussiere, Bouzidi et al. 1999; Doussiere, Bouzidi et al. 2002; 
Kerkhoff, Nacken et al. 2005). Impaired oxidase activity has been shown 
with antibody-mediated blockage of S100A8/A9 and with mutants lacking 
AA binding sites (Kerkhoff, Nacken et al. 2005).
Many of the proposed in vitro functions for S100A8/A9 derive from in 
vitro studies of the proteins. Some of the in vitro data is directly
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contradictory, while the sum of proposed roles shows a protein complex 
with an astonishingly wide array of functions. As can be seen in the next 
section many in vitro results were not reproducible within in vivo model. It 
is always desirable to examine the in vivo models when assessing 
S100A8/A9 function.
1.4.6 S100A9 null mice
Our group and another have produced and characterised S100A9 null mice 
(Hobbs, May et al. 2003; Manitz, Horst et al. 2003). Both groups found 
that the S100A9 null mouse is viable and shows no gross abnormality. 
Despite its high expression in myeloid cells S100A9 seems to be 
redundant in myelopoiesis. Many aspects of S100A9 null neutrophil 
function have been tested including phagocytosis, superoxide burst and 
apoptosis and have been found to be normal (Hobbs, May et al. 2003).
An interesting finding by both groups is that in myeloid cells the loss of 
S100A9 also caused loss of S100A8 protein but not mRNA as shown in 
fig 1.3. It seems that S100A8 protein, in myeloid cells at least, is not stable 
without its heterodimer partner, S100A9. In neutrophils, where the 
heterodimer comprises 45% of cytosolic protein, this results in decreased 
neutrophils density on a Percoll gradient (Hobbs, May et al. 2003). No 
SlOO protein family member is upregulated and on a 2D gel of neutrophil 
lysate no other protein is upregulated in S100A9 null neutrophils 
compared to wildtype. It was thought that the loss of such an abundant 
protein complex would cause severe problems and/or engage 
compensatory mechanisms. The lack of such a response was very 
surprising. The groups disagree about S100A8 expression in bone marrow 
as S100A8 expression was seen in S100A9 null bone marrow in 70% 
fewer cells compared to wildtype using cytospin and immunostaining
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Fig 1.3 Analysis of S100A8 and S100A9 mRNA and protein expression in 
wildtype and SI 00A9 null bone marrow lysates. Expression of S100A8 
and SI 00A9 mRNA In bone marrow cells from wildtype and 5100A9 null 
mice (A) is shown. Expression of 5100A8 and 51OOA9 protein from the same 
bone marrow samples is shown in western blot (B) and in 2D western blot. 
Reproduced from Hobbs et al 2003.
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(Manitz, Horst et al. 2003). Our group could not repeat this result either by 
immunostaining or by western blot or FACS staining.
Ca^ * responses to inflammatory agents like MIP-2 are altered in S100A9 
null neutrophils. The defect lies in the IPS mediated Ca^  ^ response and 
occurs at the level of PLC-|3 (McNeill, Conway et al. 2007), yet despite 
this evidence S100A9 null neutrophils can still respond to MIP-2. In vitro 
and in vivo models of peritonitis show that S100A9 null mice show no 
difference in neutrophil recruitment. One group also reports a defect in
S100A9 null neutrophil activation. Stimulation of S100A9 null neutrophils 
with IL-8 lead to a reduced CD 11b upregulation when compared with 
wildtype (Manitz, Horst et al. 2003). It was also seen that S100A9 null 
neutrophils did not migrate in a 3D collagen matrix migration assay. Our 
group could not repeat these results. The differences in the two strains of 
S100A9 null mice cannot so far be explained but could occur due to a 
fundamental difference in the mice due to strain (both groups used 
C57BL/6J mice) or due to experimental design and interpretation. Our 
S100A9 null mice also show greater susceptibility to papilloma formation 
in a skin carcinogenesis protocol although at present it is unknown 
whether this is a function of neutrophil activity or of kératinocyte function 
(E.McNeill - unpublished) as both are known to express S100A9 and 
S100A8 in this model. Recently is has been shown that S100A9 null mice 
are more resistant to models of LPS induced sepsis (Vogl, Tenbrock et al. 
2007). The S100A9 null mouse has shown that, although many functions 
can be ascribed to a protein in vitro, in vivo data are of vital importance. 
The large number of attributed in vitro functions, which are not impaired 
by an in vivo knockout, is striking. This shows that the function of 
S100A8/A9 is difficult to approach from in vitro studies.
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1.4.7 S100A8 null mice
S100A8 null mice are embryonic lethal. It has been proposed that the 
embryonic lethality occurs between E 8,5 and E 9.5 (Passey, Williams et 
al. 1999) with null embryos being resorbed by E 13.5.
It was thought that the earliest expression of S100A8 in murine 
haematopoietic development occurred in the liver at E 10.5. This has been 
shown to be in conjunction with S100A9 in early myeloid cells (Lagasse 
and Weissman 1992). It was then claimed that S100A8 mRNA was 
expressed within a subset of cells around the ectoplacental cone at E 6.5 to 
E 7.5. It was proposed that this population is responsible for mediating the 
maternal foetal interactions directly after implantation (Passey, Williams 
et al. 1999). The justification for this is that S100A8 is believed to be 
involved in inflammation and implantation can be seen as a form of acute 
inflammation (Brandon 1993; McMaster, Dey et al. 1993). Another theory 
is that S100A8 can protect the embryo against reactive oxygen species, as 
it can be rapidly oxidised (Harrison, Raftery et al. 1999).
However, there were distinct problems within the study of the S100A8 
null mouse. Data was not shown indicating the protein expression of 
S100A8. As the S100A9 null mouse has demonstrated, in some cases 
S100A8 mRNA can be expressed with no protein subsequently produced. 
The interpretation of S100A8 mRNA labelling is also controversial and 
has been stated to be of foetal origin (Passey, Williams et al. 1999) or of 
maternal origin (Hobbs, May et al. 2003). This issue is of vital importance 
as foetal expression can explain an embryonic lethal phenotype whereas 
maternal expression, on its own, cannot. It is also unclear that if S100A8 is 
responsible for establishing implantation of the embryo why the lethality 
occurs much later in development at E 9.0.
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1.4.8 Is there a role for S100A8 independent of S100A9?
One issue that arose with the S100A8 and S100A9 null mice is that the 
two proteins were believed to be co-expressed based on evidence from 
myeloid cells and disease conditions. The S100A9 null is viable but shows 
loss of S100A8 in myeloid cells. The loss of S100A8 has been shown to 
be embryonic lethal. For the two observations to be reconciled S100A8 
must be stably expressed independently of S100A9 in development. If this 
were not the case then the S100A9 mouse should also be embryonic lethal.
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1.5 Preimplantation development
Development from a fertilised 1-cell zygote through to birth in the mouse 
is an immensely complex process and is briefly summarised in fig 1.4. In 
summary an embryo divides and differentiates rapidly before implantation, 
whereupon it continues to develop and further differentiate in utero until 
birth as summarised in fig 1 A. Advances in developmental biology make 
it possible to understand many of the molecular events of this process, but 
the picture is far from complete. For convenience the events of 
development will be subdivided into preimplantation and 
postimplantation. Furthermore emphasis is placed on aspects of 
development more relevant to this thesis as is illustrated in overview form. 
Preimplantation development explains how fertilisation occurs and how 
the I-cell zygote divides and differentiates ready to implant.
1,5.1 Spermatogenesis
Spermatogenesis is the process of male gamete production and involves 
cell division and differentiation from diploid spermatogonia to haploid 
sperm cells as shown in fig 1.5 (Brinster 2007). It takes place within the 
seminiferous tubules of the testes and involves mitotic proliferation of 
spermatogonia, which form a pool of spermatogenic stem cells with self­
renewal ability (Brinster 2002). Migration of spermatogonia through 
spermatogenic supporting Sertoli cells is necessary to further differentiate. 
Meiotic cell division occurs at the primary and secondary spermatocyte 
stages to produce haploid spermatids. Finally differentiation from 
spermatids to sperm cells involves gross morphogenic changes from a 
rounded cell to a structured and functional sperm cell. Cross sections of 
the seminiferous tubules expose all sperm differentiation stages with the
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earliest stage of differentiation at the basement lamina and the last stage at 
the luminal surface.
1.5.2 Oogenesis
Oogenesis is more complex than spermatogenesis in that it occurs in 
different locations and is not a continuous process, however the 
intermediate stages are similar to spermatogenesis as shown in fig 1.5. 
Each developing oocyte grows within a follicle where they are surrounded 
by follicular cells, which are of similar origin to the Sertoli cells of 
spermatogenesis and support oocyte differentiation (Richards, Jahnsen et 
al. 1987; Buccione, Schroeder et al. 1990; Eppig 1991). The oocyte 
develops a surrounding layer of glycoprotein called the zona pellucida 
(ZP), which is composed of three major proteins, ZPl-3 (Wassarman 
1990; Wassarman 1990). As an oocyte increases in size it acquires the 
ability to enter the final stages of meiosis when stimulated correctly by 
hormones. Upon ovulation stimulation by luteinising hormone, oocytes 
undergo nuclear maturation. The nuclear membrane breaks down and 
chromosomes assemble on the spindle and polarise within the cell. One set 
of chromosomes is extruded with some cytoplasm as the first polar body. 
The other set of chromosomes remains in meiotic arrest and the oocyte is 
released from its follicle as a secondary oocyte. Oocytes remain in meiotic 
arrest until after fertilisation. Fertilisation triggers the second round of 
meiosis, which produces a second polar body to form the fully mature 
oocyte.
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1.5.3 Fertilisation
Fertilisation is the process of 2 gametes, oocyte and sperm, joining 
together to form a zygote. It comprises distinctly ordered steps starting 
with sperm and oocyte contact. There is evidence that sperm are drawn to 
the oocyte by chemo-attractants produced by oocyte follicular cells 
(Eisenbach 1999; Eisenbach 1999; Eisenbach and Tur-Kaspa 1999). The 
first part of the process begins when a sperm with an intact acrosome 
binds to the glycoprotein membrane surrounding the oocyte, which is 
called the zona pellucida (ZP) (Bleil and Wassarman 1983). This process 
is highly species specific in mammals and is mediated by receptors on 
both sperm and oocyte. In mice oocyte ZP3 is known to act as a sperm 
receptor via linked oligosaccharides (Wassarman 1990; Rosiere and 
Wassarman 1992) and is thought to interact with proteins like SEDl 
(Ensslin and Shur 2003) and CD9 (Kaji, Oda et al. 2002) on sperm.
Once bound to the ZP the sperm prepares to penetrate by undergoing the 
acrosomal reaction (Abou-Haila and Tulsiani 2000). The acrosome is a 
large lysosome derived from golgi and situated at the apical region of the 
sperm head. The acrosome reaction is similar to exocytosis and is initiated 
by sperm fusion with the ZP. The reaction causes the sperm plasma 
membrane and acrosomal membranes to fuse and release acrosomal 
contents to degrade the ZP (Abou-Haila and Tulsiani 2000). The 
acrosomal reaction makes it possible for the sperm to penetrate the ZP by 
a combination of sperm motility and acrosomal enzyme activity breaking 
down the ZP. The sperm then enters the perivitelline space. The 
penetrating sperm can then bind to the plasma membrane of the oocyte. 
After binding the sperm and oocyte membranes fuse. Fusion of a single 
sperm prevents the oocyte plasma membrane fusing again and should 
prevent other sperm from penetrating the ZP. At this point the oocyte has
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been fertilized with the entire process occurring in approx 90 mins for 
mice. Fertilisation triggers a second round of meiosis in the oocyte as 
discussed above. Nuclear membranes form round the sperm and oocyte 
chromosomes forming pronuclei (Maro, Hewlett et al. 1986; Maro, 
Johnson et al. 1986; Poccia and Collas 1996). The pronuclei each replicate 
their DNA before they meet in the centre of the oocyte (Maro, Hewlett et 
al. 1986; Maro, Johnson et al. 1986). Binding of the pronuclei and 
dissolution of their membranes allows for both sets of chromosomes to 
assemble on a common spindle. The first mitotic cleavage to a 2-cell 
zygote occurs shortly after this process.
1.5.4 Expression of the zygotic genome
Early development requires dynamic cell division soon after fertilisation 
and many macromolecules are required. In order to accomplish this the 
oocyte is provided with RNA and protein to drive the early processes 
successfully (Schultz and Heyner 1992). Integration of sperm and oocyte 
genetic material and expression of zygotic RNAs and protein is essential 
for further development and so a switch must be made. The process of 
going from exclusively maternal to zygotic gene products is called the 
maternal-zygotic transition. Degradation of maternal transcripts occurs 
(Paynton, Rempel et al. 1988) and translation of maternal transcripts is 
severely reduced. This transition is not an instantaneous event and not all 
maternal proteins are replaced. Some maternal proteins can remain active 
for many days, even up until implantation (Schultz and Heyner 1992). In 
mice the transition occurs at the 2-cell stage of development (Flach, 
Johnson et al. 1982). The zygotic genome is deliberately silenced during 
early development (Wiekowski, Miranda et al. 1991) and the transition 
mainly consists of de-repression of the zygotic genome, de-novo 
embryonic transcription and degradation of maternal transcripts. When
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approaching early development with gene silencing in mind it is important 
to bear in mind the early reliance of the oocyte, 1 and 2-cell stages on 
maternal transcripts and protein for function, as homozygous null embryos 
often have delayed exhibition of null phenotypes.
1.5.5 Cell division
With such a long way to go from 1 cell to mouse embryo, division in early 
development is rapid and must set the stage for the differentiation events 
required to produce a blastocyst ready for implantation as shown in fig 
1.6. The zygote divides from 1 cell to 2 and subsequently 4 and 8 cells. It 
was thought that in mice cell division creates equally potent blastomeres 
until the 8-cell stage of development (Tarkowski and Wroblewska 1967; 
Johnson and McConnell 2004) although current evidence has suggested 
that cell fate can be determined as early as the first division (Piotrowska, 
Wianny et al. 2001). Cell division at these stages involves increase in the 
number of cells with negligible increase in embryo size. The building 
blocks for the created cells all exist in the oocyte prior to fertilisation and 
the embryo does not significantly increase in size despite multiple cell 
divisions. Studies have shown that the cell lineage initiation events have 
their origin in early cell division before morphogenic changes make 
lineage differentiation clear beginning at the 8-cell stage.
1.5.6 Compaction
Compaction occurs at the late 8-cell stage and is the first noticeable 
change of shape and structure in the preimplantation embryo. It is 
characterised by a change from loosely associated blastomeres to 
increasingly tight cell-cell interactions (McLachlin, Caveney et al. 1983). 
Blastomeres become impossible to distinguish and the embryo takes on a
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lobular appearance. Adherens junctions (AJs) are a necessary first step 
before establishment of tight Junctions (Kemler 1993). AJs involve 
cadherins, a family of transmembrane proteins expressed in the oocyte and 
present in the developing embryo with E- cadherin being the most 
common family member in AJs (Kemler 1993; Huber, Bierkamp et al. 
1996). Cadherins are though to influence cell-cell contacts through 
cytoplasmic domain interactions with p- and/or y  catenin, which in turn 
can influence the blastomere cytoskeleton (Kemler 1993). As the players 
in this process are present throughout fertilisation and early development it 
is believed that the process of AJ formation is inhibited until compaction 
(Vestweber, Gossler et al. 1987). A candidate for this inhibition is IQGAP 
controlled by R ad and Cdc42 (Braga, Del Maschio et al. 1999). IQGAP 
can bind cadherin bound p-catenin and cause it to disassociate thus 
preventing cadherin signalling (Natale and Watson 2002). Compaction is 
promoted by signalling through Racl and Cdc42 binding of IQGAP 
releasing the inhibition of cadherin signalling.
The process of compaction also causes two polarity events. Polarity of the 
membranes of cells occurs with outward facing, apical membranes and 
inner, basal membranes Polarity occurs between cells which lie on the 
outside of the compacted embryo and those lying inside after division 
from 8-cell to 16-cell. This polarity is crucial to differentiation of the first 
new cell types of development, trophectoderm (TE) and the Inner Cell 
Mass (ICM) (Johnson, Chisholm et al. 1986). The TE will eventually give 
rise to all trophoblast cell lineages whereas the ICM becomes the embryo 
and extra-embryonic tissues such the yolk sac. After compaction, outside 
cells contribute mainly although not exclusively to the TE, whereas inside 
cells contribute mainly to the ICM (Fleming 1987). It is believed that cell 
fate is determined at the 8 cell stage with the establishment of apical and 
basement membranes, which are characterised by differential molecular 
markers. The apical membrane is characterised by Jam-1, Ezrin, PKCs and
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Par proteins D3 and D6b (Pauken and Capco 2000; Thomas, Sheth et al. 
2004; Vinot, Le et al. 2005). Basement membranes are characterised by 
Par 1, Epithin, E-cadherin and p-catenin (Vestweber, Gossler et al. 1987; 
Vinot, Le et al. 2005). Subsequent cell divisions give rise to TE or ICM 
cells determined by the plane of division (Johnson and Ziomek 1981; 
Johnson and Ziomek 1981). Symmetrical division gives rise to two TE 
fate cells each of which inherit the apical and basal domains. Asymmetric 
division gives rise to a TE fate cell, which inherits the apical membrane 
and an ICM fate cell inheriting the basal membrane (Sutherland, Speed et 
al. 1990).
1.5.7 Cavitation
Cavitation is the process that converts a compacted morula to a blastocyst. 
It involves formation of a liquid filled cavity in the centre of the embryo, 
called the blastocoel, and the tightening of junctions and flattening of TE 
cells (Diggers, Borland et al. 1977). The cavity is formed due to a 
combination of the TE tight junctions with water and ion transport 
systems. It was thought that Na+ K+-ATPase is a main regulator of cavity 
formation by promoting ionic gradients across the TE (Watson and 
Barcroft 2001). An alternative explanation involving water channels called 
Aquaporins (AQPs) has been proposed (Offenberg, Barcroft et al. 2000). 
Diffusion is the most efficient method of moving water across the TE but 
it has not been shown that the necessary gradients across the TE exist. 
AQPs can transport water across the TE at near iso-osmolar levels (Deen 
and van Os 1998). Functional AQPs have been shown to be present in TE 
membranes (Barcroft, Offenberg et al. 2003). Tight junction formation is 
essential in forming the blastocoel as it prevents free diffusion and the 
collapse of gradients.
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1.5.8 Blastulation
The blastocyst once formed is itself polarised with TE forming a flattened 
outer cell layer and ICM concentrated at one pole. This polarisation is 
reflected in the TE with the trophoblasts at the same pole as the ICM 
becoming the polar trophectoderm and those surrounding the blastocoel 
becoming the mural trophectoderm. 24 hours after blastocyst formation a 
further lineage event occurs with the ICM segregating to form the epiblast 
(EPI - future embryo) and primitive endoderm (PE - future yolk sac) 
(Gardner and Rossant 1979). The PE forms a monolayer on the ICM 
facing the blastocoel. It was originally believed that the establishment of 
the EPI and PE lineages was determined by cell position within the ICM 
with the cells facing the blastocoel becoming PE and the inner, enclosed 
ICM cells becoming EPI (Martin and Evans 1975). However current 
evidence points to a model of ICM heterogeneity where the two cell types 
exist within the ICM and the two lineages are sorted by migration to form 
the structure of EPI and PE (Chisholm and Houliston 1987; Chazaud, 
Yamanaka et al. 2006).
1.5.9 Hatching
In order to prepare for implantation a blastocyst must shed its outer zona 
pellucida in a process called hatching. The zona is thought necessary not 
for the development of the blastocyst but in preventing premature 
adhesion of the developing blastocyst. At approx E 5.0 the blastocyst 
hatches from the surrounding zona pellucida using a combination of 
physical and enzymatic action. Enzymes from the mural trophectoderm 
and maternal uterus are believed to digest the ZP matrix (Perona and 
Wassarman 1986; Sharma, Liu et al. 2006). Hatching is also facilitated by 
rhythmic contraction and expansion of the blastocyst, which helps rupture
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the weakened ZP (Niimura 2003). The embryo emerges lead by the mural 
trophectoderm.
1.5.10 Preimplantation lethal phenotypes
There are a number of common preimplantation lethal phenotypes and it is 
always possible that a new phenotype may be displayed when studying a 
new lethal phenotype. Increasingly work with RNAi and morpholinos is 
extending the range of preimplantation phenotypes. It is possible that no 
mutant embryos are generated, which is caused by a haploid effect on 
sperm or oocytes (Gliki, Ebnet et al. 2004). Mutant embryos may delay or 
arrest during early cell division processes ultimately causing lethality. 
Compaction could be defective with failure of cell adhesion being a 
common cause of lethality at this stage (Riethmacher, Brinkmann et al. 
1995; Natale, Paliga et al. 2004). Failure to cavitate can be caused by 
arrest or a failure to form and maintain a fluid import across the 
trophoblast layer (Thomas, Sheth et al. 2004). Abnormal blastocyst 
morphology can occur such as loss of tight junction integrity or lack of an 
ICM due to defective cell signals (Nichols, Zevnik et al. 1998). Excessive 
cell death at this stage can cause problems forming a functional blastocyst. 
Failure to hatch from the zona pellucida is typically caused by defects in 
the trophectoderm and is common in wildtype (approx 20%) and could be 
completely prevented in a mutant embryo. Preimplantation development is 
extremely complex and involves many processes, any of which can 
potentially go wrong and cause embryo lethality.
1.5.11 Implantation
If development proceeds successfully to the formation of blastocyst the 
next step is implantation. The zona pellucida is shed and the embryo must
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establish an interface with the maternal endometrium. Implantation is 
necessary to allow an embryo to fuel its accelerating development by 
accessing the maternal blood supply and its nutrients. Three steps occur in 
implantation; apposition is where trophoblast cells are apposed to the 
luminal epithelium of the uterus, adhesion where trophoblast and luminal 
epithelial become attached strongly enough to resist luminal flushing and 
invasion where trophoblast cells invade the uterine epithelium resulting in 
loss of the maternal epithelium by apoptosis (Schlafke and Enders 1967; 
Enders and Schlafke 1969) as shown in fig 1.7. The process is continuous 
and involves complex mechanisms of hormonal control, adhesion, tissue 
remodelling and of course an array of signalling events to co-ordinate the 
process (Makrigiannakis and Minas 2007). Implantation is eccentric in 
mice, which means that the maternal decidua forms an invagination upon 
embryo attachment.
Apposition involves uterine swelling or oedema, which closes the uterine 
lumen. This has been shown to happen in response to ovarian steroids and 
will occur even in the absence of blastocysts. The receptivity of the uterus 
is highly important in implantation and is largely controlled by the ovarian 
steroids progesterone and oestrogen. The actions of oestrogen and 
progesterone co-ordinate the proliferation and differentiation of the uterine 
cells especially the epithelium (Huet-Hudson, Andrews et al. 1989). In 
mice oestrogen is crucial in promoting receptivity of the endometrium but 
less essential in subsequent implantation events. Trophectoderm and the 
luminal epithelium become apposed before the attachment reaction occurs. 
The uterine lumen closes due to the action of progesterone (Finn and 
Martin 1976), which brings uterine luminal epithelium and blastocyst 
trophoblast in close proximity. Vascular permeability increases 
significantly at sites of apposition, which can be shown by molecular dye 
penetration (Ljungkvist and Nilsson 1974).
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Fig 1.7 Stages of im plantation. Implantation of m ouse blastocyst showing 
apposition, attachm ent and invasion.
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Successful attachment depends on the embryo reaching an appropriate 
stage of development and receptiveness of the endometrium. The mural 
trophectoderm leads implantation in mice adhering to the uterine wall and 
attachment involves many molecules including proteoglycans, integrins, 
selectins, cadherins and other adhesion molecules (Kimber and Spanswick 
2000) but also the downregulation of anti-adhesive markers such as MUC- 
1 (Surveyor, Gendler et al. 1995), which may be key to uterine receptivity. 
After attachment the uterine epithelial cells proximal to the site of 
implantation detach from the basement membrane undergo apoptosis 
allowing trophoblast cells, which phagocytose the cells, to invade the 
epithelium. Epithelial basement membrane breakdown is facilitated 
initially by decidual cells but also trophoblast cells, which pause briefly 
upon invading the epithelium. This process brings developing embryos 
into contact with the maternal blood supply after about 6 hours of 
implantation.
Exactly how an embryo implants without triggering an immune response 
from the mother is an interesting question. This case has been likened to 
an allograft reaction and is highly unusual and as such must be highly co­
ordinated to prevent rejection of the embryo. This process involves 
establishing a unique environment of chemokines and immune cell types 
(Femekom and Kruse 2005). It is thought that recruitment of regulatory 
immune cells and exclusion of potentially damaging immune cells could 
be critical to the success of implantation. This process is regulated by 
compartmentalisation of the decidua and expression of adhesion molecules 
such as selectins on endothelial cells. Neutrophils are restricted to necrotic 
areas of cell digestion at the maternal foetal interface (McMaster, Dey et 
al. 1993). Macrophages are excluded from the foetal maternal interface 
(Brandon 1993) and macrophages in the decidua are associated with poor 
implantation success and macrophage activation markers indicate poor 
prognosis for pregnancy (Haddad, Duclos et al. 1997).
56
Chapter i : Introduction
1.6 Postimplantation development
1.6.1 Decidualisation
Implantation of the embryo triggers a massive response in the endometrial 
stromal fibroblast cells, which proliferate and differentiate in a process 
called decidualisation (Abrahamsohn and Zorn 1993) as shown in fig 1.8. 
The process is dependent upon signalling through ovarian steroids in the 
stroma surrounding the implanting embryo, and results in a new tissue, the 
decidua, being formed. Decidual cells are larger, more granular and 
fibrous and have more organelles than undifferentiated stromal cells. 
Decidualisation begins in the stroma surrounding the implanting embryo, 
the primary decidual zone, and occurs initially in the sub-epithelial, 
antimesometrial area (area apposed to the inner cell mass). The first 
decidual cells are in place when trophoblast cells invade the uterine 
epithelium. There are regional differences in the extent and timing of 
decidualisation, which are important to bear in mind for the purposes of 
this thesis. Decidualisation proceeds through the antimesometrium 
although the extent of decidualisation recedes as distance from the embryo 
increases. Decidualisation occurs later (around E 7.5 in mice) in the 
decidual crypt and mesometrium, which develops into two distinguishable 
regions a glycogen rich region proximal to the anti-mesometrium and a 
region of largely undifferentiated stromal cells (Abrahamsohn and Zom 
1993).
This processes of attachment, invasion and spreading of the trophoblast 
lineages involves many components of the extracellular matrix. Basement 
membrane and extracellular matrix components such as fibronectin, type 
IV collagen and laminin can interact with trophoblast cells receptors and 
promote attachment and growth. Penetration of the basement membrane
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BFig 1.8 Decidualisation in the maternal endom etrium . Representation of 
maternal decidual orientation. (A) Embryo developm ent at E 7.0 with the 
areas of decidua. (B) Extent of decidualisation in the  maternal decidua at E
7.0 showing differentiation gradients.
58
Chapter 1 : Introduction
and invasion of the surrounding stroma is important and must be precisely 
controlled. Remodelling of the extracellular matrix is largely mediated by 
matrix metalloproteinases (MMPs) themselves regulated by endogenous 
tissue inhibitors of MMPs (TIMPs) (Brenner, Adler et al. 1989), which 
together mediate and restrict the remodelling to ensure the appropriate 
level of embryo invasion into the uterine stroma and the correct stromal 
response to invasion.
1.6.2 Placental development
Embryo development postimplantation is highly dependent on the 
formation and growth of a functioning placenta as shown in fig 1.9. The 
roles of the placenta include establishing a foetal/maternal interface for 
exchange of metabolites and gases, waste product removal, hormonal 
regulation of both maternal and foetal tissues and a successful interaction 
with the maternal immune system (Cross, Werb et al. 1994; Adamson, Lu 
et al. 2002). The mature placenta consists of three layers with 
contributions from both mother and foetus. There is an outer layer of 
maternal decidual cells and vasculature, an interface layer comprised of 
foetal trophoblast cells that have invaded the maternal decidua and an 
inner layer of highly branched foetal villi for efficient exchange.
Placental development begins in the blastocyst with the differentiation of 
the trophectoderm from the inner cell mass (Sherman 1975) with 
trophectoderm cells proceeding to form the mature placenta. Upon 
blastocyst implantation the mural trophectoderm cells, which are not in 
contact with the inner cell mass, enter a process called endoreplication. 
The cells stop dividing yet continue replicating their DNA to become 
polyploid (Gardner and Davies 1993; MacAuley, Cross et al. 1998). These 
cells increase in size and are called trophoblast giant cells. The polar
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Fig 1.9 Developm ent of the placenta. Development of the  placenta in 
mice through various time stages, showing em ergent cell and tissue types.
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trophectoderm is in direct contact with the inner cell mass and produces 
the extraembryonic ectoderm and the ectoplacental cone (Copp 1978; 
Copp 1979). The extraembryonic ectoderm becomes the trophoblast 
contribution to the chorion. The ectoplacental cone lies between the 
trophoblast giant cells and the developing villi structure of the chorion 
providing structural support. The development of vasculature within the 
placenta begins with the allantois, a structure, which arises in the posterior 
end of the embryo (Cross, Simmons et al. 2003). Connection between 
allantois and chorion occurs at E 8.5 (Downs, Temkin et al. 2001). This 
begins a process of chorionic folding to provide villi structure for the 
developing allantois vasculature (Cross, Simmons et al. 2003). Further 
differentiation occurs within the chorion with the multinucleated 
syncytiotrophoblast cells, formed from fusion of trophoblast cells, lining 
the endothelium of foetal blood vessels. Mononuclear trophoblast cells 
also arise that line the maternal blood vessels.
1.6,3 Haematopoiesis and Vasculogenesis
Development of the vascular and haematopoietic systems are intrinsically 
linked in embryonic development as shown in fig 1.10. The first 
haematopoietic and vascular precursors arise in the primitive streak 
mesoderm (Huber 04) in response to basic fibroblast growth factor (bPGF) 
and bone morphogenic protein 4 (BMP-4). It is thought that a precursor 
for both haematopoiesis and vasculogenesis arises here and is called the 
haemangioblast (Kennedy, Firpo et al. 1997; Choi 1998; Choi, Kennedy et 
al. 1998)(Wagner 80). Haemangioblasts respond to bFGF and BMP4 
signalling becoming positive for vascular endothelial growth receptor-2 
(VEGFR-2) also called Flk-1 (Millauer, Wizigmann-Voos et al. 1993; 
Choi 1998). While there is substantial evidence for the existence of a dual 
haematopoietic and vascular precursor recent studies have raised the
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Fig 1.10 Vasculogenesis and Haem atopoiesis in developm ent. Develop­
m ent of haematopoietic precursors from flk-1 positive m esodermal cells 
(Yellow) and progress to NP-1 (arterial) and NP-2 (Venous) angiogenic 
precursors (Purple) and haem atopoietic precursors (Red).FLk-l - vascular 
endothelial growth factor receptor, NP - neuropilin.
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possibility that haematopoietic and vascular precursors can be 
distinguished in the primitive streak mesoderm by CD41 expression 
(Ferkowicz, Starr et al. 2003). Precursors migrate from the primitive streak 
to the extraembryonic tissue of ectoderm, yolk sac and allantois (Huber, 
Kouskoff et al. 2004). Precursors aggregating in the yolk sac form 
structures called blood islands with outer endothelial cells characterised by 
expression of neuropilin (NP) 1 or 2 (arterial or venous endothelium) and 
inner haematopoietic cells characterised by NP-1 and 2 expression 
(Herzog, Guttmann-Raviv et al. 2005).
Blood island structures can link to form capillary networks called the 
primary plexus (Drake and Fleming 2000). The yolk sac vascular network 
undergoes extensive remodelling in order to form more complex mature 
circulatory vessels that are capable of connecting with the embryonic heart 
via intraembryonic vessels to establish circulation at around E 8.5 (Drake 
and Fleming 2000). Circulation is initially limited to the yolk sac, heart 
and embryo developing with the vasculature to connect with developing 
organs. It is in the developing vasculature of the yolk sac blood islands 
that embryonic haematopoiesis first occurs from precursor cells.
1.6.4 Haematopoietic development
In adults haematopoiesis involves constant production of haematopoietic 
cells from haematopoietic stem cells (HSCs) in the bone marrow. 
Haematopoietic stem cells are defined by ability to produce multiple blood 
cell types and the ability to self renew. The way to test for HSCs is their 
ability to repopulate a lethally irradiated mouse. In embryogenesis HSCs 
develop in a complex way with multiple sites of origin coupled with a 
progressive change in HSC location until colonisation of the bone marrow 
prior to birth brings us to the adult state (Cumano and Godin 2007) as
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shown in fig 1.11. The first blood cells arise from mesodermal precursors, 
which migrate to form the yolk sac blood islands making the blood islands 
the first embryonic site of haematopoiesis (Moore and Metcalf 1970). 
These primitive precursors produce only primitive erythrocyte cells, which 
are characterised by their nucleus, large size and expression of both foetal 
and adult globin genes (Haar and Ackerman 1971; Ingram 1972; 
Ferkowicz, Starr et al. 2003), Primitive erythrocytes are generated 
between E 7.0 and E 8.5 and are gradually replaced by myeloerythroid 
precursors in the yolk sac (Cumano, Dieterlen-Lievre et al. 1996). 
Myeloerythroid precursors produce definitive erythrocytes, which can be 
characterised by their smaller size, expression of adult globin genes and 
loss of nucleus in the circulation.
None of the early yolk sac progenitors are truly HSCs as they cannot 
produce all the blood cell types and are relatively short lived with no 
repopulation ability. It is not clear whether the yolk sac gives rise to HSCs 
or is a potential host site to HSCs when they arise (Cumano, Dieterlen- 
Lievre et al. 1996; Cumano, Ferraz et al. 2001). More recently studies 
have shown that the placenta is also a site of haematopoiesis as early as E
9.0 and could also generate HSCs (Alvarez-Silva, Belo-Diabangouaya et 
al. 2003). It is very clear that HSCs arise within the embryo proper in a 
region called the para aortic splanchnopleurae (pSP), which later develops 
into the aorta-gonad-mesonephros (Medvinsky, Samoylina et al. 1993; 
Medvinsky and Dzierzak 1996). HSCs can be found in this region at E
10.5 and have been shown to originate from that site. The AGM HSCs are 
thought to be a small population of HSCs but that they contribute 
predominantly to adult bone marrow HSCs (Lassila, Eskola et al. 1978). 
One of the reasons for controversy over the origins of HSCs is that it is 
known that AGM HSCs can migrate to the haematopoietic sites of the 
yolk sac and placenta. Development of haematopoietic cells continues 
with migration from early sites to later and more mature tissues.
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Fig 1.11 Timing and location of embryonic haem atopoiesis. Timing of 
haematopoietic onset in embryonic tissues (A) at embryonic stages (E) days 
post coitum. Migration of haematopoieticaliy fated cells in developing 
embryo (B) includes known migrations and suspected migrations like AGM 
to foetal liver. Key, AGM = Aorta-Gonad-Mesonephros.
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Myeloerythroid precursors, originating from the yolk sac migrate to the 
foetal liver beginning at E 9.5 (Johnson and Moore 1975) and are key to 
liver development.
1.6.5 Foetal liver development
In mice, the liver develops as an endodermal invagination formed from the 
ventral foregut at E 8.5 (Douarin 1975; Gualdi, Bossard et al. 1996; Rossi, 
Dunn et al. 2001) in response to FGF signalling from cardiac mesoderm 
(Jung, Zheng et al. 1999) and BMP signalling from the mesenchymal 
septum transversum (Rossi, Dunn et al. 2001). This forms a bud of 
proliferating cells destined to become hepatocytes. Hepatic vascular 
development begins within the liver bud at this stage and is promoted by 
endothelial cells (Matsumoto, Yoshitomi et al. 2001). The basement 
membrane of the liver bud breaks down, allowing cords of hepatocytes to 
invade the surrounding septum transversum. This invasion is confined by 
endothelial and angiogenic cells, which surround and define the 
developing liver within the septum transversum. The process is 
summarised in fig 1.12.
Links between haematopoiesis and vasculogenesis are extremely 
important as the developing and connecting vascular system allows 
migration of haematopoietic cells. The first circulation is established 
between the heart, dorsal aorta and yolk sac at E 8.5. The heart starts to 
beat and predominantly erythrocytes enter the circulation. Migration of 
haematopoietic cells has been shown to be of vital importance in the 
developing liver providing key maturation signals (Kamiya, Kinoshita et 
al. 1999; Kinoshita, Sekiguchi et al. 1999). At E 9.5 myeloerythroid 
haematopoietic precursor cells migrate to the foetal liver, primarily from 
the yolk sac, where they proliferate and differentiate. HSCs first arrive in
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Fig 1.12 Liver organogenesis in the developing embryo. Development of 
the embryonic liver from ventral endoderm  (blue) in response to signalling 
from the septum  transversum (Green) and the cardiac mesoderm (red). 
Development of liver bud (blue and invasion of th e  septum  transversum 
with the assistance of endothelial cells (white). O ther embryonic tissues are 
shown (yellow) to give context to liver developm ent.
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the foetal liver at E 11.5 although it is not clear where these cells originate. 
The timing of vascular development suggests that the AGM region and 
placenta may be the original contributors of HSCs to the foetal liver. At E
12.5 the foetal liver is the predominant haematopoietic tissue, with HSCs 
proliferating and differentiating there. It is thought that the foetal liver 
could be the most supportive environment for HSCs proliferation, more so 
than adult bone marrow where most HSCs are quiescent. Haematopoiesis 
within the foetal liver is more extensive than in previous haematopoietic 
tissues with expansion of myeloid and lymphoid precursors. The first 
macrophages are seen in the liver at E 11.0 (Morris 91) and the first 
neutrophils can be seen in foetal liver at E 12.5. SI00AS and S100A9 are 
first seen together at E 12.0 in cells believed to be neutrophils (Lichanska, 
Browne et al. 1999). Establishment of HSCs in the developing bone 
marrow occurs at E 17.5 and continues past birth into the adult.
1.6.6 Postimplantation lethal phenotypes
Lethality occurring postimplantation has many possible causes relating to 
the many cell and organ functions that can go wrong. A common time of 
lethality is periimplantation where failure to correctly implant or initiate 
growth signalling can occur (Feldman, Poueymirou et al. 1995). 
Continuing this theme a failure to gastrulate correctly can cause lethality at 
E 6.5-9.5 (Liu, Wakamiya et al. 1999). Another common cause of lethality 
in this time frame is failure of the extraembryonic tissues or placenta to 
develop. This can be caused by failure of allantoic fusion (Naiche and 
Papaioannou 2003), failure of vasculogenesis (Shalaby, Rossant et al. 
1995) or failure of extraembryonic membrane function (Morasso, 
Grinberg et al. 1999). Failure of cardiac development is common between 
E 7.5 and E 10.5 (Lin, Schwarz et al. 1997). Lethality due to yolk sac 
defects can also be seen (Davenport, Jerome-Majewska et al. 2003). With
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so many possible causes of lethality it is important to analyse a model 
closely. It has also been known for a null lethal phenotype to be affected 
by mouse genetic background,
1.7 Aims of this thesis
The purpose of this thesis is to re-examine the role of S100A8 in 
development and to determine whether it needs to be reassessed following 
on from the work of Passey et al 1999. One aim is to discover what the 
non-redundant role of S100A8 might be. Is S100A8 expressed 
independently of S100A9, and if so how is it stabilised. It is also 
considered that revealing the role of S100A8 in development might 
provide insights into the role of the S100A8 and S100A9 heterodimer in 
the adult animal.
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CHAPTER 2
2 Materials and Methods
2.1 Materials
2.1.1 Buffers/Serum
Reagent Further Information
FACS wash PBS containing 0.2% bovine serum albumin
FACS fix PBS containing 2% formaldehyde
Saponin Buffer PBS containing 0.5 bovine serum albumin and 0.5% 
saponin
HESS Hanks Balanced Salt Solution (Gibco)
DMEM Dulbecco’s modified Eagle’s medium (Sigma)
HEPES (Gibco)
M16 Embryo culture buffer (Sigma)
M2 Embryo culture buffer (Sigma)
IMDM Iscove's modified Dulbecco’s medium (Gibco)
FCS Foetal calf serum (PAA cell culture)
2.1.2 Antibodies and detection reagents
Antibody Conjugate Epitope Species Supplier
NH9 S100A8 Rabbit CRUK
70
Chapter 2: Materials and Methods
Calgranuiin A C-terminal 
peptide of 
S100A8
Goat Santa Cruz
6A4 S100A8 Rat CRUK
2B10 S100A9 Rat CRUK
F4/80 160kD
macrophage
glycoprotein
Rat Serotec
7/4 Neutrophil/ 
monocyte 40kD 
protein
Rat Caltag Medsystems
IgG2a Y13 Rat CRUK
IgG2b PyLT-1 Rat CRUK
Rabbit anti rat HRP IgG Rabbit Southern
Biotechnology
Goat anti Rabbit HRP IgG Goat Dako-Cytomation
Rabbit anti 
mouse
HRP IgG Rabbit Dako-Cytomation
Goat anti rabbit Alexa 488 IgG Goat Sigma
Goat anti rabbit Alexa 568 IgG Goat Sigma
Rabbit anti goat Alexa 488 IgG Rabbit Sigma
Goat anti rat FITC IgG Goat Jackson
Immunoresearch
Rabbit anti goat FITC IgG Rabbit Sigma
Goat anti rabbit FITC IgG Goat Sigma
2.1.3 Gifts
Embryonic stem (ES) cell derived cultures differentiated down erythrocyte 
lineage -  Valerie Kouskoff (Kouskoff, Lacaud et al. 2005). 10^  cell samples 
for RT-PCR and 10^  cells for western blot analysis.
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2.2 Methods
2.2.1 Animal husbandry
S100A9 (Hobbs 03) and S100A8 null mice were generated by R.May in the 
Leukocyte Adhesion Laboratory. Transgenic SV129 x C57BL/6J mice were 
derived from two independent clones for each strain and backcrossed against 
C57B1/6J mice to a minimum of 6 generations. Offspring were genotyped 
using the PCR methods outlined in 2.2.2. Mice were maintained in a 
pathogen-free environment and all procedures were in accordance with Home 
Office guidelines.
2.2.2 Genotyping
2.2.2.1 Tailsnip preparation
Mouse tailsnips of approx 5mm were cut into Eppendorf tubes and digested in 
700 pi of tail digestion buffer (50mM Tris pH 8, lOOmM EDTA, lOOmM 
NaCI, 1% SDS, 25pi lOmg/ml proteinase K) at 55®C overnight. Samples were 
boiled at 95°C for 15 mins and then spun at full speed in a microfuge for 10 
mins at 4°C. 400pi supernatant was added to an Eppendorf tube with 400pl 
isopropanol. 80pl 3M sodium acetate is added and the Eppendorf inverted 
several times vigorously to mix the solutions. Eppendorf spun at 4®C for 20 
mins. Supernatant was aspirated and the pellet washed with 500pi 70% 
ethanol. The Eppendorf tubes were spun for 20 mins and the supernatant 
aspirated. Eppendorf tubes were left to air dry for approx 2 hrs at RT prior to 
resuspension in 20 pi water.
2.2.2.2 Preimplantation embryo DNA preparation
Preimplantation embryos were generated by the CRUK Transgenic Services
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unit as detailed in 2.2.10. Embryos were snap frozen in Ipl DDW in 
individual Eppendorf tubes. Embryos were defrosted by adding 5pl 4°C lysis 
buffer (5mM Tris pH8, 0.1% SDS, 2mM NaCl + lU Proteinase K; Promega) 
to frozen Eppendorf tubes. The Eppendorf tubes were spun down and the 
samples transferred to PCR wells to undergo digestion in a PCR cycle 
machine with the following programme.
Time Temperature ®C Cycles
60 mins 60 1
5 mins 95 1
Holding 4 forever
1 p,l of digested sample was used as DNA template in 2-step PCR reactions.
2.2.2.3 Postimplantation embryo DNA preparation
Postimplantation embryos were generated from timed matings. Mice were 
euthanised by asphyxiation followed by cervical dislocation. Embryos were 
extracted from maternal decidua using a dissecting microscope and then 
digested using the same protocol for tailsnip DNA preparation in 2.2.2. DNA 
is resuspended in 20 pi water with Ipl used as template for the 1-step PCR 
protocol outlined in 2.2.2.
2.2.2.4 1-step PCR process
Ipl of DNA template is mixed with 1.5 U TAQ polymerase (CRUK), 125ng 
of each primer (S100A8 2"^  reaction primers for S100A8 genotyping, S100A9 
primers for S100A9 genotyping) and PCR buffer (1 x Thermophilic PCR 
buffer, 1.5 mM MgCl^, 200pM dATP/dGTP/dTTP/dCTP; Promega) to a final 
volume of 25 pi. Samples are amplified using Peltier Thermal Cycler (MJ 
Research). The basic cycle programme is shown below.
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Time Temperature “C Cycles
5 mins 95 1
30s 95
30s 55 32 (typical)
60s 72
5 mins 72 1
Holding 4 forever
2.2.2.S 2 Step PCR protocol
Ipl of each DNA sample was mixed with 1.5 U TAQ polymerase (CRUK), 
125ng of each primer and PCR buffer (1 x Thermophilic PCR buffer, 1.5 mM 
MgClz, 200pM dATP/dGTP/dTTP/dCTP; Promega) to a final volume of 25 
pi. The first round of PCR used S100A8 reaction PCR primers (as shown in 
fig 2.1) using the programme shown below.
Time Temperature C Cycles
5 mins 95 1
10 mins 95
5 mins 55 24
4 mins 60
5 mins 60 1
Holding 4 forever
Products undergo a second PCR cycle using Ipl of T* reaction round product 
as DNA template and using S100A8 2"‘* reaction primers (as shown in fig 2.1) 
in an otherwise identical reaction mixture. The samples were placed in the 
programme shown below.
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W ildtype Allele 
0F1 GFl
-CZZHZZÜZZH E3 
GB10B1
Null A llele  
0F1 GFl
- I  E1 j - l l  N e o  I  E .  H  E3 ] _
GNeo ONeo
1 St reaction primers 0F1 OBI ONeo 
2nd reaction primers GFl GB1 GNeo
Fig 2.1 1st and 2nd PCR reaction primers in relation to  S100A8 gene  
structure. Primer combination for 1st reaction (blue) and 2nd reaction (red) 
shown in relation to  wildtype and null allelles.
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Time Temperature ®C Cycles
5 mins 95 1
10 mins 95
5 mins 50 32
4 mins 60
5 mins 60 1
Holding 4 forever
Products of the final reaction are run on agarose gels as shown below in 2.2.2.
2.2.2.6 PCR Primers
All primers were synthesised by Sigma-Genysis
S100A8- 2™^ reaction Primers 
GFl- AGCCTCACATATCCTTTGTCA 
GB1 -GACATCAATGAGGTTGCT CAA 
GNEO-ACCGCTTCCTCGTGCTTTACG
S100A8- r ‘ reaction primers 
OFl- GCAGCTGACACTTAGCCTCAC 
OBI- CCATCCCAGCACCATTAGAA 
ONEO-ACATAGCGTTGGCTACCCGTG
S100A9 primers
GF2-AACATCTGTGACTCTTTAGCC
GB2-CATCTGAGAAGGTGCTTTGTT
GNEO-ACCGCTTCCTCGTGCTTTACG
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2.2.2.7 Agarose gel electrophoresis
TAE buffer (from a 50 x solution containing 242g Tris-base, 100ml 0.5M 
EDTA, 57.1ml glacial acetic acid made up to 1 1, pH8) containing 1.8% 
agarose (Invitrogen) was heated by microwave to dissolve the agarose (approx 
3 mins). Ethidium bromide was added (5p-l/100ml; Sigma) before pouring the 
mixture into a gel mould with lane marker combs. Blue/Orange loading buffer 
(Promega) was added at a ratio of 1:10 to PCR products before loading to 
track progress. PCR products were electrophoresed at 100-120mV in 1 x TAE 
buffer with 5pI/L ethidium bromide. Bands were visualised by UV 
illumination.
2.2.3 DNA sequencing
PCR bands were cut from agarose gels and DNA purified using Qia quick gel 
extraction kit (Qiagen) according to manufacturers instructions. lOng of DNA 
template was added to PCR tubes along with 150ng of template primer, 8pl 
terminator ready reaction mix (Qiagen) and water to a final volume of 20p.l. 
PCR cycling was performed as follows.
Time Temperature ®C Cycles
5 mins 95 1
10 mins 95
5 mins 55 25
4 mins 60
5 mins 60 1
Holding 4 forever
Reaction products were prepared for sequencing by purification using a 
DyeEx spin column (Qiagen). Purified reaction products are dried and 
resuspended in 20p,l Hi Di formamide. 15p,l of sample were loaded into 96 
well plates and denatured at 96 °C for 2 mins. The samples were then loaded
77
Chapter 2: Materials and Methods
into a capillary sequencing Prism 3730 machine (Applied Biosytems).
2.2.4 SDS-PAGE
Samples for SDS-PAGE were prepared by addition of lysis buffer (7 M urea, 
10% glycerol, 10 mM Tris-HCl (pH 6.8), 1% sodium dodecyl sulphate (SDS), 
5 mM dithiothreitol (DTT), 0.5 mM phenylmethyl sulfonyl fluoride (PMSF) 
with 1 mg/1 aprotinin, pepstatin and leupeptin) and pipetted using a 20-gauge 
0.9mm needle with a 2ml syringe. The sample is then spun down and the 
supernatant stored at -20“C. SDS-PAGE was conducted using the NuPAGE 
precast gel system (Invitrogen) and specifically 10% Bis-Tris Gels run with 
MOPS buffer (Invitrogen). Lysates were diluted 1:1 with loading buffer (2% 
SDS, 0.5M Tris pH6.8, 25% glycerol, bromophenol blue and 1% 
mercaptoethanol). Samples were loaded in each well and run for Ihr at 180V.
Following SDS-PAGE, proteins were transferred to a nitrocellulose membrane 
(Hybond ECL; Amersham Biosciences) at 60 V for 1 hr in a Transblot cell 
(Biorad) in transfer buffer (25mM Tris, 192mM Glycine, 20% Methanol). 
Ponceau S solution (Sigma) is used to confirm transfer before blocking in 
PBS/Tween (PBS + 0.1% Tween 20) containing 5% milk powder either for 1 
hr at RT or overnight at 4°C. Membranes are then incubated at RT for Ihr with 
1° antibody in PBS/Tween + 5% milk. After 3 washes in PBS/Tween 
membranes were then incubated with a HRP conjugated 2° antibody in 
PBS/Tween + 5% milk. After a further 3 washes with PBS/Tween, bound 
antibody is visualised using ECL chemiluminescent detection kits (Amersham 
Biosciences) for 1 min at RT, followed by exposure to film (Hyperfilm; 
Amersham Biosciences). S100A8 was detected using antibodies (Ab) NH9 
(1:2000, CRUK antibody service) and Calgranulin A (1:20(X); Santa Cruz) 
followed by anti-rabbit HRP (1:7000; Dako Cytomation) or anti-goat HRP 
(1:7000; Dako cytomation). Each polyclonal antibody was compared to 
control species serum. S100A9 was detected using monoclonal antibody 
(mAb) 2B10 (1:2000; CRUK antibody service) followed by anti-rat HRP 
(1:7000; Southern Biotechnology). 2B10 was compared with control IgG2a
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mAb.
2.2.5 2.2.5 Immunohistochemistry
For immunohistochemistry, samples were fixed in neutral buffered formalin 
(NBF; 10% formalin, 45mM Na^HPO^, 29mM NaH^PO^.H^O, pH7) for 24 hr 
before being transferred to 70% ethanol solution. Samples were then 
embedded in paraffin before cutting. Sections of 8 pm were cut from fixed, 
embedded tissue blocks and placed on glass slides. Sections are dewaxed 
using xylene and hydrated using a succession of 100% ethanol, 70% ethanol 
and DDW steps. Endogenous peroxidase is blocked before sections undergo 
antigen retrieval methods (10 mins in lO'^ C citrate buffer, 10 mins in 1 mg/ml 
trypsin or no treatment). Sections are cooled for 20 mins and then placed in 
PBS buffer. Sections are then blocked using normal serum. Primary antibody 
was applied for Ihr followed by 3 washes (all washes in PBS). Secondary 
antibody is applied for 45 mins followed by 3 washes. Sections are then 
treated with avidin-biotin complex (ABC) reagent (Vector) for 30 mins 
followed by 3 washes. Sections are stained with 3,3’-diaminobenzidine (DAB) 
stain for approx 1-2 mins and then soaked in DDW to prevent further DAB 
action. Slides were counterstained in Harris’ haematoxylin solution for 3 mins 
followed by dehydration using a sequence of DDW, 70% EtOH and 100% 
EtOH steps. Sections are rinsed in xylene and coverslips applied using 
mounting solution. S100A8 was detected using mAb 6A4 (1:50; CRUK), 
S100A9 using mAb 2B10 (1:50; CRUK), macrophages using mAb F4/80 
(1:50 Serotec) and neutrophils and monocytes using 7/4 (1:50; Caltag 
Medsystems). Secondary Ab used was anti-rat biotinylated (1:400; Vector) for 
mAbs 6A4, 2B10, F4/80 and 7/4. mAbs were compared with appropriate 
control IgG isotype mAb.
2.2.6 2.2.6 Flow cytometry
1x10® cells in 20pl were placed in each well. Cells were fixed for 15 mins
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using FACS fix (2% PFA in PBS). Cells were then washed 3 times in FACS 
wash (PBS containing 0.2% BSA) before resuspension in O.IM Glycine 
solution for 10 mins. A further 3 washes were performed before cells were 
permeabilised and blocked by incubation in lOOpil saponin buffer (PBS 
containing 0.5% saponin and 0.5% BSA) with 1 % normal serum for 30mins, 
lOOp.1 of saponin buffer with T antibody was added and incubated for an 
additional 45 mins (mAbs 6A4 and 2B10 (CRUK), Abs calgranulin A (Santa- 
Cruz), and NH9 (CRUK) were all used at 1:100). Cells were washed 3 times 
in saponin buffer before incubation with 2° antibody in saponin buffer for Ihr 
(secondary Ab for mAbs 6A4 was goat-anti rat FITC conjugated (Jackson 
Immmunoresearch), for calgranulin A, rabbit anti-goat FITC conjugated 
(Sigma), and for NH9 goat anti rabbit FITC conjugated (Sigma) were all used 
at 1:400). Finally cells were washed 3 times in saponin buffer before 
resuspension in FACS fix solution ready for analysis. Cells were analysed 
using a FACScalibur machine (BD biosciences)
2.2.7 2.2.7 In situ hybridisation
In situ hybridisation in this thesis was conducted by CRUK in situ 
hybridisation service. For in situ hybridisation samples were fixed in neutral 
buffered formalin (NBF; 10% formalin, 45mM Na^HPO^, 29mM 
NaH2P0 4 .H2 0 , pH7) for 24 hr before being transferred to 70% ethanol 
solution. Samples were then embedded in paraffin. Localisation of S100A8 
and S100A9 mRNA was shown by in situ hybridisation. Complementary 
antisense mRNA probes for the full-length cDNA sequences of S100A8 and 
S100A9 were labelled with 35S-UTP (800Ci/mM; Amersham). All in situ 
hybridisation was conducted on 4p,m serial section of formalin fixed and 
paraffin embedded decidual tissues. The in situ method involves pre­
treatment, hybridisation, washing and dipping of slides in photographic 
emulsion for autoradiography and has been previously described (Senior 
1988). Autoradiography was carried out at 4°C for 3-10 days before 
developing and counterstained with Giemsa.
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2.2.8 2.2.8 RT-PCR
RNA was isolated using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. Once purified, RNA was eluted into 40p,l of 
RNAse free water. RNA was used to create cDNA using the First Strand 
cDNA Synthesis Kit (GE healthcare) according to manufacturers instructions. 
A random hexamer primer was provided in the kit and was used for all cDNA 
production. The cDNA produced was then used as a DNA template for PCR 
reactions as described in section 2.2.2.
2.2.9 2.2.9 Tissue sample generation
2.2.9.1 Murine bone marrow extraction
Murine femur and tibia bones were harvested and separated from soft tissues 
using a scalpel. Bone marrow was flushed into a Petri dish in HESS buffer 
containing 0.2% BSA using a needle and 1ml syringe. Bone marrow cells 
were suspended using repeated pipetting and passed through a cell filter into a 
15ml Bppendorf. Cells were pelleted at 15,000rpm for 5mins. The supernatant 
was discarded and the cells resuspended in Erylyse (0.144M NH4CL/0.017M 
Tris HCl, pH 7.0) for 3 mins to destroy erythrocytes. The cells were pelleted 
again and the supernatant discarded. Cells were resuspended in HESS buffer 
ready for use in western blot as illustrated in 2.2.4 or in flow cytometry as 
shown in 2,2.6 or in RT-PCR as shown in 2.2.8,
2.2.9 2 Decidua generation
Decidual tissue was generated from timed matings where vaginal plugs 
indicate a conception of midnight the evening before detection. The morning 
the plug is discovered is assigned E 0.5, Pregnant female mice of the correct 
embryonic stage were euthanised by carbon dioxide asphyxiation followed by 
cervical dislocation. The uterine horns were dissected and placed in PBS.
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Decidual tissue samples were extracted under a dissecting microscope and 
placed in PBS ready for the next stage. Decidual tissue was lysed for western 
blot as shown in 2.2.4 or prepared for RT-PCR as outlined in 2.2.8.
2.2.9.3 Yolk sac generation
Yolk sac samples were generated from timed matings. Mice were euthanised 
at the correct stage and uterine horns were dissected and individual embryo- 
decidua units isolated in PBS. Yolk sac tissue was isolated from decidua and 
embryo by physical manipulation under a dissecting microscope. Isolated yolk 
sac tissues were held in PBS before either lysis for western blot analysis as 
shown in 2.2.4, passed through a cell filter into HBSS for flow cytometry as 
shown in 2.2.6 or prepared for RT-PCR as shown in 2.2.8.
2,2.10 Embryo and oocyte generation
Embryos were generated from timed matings by the Transgenic Services at 
CRUK, Plugs confirmed embryo status at embryonic stage E 0.5. Mice were 
euthanised at appropriate embryonic stage and dissected using sterile 
technique. The uterus was trimmed free of fatty tissue and placed in a Petri 
dish. The uterine horns were isolated and flushed from both ends using 
DMEM with HEPES medium. Embryos in the Petri dish were then pooled into 
small drops of M16 media ready for the next stage including genotyping as 
detailed in 2.2.2, in vitro culture shown below in 2.2.10 and fixation for 
confocal microscopy as shown in 2.2.11. Oocytes were collected from the 
ovaries of mice primed with equine chorionic gonadotrophin (eCG) and held 
in M2 medium prior to fixation as shown in 2.2.11.
2.2.10.1 Embryo culture
Embryos were cultured in Petri dishes with M l6 medium, covered with 
mineral oil and placed in an incubator at 37”C with 5% CO2. Embryos were 
monitored at 10am and 5pm each day of culture and records kept.
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2.2.11 Embryo and oocyte staining for confocal staining
Embryo and confocal staining was conducted in collaboration with the 
laboratory of John Carroll (UCL). Isolated embryos and oocytes were 
transferred from M16 medium and fixed in 3.7% paraformaldehyde in PBS 
solution for 30 mins at RT before being washed in PBS and held in M16 
buffer before staining. Fixed embryos and oocytes were washed in PBS before 
permeabilsation in PBS + 0.25% Triton XlOO (Sigma) for 30 mins. After 
washing in PBS, embryos and oocytes were blocked using PBS + 2% BSA 
along with an appropriate normal serum for 2 hrs. Embryos were then washed 
before incubation with PBS and r  antibody 1:100 at 4°C overnight 
(Calgranulin A, NH9 or GM-130; each at 1:100). Samples were then washed 3 
times in PBS before incubation with 2” antibody for Ihr at 37'^C (Alexa Fluor 
488 rabbit anti-goat (Sigma) for calgranulin A, Alexa Fluor 568 goat anti-rabbit 
(Sigma) for GM-130 and Alexa Fluor 488 goat anti-rabbit (Sigma) for NH9 
each at 1:400). After washing in PBS, all samples were counterstained with 
5p,g/ml Hoechst 33342 (Invitrogen) for 10 mins. Embryos and oocytes were 
placed in PBS ready for imaging. All aqueous stages with embryo and oocyte 
staining took place under mineral oil (Sigma) to prevent excessive evaporation 
of solutions. Confocal images were acquired using an LSM510meta confocal 
microscope (Carl Zeiss Microimaging, Inc) and analysed using LSM software. 
All positive samples were corrected by normalisation against control sample 
background levels.
2.2.12 ES cell culture and differentiation
ES cell culture was performed in the laboratory of Valerie Kouskoff (Paterson 
Institute, Manchester). ES cells were cultured on irradiated embryonic feeder 
cells (EEC) in Dulbecco's Modified Eagle Medium (DMEM) with 15% foetal 
calf serum (ECS), streptomycin, penicillin, leukaemia inhibitory factor (LIE; 
1% conditioned medium) and 1.5x10^ M monothioglycerol (MTG; Sigma) 
(Kouskoff 05, Fehling 03). 48 hours prior to differentiation, ES cells were 
transferred to gelatine coated plates in the same media. For the generation of
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embryoid bodies (EBs), ES cells were trypsinized and plated at various 
densities in differentiation cultures. To generate erythrocyte lineages, EBs 
cells were placed in 60 mm Petri grade dishes in IMDM supplemented with 
15% PCS, transferrin (200 //g/ml), 2 mM L-glutamine (Gibco/BRL), 0.5 mM 
ascorbic acid (Sigma), and 4.5x10 M MTG (Sigma). Cells were cultured at a 
density of 4xl0^/ml in ultra low attachment 24-well plates (Costar). Cells were 
cultured in a humidified chamber in a 5% COj/air mixture at 37°C (Fehling, 
Lacaud et al. 2003; Kouskoff, Lacaud et al. 2005). Cells at days 0,1,4,5 and 6 
of culture were either lysed using western blot lysis protocol as shown in 2.2.4 
or prepared for RT-PCR as shown in 2.2.
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CHAPTER 3 
3 The S100A8 null mouse phenotype
3.1 Introduction
The SI00 protein family members, S100A8 and S100A9, are abundant in 
adult myeloid cells where they form a stable heterodimer (Edgeworth, Gorman 
et al. 1991). Bone marrow is a good source of myeloid cells and is a good 
source of positive control cells for S100A8 and S100A9 protein. Many 
functions have been proposed for the two SlOO proteins especially in 
neutrophils where the heterodimer forms 45% of cytosolic protein 
(Edgeworth, Gorman et al. 1991). To investigate the function of S100A8 and 
S100A9 mouse models were generated lacking either S100A8 or S100A9. 
S100A9 null mice were viable and showed no gross abnormalities (Hobbs, 
May et al. 2003). It was of interest that S100A9 null myeloid cells lacked 
S100A8 protein but not S100A8 mRNA (Hobbs, May et al. 2003). 
Throughout this thesis the S100A9 null mouse is frequently used as a model 
for studying the S100A8 null phenotype. There are distinct advantages to this 
approach the most important being that in wildtype mice circulating myeloid 
cells contain abundant amounts of S100A8 and S100A9 heterodimer. This will 
inevitably contaminate tissue samples for techniques like western blot and RT- 
PCR amongst others. In the S1(X)A9 null mouse circulating myeloid cells do 
not stably express S100A9 or S100A8 protein. This allows tissue samples 
from this model to be assessed for S100A8 protein expression free from 
myeloid cell contamination. As the S100A9 null mouse is viable and grossly 
normal it is assumed in these studies that this S100A8 and S100A9 protein 
expression is the only significant difference with wildtype.
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The S100A9 null mouse was viable and exhibited no gross abnormalities so 
expectations were similar for the S100A8 null mouse. However, the S100A8 
null mouse was reported as embryonic lethal at E 9.0 (Passey, Williams et al. 
1999). The report states that this is due to lack of S100A8 expression in a 
subset of infiltrating cells from the ectoplacental cone at E 6.5-7.S. There were 
inconsistencies both within the report and with unpublished data from our own 
lab, which have not been clarified or expanded upon since this publication. 
Passey et al 1999 proposed a cause of lethality and time of lethality that were 
separated by almost 2 days of development. Only speculation is offered as to 
the function of the expression or why it takes 2 days before the S100A8 null 
embryos are lost. The expression of S100A8 mRNA is shown only at limited 
stages (E 7.5 -  E 8.5) and the expression of S100A8 protein is not shown. This 
was a key issue as S100A9 null myeloid cells were positive for S100A8 
mRNA but not S100A8 protein suggesting S100A8 protein needs stabilisation 
in vivo. It was also not stated which strain of mouse was used in the Passey et 
al 1999 report. This became clear only through personal communication. Our 
initial characterisation experiments agreed that the S100A8 null mouse was 
embryonic lethal. It was shown with Y-chromosome staining of male embryos 
that S100A8 mRNA expression in the decidua is of maternal origin and not 
foetal (Hobbs, May et al. 2003). This is an important observation as no 
embryonic lethal phenotype can be attributed to maternal expression. We 
could also not find any S100A8 null embryos after implantation (dissected 
embryos at E 7.5, 8.5 and 9.5 genotyped by M.Mathies).
S100A8 null lethality caused solely by cells from the ectoplacental cone 
region should be overcome through a technique called tetraploid aggregation. 
In this technique a chimera is formed between an early embryo and embryonic 
stem cells. The embryonic stem cells give rise to all trophoblast tissues and 
extra-embryonic tissues. If the cells causing a null lethality are of trophoblast 
or extra-embryonic origin then the tetraploid aggregation will rescue the 
mouse. We conducted a tetraploid aggregation experiment with S100A8 
heterozygous crosses to generate blastocysts coupled with wildtype embryonic 
stem cells. We genotyped the resultant mice bom and found that no S100A8 
null mice were bom. This showed that the S100A8 null lethality could
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not be, exclusively, caused by cells of trophoblast or extra-embryonic origin. 
It is still possible that S100A8 could have a non-redundant function in these 
cells but it would have also to be involved in foetal tissues.
The different phenotypes displayed by the S100A9 and S100A8 null mice 
have been highlighted. The loss of S100A9 in myeloid cells prevents stable 
S100A8 protein expression. If S100A9 is always required to stabilise S100A8 
then the S100A8 null mouse should have an identical phenotype to the 
S100A9 null mouse. The S100A8 null phenotype shows that there must be at 
least one situation in mouse development where S100A8 protein is expressed 
and stable, independently of S100A9 protein. This suggests different roles for 
S100A8 and S100A9 in development with S100A8 performing a critical role.
The inconsistencies between our experiments and the reported phenotype lead 
to the conclusion that a more thorough examination of the model would yield 
more information on the S100A8 null phenotype. It was believed that the role 
of S100A8 could be more complex than portrayed in Passey et al 1999 and 
could yield more details on the function of S100A8 and S100A9 in myeloid 
cells and epithelia. The S100A8 null mouse is the most severe and only lethal 
phenotype reported to date for an SlOO family protein deletion. It is of 
considerable interest to know what the function of SlOOA8 in development is.
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3.2 Results
3.2.1 No S100A8 null embryos are found postimplantation
The Passey et al 1999 paper detailing the S100A8 null lethal phenotype 
presents evidence of genotyping of dissected embryos from S100A8 
heterozygous crosses. A heterozygous cross should yield a 1:2:1 ratio of 
wildtype, heterozygous and null embryos respectively. The S100A8 null lethal 
phenotype should present as a loss of null embryos with no loss of wildtype or 
heterozygous embryos. The embryos were digested and using PCR the 
S100A8 genotype assessed. The evidence presented shows normal levels of 
S100A8 wildtype, heterozygous and null embryos at E 6.5-7.5. At E 8.5 there 
were lower levels than expected of SlOOA8 null embryos. At E 9.5 no S100A8 
null embryos could be detected and it was concluded that S100A8 null 
embryos terminate at approximately E 7.5-8.5 although it takes a further 2 
days for all embryos to resorb. This evidence was at odds with unpublished 
data from M.Mathies in our lab showing that no S100A8 null embryos could 
be detected postimplantation. It was decided to reassess the S100A8 
heterozygous cross genotyping to determine whether there really was a 
discrepancy between the two sets of data. S100A9 heterozygous crosses were 
also analysed for S100A9 wildtype, heterozygous and null embryos. The 
S100A9 null phenotype is not embryonic lethal and so no loss of S100A9 null 
embryos should be seen. This is an elegant control for the genotyping of 
S100A8 heterozygous crosses because the S100A9 heterozygous control 
crosses will detect whether all possible genotypes can be cleanly determined. 
The results are shown in as shown in fig 3.1 and include highlighted data 
contributed by M.Mathies.
Embryos from S100A8 and S100A9 heterozygous crosses were dissected at E
7.0 and digested. The genotypes were analysed using the appropriate primers 
for S100A8 and S100A9. No S100A8 null embryos were found showing that 
the S100A8 lethality occurs prior to E 7.0 in our model. The ratio of S100A8
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Embryos Controls
KO band 
WTband
B
Embryos Controls
WT band
KO band
Strain Stage + /+ + /- Total
S100A8 E8.5 3 6 0 9 *
S100A8* E7.5 9 22 0 31*
S100A8 E7.0 5 10 0 15
S100A9 E7.0 4 3 5 12
Fig 3.1 G enotyping of post-implantation em bryos generated by 
S100A8 heterozygous crosses. PCR of disected embryos looking at the  
S100A8 genotypes from S100A8 heterozygous crosses (A) and the S100A9 
genotypes from S100A9 heterozygous crosses (B) with genotyping results 
shown in table format (C).* = These data contributed by M.Mathies. #= 
Cross showed significant deviation from expected genotype ratios p < 0.01
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wildtype, heterozygous and null embryos was approximately 1:3:0 
respectively. Confirmation of this result is that all 3 possible S100A9 embryo 
genotypes are clearly detected at the same embryonic stage, which discounts 
the possibility of maternal cell contamination of the embryo samples. This 
confirms the earlier observations of M.Mathies and conflict with the 
observations reported in Passey et al 1999. The increase in the relative 
proportion of heterozygotes in the S100A8 heterozygous crosses was noted 
although its significance is unknown. The S100A9 heterozygous crosses 
showed that S100A9 null embryos can be detected in this system.
3.2.2 Genotyping of S100A8 heterozygous crosses shows 
reduced S100A8 null blastocysts at E 4.5
Our previous experiment showed that our results for the S100A8 null 
phenotype differed from the reported phenotype in Passey et al 1999, In that 
report the level of S100A8 null blastocysts was shown as normal. Our data 
indicate that the S100A8 null lethality could occur earlier in development than 
previously thought. Attempts were made to genotype embryos earlier than E
6.5 but this proved to be technically too difficult and so it was decided to 
genotype S100A8 heterozygous crosses at the blastocyst stage as shown in fig 
3.2. Genotyping the blastocysts would show whether S100A8 null embryos 
were present at normal levels prior to implantation. It would also provide 
another comparison between our observations and the reported S100A8 null 
phenotype,
E 4.5 blastocysts were generated from S100A8 heterozygous crosses, digested
and genotyped using the 2-step PCR protocol detailed in chapter 2, The level
of S100A8 null blastocysts was significantly reduced but they were seen. The
results show S100A8 null blastocysts at approx 80% of expected levels from
Mendelian ratios. This result was the first time S100A8 null embryos had been
seen in our mouse model. The data indicate that the majority of S100A8 null
embryos are lost by E 4.5 and suggests that the point of lethality for the
S100A8 null mouse is earlier than E 4.5. The small number of S100A8
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Blastocysts Controls
KO band 
WT band
B
G enotype +/+ +/- -/- Total
E4.5*^ 11 28 2 41
Fig 3.2 PCR of blastocysts generated from S100A8 heterozygous 
crosses. PCR genotyping E 4.5 blastocysts generated from S100A8 hetero­
zygous crosses (A) with the results in table format (B). Cross showed signifi­
cant deviation from expected genotype ratios p < 0.01.
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null embryos that survive to E 4.5 are of interest although it must be noted that 
the previous figure showed that none of the S100A8 null embryos seem to 
survive implantation.
3.2.3 Sequencing of PCR bands confirms the S100A8 null 
embryos
The evidence from our genotyping studies suggests that there is a discrepancy 
between our observations and the reported phenotype of the S100A8 null 
phenotype. It is important to verify that the differences in the observations are 
caused by the S100A8 gene and not due to problems with the genotyping 
evidence or with mouse strain effects. There was a concern that the bands seen 
in blastocyst PCR might not correlate with S100A8 null bands. Sequencing of 
the PCR bands would confirm that we are indeed looking at the effects of the 
S100A8 gene. This is of help especially where we have used multiple step 
PCR processes. The S100A8 gene silencing produced a null allele that is easy 
to distinguish due to the presence of a NEO cassette inserted into the second 
exon of the S100A8 gene. Sequencing of the S100A8 null bands from PCR 
gels should show the S100A8 gene sequence with a correctly inserted NEO 
cassette. The null band primers will produce a section of DNA with 468bp of 
S100A8 gene followed by the Neo cassette sequence. The results of 
sequencing are shown in fig 3.3.
S100A8 null bands were analysed from two previously genotyped E 4.5
S100A8 null embryos after the 2-step PCR protocol. The bands were
compared to the null band from known S100A8 heterozygous mouse tailsnip,
which is processed after the one step S100A8 PCR protocol. S100A8 null
PCR bands were cut from agarose gels, digested and sequenced. Sequencing
showed that the S100A8 null bands from both the blastocyst PCR bands were
identical to the null band from the control S100A8 heterozygous tail snip
sample. The sequenced bands show the correct part of the S100A8 gene along
with the correctly positioned NEO cassette site from homologous
recombination used in gene silencing. Homology is not 100% but this is
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Fig 3.3 Sequencing of S100A8 null blastocyst PCR bands. Sequencing 
results of PCR bands are shown (A) with S100A8 null blastocyst bands (K1 
and K2) compared with null bands from S100A8 heterozygous tailsnip 
bands (K4) Full homology is shown (orange), partial homology (yellow) 
transcription start site (blue), Neo insert (green) and Neo primer (red). 
Alleles of S100A8 are represented (B) with primer combinations shown for 
wildtype and null S100A8 bands.
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considered normal within the sequencing technique used with the shortest and 
longest sequencing products (beginning and end of the sequence) showing 
lowest homology This result confirmed the blastocyst genotyping in the 
previous figure correctly showed the S100A8 heterozygous cross results.
3.2.4 CD-I backcrossed S100A8 heterozygous crosses show 
identical patterns of genotyping at £  4.5
The mouse strain under study can have a large effect on a lethal phenotype 
due to varied indirect effects of many genes. It is often an unpredictable cause 
of discrepancies in lethal phenotype reports. It was important to address the 
issue of mouse strain to discount the possibility that this is the cause of any 
discrepancy in reported phenotypes. Our C57BL/6J mice were backcrossed 
initially to the SV129 strain to check whether the S100A8 null phenotype 
presented on both strains. We found that S100A8 null mice are not bom to 
SV129 heterozygous crosses (data not shown). This confirmed to us that strain 
was not an issue in the lethality of the phenotype but did not address the 
timing of the S100A8 lethal phenotype. In this study we are seeking to address 
the issue of discrepancies in our observations and those previously reported 
and to do so we must cross our mice onto the same background used in Passey 
et al 1999. Our C57BL/6J mice were backcrossed against the CD-I 
background used in the S100A8 null phenotype report (information from 
personal communication). The CD-I strain is also a highly outbred mouse line 
and it was hoped that such a backcross would show whether genetic 
background was a factor in the S100A8 null phenotype. It would be expected 
that crossing our C57B1/6J mice onto the CD-I line will either confirm the 
findings in our mouse strain or show the same result seen in Passey et al 1999 
- normal levels of SI00A8 null blastocysts. The blastocyst stage was chosen, 
as there was a distinct difference between our data and the reported S100A8 
null lethality at this stage. It was a possibility that the CD-I backcross could 
give a novel third phenotype and therefore the blastocyst stage was deemed 
early enough to measure any potential outcome. The results are shown in fig 
3.4.
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Blastocysts Controls
KO band 
WT band
B
Genotype -H/+ +/- -/- Total
E4.5'* 11 33 1 45
Fig 3.4 PCR of blastocysts generated from CD-I backcrossed S100A8 hetero­
zygous crosses. CD-I backcrossed blastocyst genotypes from S100A8 heterozy­
gous crosses were analysed (A) and the results presented In table format (B). Cross 
showed significant deviation from expected genotype ratios p < 0.01
96
Chapter 3: The S100A8 null mouse phenotype
CD-I backcrossed S100A8 heterozygous crosses produced blastocysts that 
were flushed, digested and analysed by 2-step PCR. The cross should see 
Mendelian ratios of 1:2:1 for S100A8 wildtype, heterozygous and null 
embryos. Instead we see a 90% reduction in S100A8 null embryos and the 
ratio is closer to 1:3:0. The result is approximately the same as the genotyping 
results in our C57BL/6J mice in that there is a significant loss of S100A8 null 
embryos. The data show that genetic background is not a factor in the S100A8 
null phenotype, as it seemed that highly outbred CD-I mice gave the same 
result for S100A8 as our C57BL/6J strain. It is further evidence that the 
S100A8 null lethal phenotype occurs prior to E 4.5. Another notable point is 
that in the CD-I strain as well as the C57BL/6J strain there is an increase in 
the levels of heterozygous embryos from the heterozygous crosses.
3.2.5 S100A8 mRNA expression occurs between E 7.5 and E 
14.5 in the maternal decidua.
It was reported in Passey et al 1999 that SI00AS mRNA expression is seen in 
embryonic cells infiltrating the maternal decidua from the ectoplacental cone 
at E 7.0. To explain the SI00AS null lethal phenotype the cells are proposed to 
have a non-redundant function. Conflicting evidence is presented as to the 
origin of the SI00AS mRNA expression in Passey at al 1999 and Hobbs et al 
2003, The former report states that the expression is embryonic while the later 
maintains that the expression is maternal. As the data and its interpretation are 
important in the analysis of the S100A8 genotype and in light of other 
discrepancies in our SI00AS null model it was decided to reassess this mRNA 
expression. Expression of SI00AS and S100A9 through this period could 
provide further evidence as to which tissue expresses S100A8 mRNA and 
whether this is indeed linked to the SIOOAS null phenotype. The expression 
pattern would be analysed from implantation through to birth. In order to 
investigate the expression of SIOOAS and S100A9 mRNA in development in 
situ hybridisation was used as shown in fig 3.5.
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Fig 3.5 SIOOAS and SIOOAS expression in maternal decidua shown by 
in situ hybridisation. E 12.5 embryonic liver probed with SIOOAS (Al) and 
5100A9 (A2) mRNA probes as positve control for decidual expression of 
SIOOAS and SIOOAS (B) at E 6.5 (B1,2) 7.5 (B3,4) S.5 (B5,6) 10.5 (B7,S) 12.5 
(B9,10) and placenta at birth (B11,12). Embryonic tissues (E) and matrnal 
tissues (M) are highlighted. Dashed white lines - maternal-foetal boundary.
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In situ hybridisation was performed on sections of embryo and maternal 
decidua at E 6.5, 7.0, 8.5, 10.5, 11.5, 14.5 and placenta prior to birth. S100A8 
and S100A9 mRNA expression is probed using P32 radioactively labelled 
anti-sense probes for S100A8 and S100A9 mRNA. As a positive control 
known S100A8 and S100A9 mRNA expression is shown by E 12.5 embryonic 
liver expression consistent with previous reports (Lagasse and Weissman 
1992), No S100A8 mRNA expression can be seen at E 6.5 or E 7.5. S100A8 
expression in the decidua is more prolonged than previously thought with 
expression detected at E 8.5, 10.5, 12. E 14.5. Expression can be seen in 
decidual tissues, is extensive yet has clear boundaries. The pattern of 
expression shows that the cells expressing the S100A8 mRNA are most likely 
maternal due to the widespread nature of the expression and the fact that it 
stretches deep into the maternal decidua. The possibility of S100A8 mRNA 
expressing infiltrating cells seems unlikely although it could be masked by the 
widespread maternal expression. Expression of S100A9 mRNA is also seen in 
decidual tissues from E 8.5 through to E 14.5 although the expression is very 
restricted compared with S100A8 mRNA. Throughout this E 8.5-14.5 
timeframe a pronounced difference in expression of SI00A8 and S100A9 can 
be seen. As previously shown (Hobbs, May et al. 2003) S100A8 expression is 
more widespread and abundant in maternal decidua than S100A9 expression. 
This difference in S100A8 and S100A9 is true at all stages through to E 14.5. 
In placenta prior to birth S100A8 and S100A9 mRNA expression have a 
similar and less extensive pattern suggesting that the difference in expression 
in earlier stages no longer applies.
3.2.6 S100AS mRNA expression in maternal decidua is 
localised to vasculature
A detailed study of the S100A8 mRNA expression in maternal and embryonic
tissues is important to analyse. The expression of S100A8 mRNA has a
distinct boundary and appears to be in maternal decidual tissue. The maternal
foetal boundary is marked by the embryo derived trophoblast giant cells,
which are distinct in appearance and form a discrete layer, which can be
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used to determine embryonic and maternal tissues. To see whether expression 
of S100A8 mRNA is maternal, foetal or both detailed analysis was undertaken 
as shown in fig 3.6. Comparison of S100A8 and S100A9 mRNA expression 
will also show whether there is any overlap in expression in the decidua or 
whether SI00A8 mRNA is expressed differentially.
Expression of S100A8 mRNA is clearly observed in maternal decidual tissue 
and not foetal tissue. Analysis of the foetal maternal boundary, delineated by 
trophoblast giant cells, shows S100A8 expression on the maternal side. 
S100A8 mRNA expression is not seen in the trophoblast cell layer or any cells 
on the foetal side of this layer. S100A8 expression at all stages is on the 
maternal side of the trophoblast giant cell layer. Staining also shows that 
SI00AS expression is particularly strong around the vasculature in maternal 
decidua. This suggests possible endothelial cell expression or a sub- 
endothelial cell type. It should be noted though that in a highly vascular tissue 
like decidua most cells are within proximity of the vasculature. In addition to 
this the vast majority of cells in the decidua are positive for SI00AS mRNA 
showing that the decidual cells themselves are positive. Overlap analysis of 
SI00A8 and S100A9 mRNA expression clearly shows that there is a 
population of both S100A8 and S100A9 mRNA expressing cells in the 
decidua. This expression is close to the trophoblast giant cell layer and does 
not extend deeply into the maternal decidua. This population could be 
neutrophils, which have been shown to localise to the foetal maternal 
boundary to clear apoptotic cells (McMaster, Dey et al. 1993). This S100A8 
and S100A9 mRNA expressing population is small compared to the S100A8 
only expressing maternal decidual cells. S100A8 mRNA expression extends 
deeply into the maternal decidua and it seems clear that this is a different 
population. The data show that there are two S100A8 mRNA expressing 
populations in the maternal decidua.
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Fig 3.6 Expression of S100A8 mRNA is confined to maternal decidua 
and is more extensive than expression of S100A9 mRNA. Maternal 
S100A8 mRNA expression has a distinct boundary in developm ent shown 
here at E 12.5 (Al), which is delineated by the Trophoblast Giant cells of the 
embryo (A2). Within the decidual tissue staining is highly localised to  the 
vasculature (A3).Comparison of S100A8 and S100A9 expression a t E 8.5 
(B1,2) shows overlap of S100A8 and S100A9 expression at the  trophoblast 
giant cell boundary (B3). Expression of S100A8 alone is seen throughout the 
surrounding décidai tissue. M- maternal E-embryonic. Green- S100A8 Red- 
S100A9
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3.2.7 RT-PCR in WT and S100A9 null decidua confirms 
S100A8 expression in decidual tissues
Expression of S100A8 and S100A9 by in situ hybridisation must be confirmed 
by using RT-PCR of the tissues to see whether the S100A8 and S100A9 PCR 
bands agree with the staining and timing of S100A8 and S100A9 mRNA 
expression. S100A8 expression can be analysed in S100A9 null decidua to 
show that S100A9 mRNA expression is not necessary for S100A8 mRNA 
expression. It is known in S100A9 null myeloid cells that S100A8 mRNA 
expression is not affected so it is of interest if this is the case in maternal 
decidual tissues. The results of this experiment are shown in fig 3.7.
Maternal decidual tissue at stages E 8.5, 10.5 and 12.5 was extracted from 
wildtype and S100A9 null implantation sites, digested and analysed using RT- 
PCR for expression of S100A8 and S100A9 mRNA. Digested wildtype bone 
marrow cells were used as a positive control for both S100A8 and S100A9 
mRNA expression. Wildtype decidual tissue was positive at all stages for 
S100A8 and S100A9 mRNA expression, which reflects the in situ mRNA 
expression data. S100A9 null decidual tissue samples are all positive for 
S100A8 mRNA expression. As expected all S100A9 null decidual samples 
were negative for S100A9 mRNA expression. The RT-PCR result does not 
show relative amounts of mRNA expression, which is more clearly shown by 
in situ staining in fig 3.5.
3.2.8 Neutrophils are the small S100A8 and S100A9 mRNA 
expressing population in maternal decidua.
Expression of high levels of S100A8 and S100A9 mRNA is a distinct marker 
for neutrophils. It was highly likely that the S100A8 and S100A9 mRNA 
expressing population in the maternal decidua were neutrophils. The 
expression patterns were also consistent with previous reports of neutrophil
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Fig 3.7 RT-PCR of maternai decidual tissue. RT-PCR of decidual tissue 
from wildtype and SI 00A9 null mice at E 8.5,10.5 and 12.5. Expression of 
S100A8 mRNA (A) and S100A9 mRNA (B) are shown.
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localisation in the decidua (McMaster, Dey et al. 1993). In order to verify this 
we used immunohistochemistry to examine the maternal decidua for 
neutrophil markers. Antibody 7/4 was used as a neutrophil marker known to 
stain myeloid lineage leukocytes, including monocytes and neutrophils as 
shown in fig 3.8, Patterns of 7/4 staining similar to the S100A8 and S100A9 
mRNA population in the maternal decidua should confirm the population as 
neutrophils.
Tissue samples were taken at E 7.0, 8.5, 10.5 11.0, 12.5 and 14.5 and prepared 
for immunohistochemistry. 7/4 was used to immunostain neutrophils. The 
results showed a population of 7/4 positive cells concentrated close to the 
matemal/foetal interface at the trophoblast giant cell layer at all stages. The 
pattern is extremely similar to the SI00AS and S100A9 mRNA expressing 
population shown in fig 3.6. The pattern of expression is not extensive in the 
maternal decidua and does not show similarity to the S100A8 mRNA only 
expressing population.
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Fig 3.8 7/4  staining in maternal decidua. Immunohistochemistry showing 
7/4 staining at E 7.5 (A 1-3) E 8.5 (B1) E 10.5 (B3) E 12.5 (B5). Controls for the 
stages are also shown (B2,4,6). 7/4 staining using 7/4 Ab followed by anti­
rabbit secondary. Positive 7/4 staining shown in brown. M - maternal, E - 
embryo. Dashed white line -foetal-maternal interface. Scale bar = 20 pM.
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3.3 Discussion
3.3,1 The S100A8 null lethality
The data presented in this chapter has shown significant differences from the 
report of Passey et al 1999. In this study S100A8 null embryos were not 
detected by PCR postimplantation. The technique of genotyping embryos was 
validated using S100A9 heterozygous crosses. This showed that S100A8 null 
embryos could be detected from heterozygous crosses if they were present and 
that indeed the S100A8 null embryos were lost postimplantation. It was then 
shown that S100A8 null embryos are significantly reduced at the E 4.5 
preimplantation blastocyst stage. Backcrossing against the CD-I strain showed 
similar results with significant loss of S100A8 null blastocysts at E 4.5. The 
validity of the genotyping of null embryos and blastocysts was confirmed by 
sequencing of S100A8 null allele bands compared to known controls.
This data brings into question the S100A8 null lethal phenotype reported in 
Passey et al 1999. The evidence presented shows that the S100A8 null lethal 
phenotype could occur prior to implantation, far earlier than previously 
thought. It is still possible that differences in mouse strain or the creation of 
the S100A8 null mouse could account for the discrepancies between our 
model and the report. It is also possible that there are multiple distinct 
functions for S100A8 in development, which could cause lethality at different 
stages in different mouse models. If this were the case differences in mouse 
background could account for different stages of lethality in separate models. 
If this is not the case then the phenotype of the S100A8 null mouse could be 
very different from the published report and shed new light on SI00A8 
function in development.
Embryonic lethality prior to implantation in the S100A8 null mouse would be 
of considerable interest and would provide vital insight into the function of the 
protein. Embryonic development prior to implantation is a strictly controlled
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sequence of events, which will involve distinct developmental pathways and 
control mechanisms. It can be postulated that S100A8 will be involved in 
these developmental processes. It could be that S100A8 null embryos will 
present a distinct preimplantation phenotype, which can be connected to a 
known developmental process. However, the nature of the genotyping results 
in fig 3.2 and fig 3.4 suggest that this may not be the case. The small number 
of S100A8 null embryos that survive to blastocysts at E 4.5 in both C57BL/6J 
and CD-I crosses implies that the S100A8 null embryos do not die 
immediately upon encountering the S100A8 dependent function but may die 
slowly thereafter. It might be possible to observe either an abrupt loss or slow 
death of S100A8 null embryos by culturing embryos in vitro. Such 
observations could also indicate the exact timing of S100A8 null lethality.
3.3.2 Maternal decidual expression of S100A8 mRNA
It has been shown that there is extensive expression of S100A8 mRNA in 
maternal decidua between E 7,5 and E 14.5 occurring in two distinct 
populations. The data was consistent with previous reports but showed a more 
prolonged expression of S100A8 mRNA than previously thought. One 
population of S100A8 and S100A9 mRNA expressing cells is in all 
probability neutrophils. The expression of both S100A8 and S100A9 was a 
distinct marker for neutrophils and the vascular area close to the trophoblast 
giant cell layer should contain circulating neutrophils. It is known that 
neutrophils are restricted to the foetal maternal boundary where necrotic cells 
need clearing (McMaster, Dey et al. 1993; Femekom and Kruse 2005). The 
further confirmation of positive 7/4 staining reinforces the identity of this 
population. The pattern of S100A8 mRNA, S100A9 mRNA and 7/4 is highly 
correlated in this population The second population of S100A8 mRNA-only 
expressing cells is a population resident in the maternal decidua throughout 
development to E 14,5 and certainly includes mesometrial decidual cells. It is 
not clear if this population is present in virgin endometrium or whether it is a 
population resulting from the decidual reaction postimplantation. At 7.0 the 
mesometrium begins to differentiate (Abrahamsohn and Zorn 1993) and from
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the literature it seems certain that expression of S100A8 mRNA occurs in 
differentiating mesometrium. Whether it is a resident cell type or a product of 
differentiation then it is of interest to discover what the trigger for S100A8 
mRNA expression is. The implantation of an embryo into maternal decidua is 
a specialised immune reaction in that the embryo is genetically distinct from 
the mother. With this in mind the cells expressing S100A8 mRNA could 
include immune cells responding to this specialised inflammatory situation. If 
this is the case the timeframe of S100A8 mRNA expression could reflect the 
profile of immune cell recruitment to the decidua. It is of interest why S100A8 
expression only occurs 48 hours after implantation although this is possibly 
due to differentiation within the decidua.
The pattern of S100A8 mRNA expression did not extend to the embryonic 
contribution to the placenta. Specifically no S100A8 mRNA was seen at E 6.5 
or E 7.0 as was reported in Passey et al 1999. Embryonic S100A8 mRNA 
expression is an essential requirement to demonstrate an embryonic lethal 
phenotype for the S100A8 null embryo yet was not seen in this 
postimplantation study. Our finding was supported by the lack of S100A8 null 
embryos identified in postimplantation studies in fig 3.1. The possibility of 
embryonic expression postimplantation in wildtype cannot conclusively be 
ruled out but the evidence of widespread and continued S100A8 mRNA 
expression in the maternal tissues suggests that there is clearly a maternal 
expression and casts doubt upon any embryonic expression. With such high 
S100A8 mRNA expression in the maternal decidua it is possible to misread a 
possible embryonic expression, which may have occurred in Passey et al 1999. 
The report of infiltrating cells expressing S100A8 mRNA was further 
undermined by the existence of 7/4 staining cells close to the EPC at E 7.0. 7/4 
expressing neutrophils or monocytes both express S100A8 mRNA and could 
have caused confusion and incorrectly attributed to “infiltrating” embryonic 
cells.
Existence of a cell type that expresses S100A8 mRNA but not S100A9 mRNA 
is of interest for two reasons. It may point to the existence of an in vivo 
situation where S100A8 protein is expressed that is not stabilised by
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S100A9 protein. In the S100A9 null myeloid cells S100A8 protein is not 
stable without S100A9 protein. In has been widely shown that S100A8 can 
form stable homodimers and multimers in vitro under many conditions. Many 
roles have been assigned to such S100A8 complexes in vitro including anti­
oxidant activity (Harrison, Raftery et al. 1999) and chemoattraction 
(Lackmann, Cornish et al. 1992). All of this work has been conducted in vitro 
and as yet few in vivo studies have supported an in vivo role for S100A8 
homodimers. It has been proposed that S100A8 homodimers are not 
energetically favourable as they lack appropriate complementary residues in 
the dimérisation plane (Hunter and Chazin 1998). A cell type that expresses 
S100A8 mRNA independently of S100A9 mRNA could therefore provide an 
in vivo source of S100A8 multimers. It is also possible that SI00A8 can bind 
an as yet unidentified alternative binding partner. A putative S100A8 partner 
could provide insight into the role of S100A8 in the maternal decidua or 
indicate a specialised role distinct from the function of the S100A8/S100A9 
heterodimer in myeloid cells. Our data show a potential role for S100A8 in 
maternal decidual tissue postimplantation. This role is not clear but it is clear 
that any role is highly unlikely to explain the S100A8 null phenotype.
3.3.3 Conclusions and further study
Two general conclusions can be reached from the data presented in this 
chapter. The SI00AS null phenotype is more complex than originally thought. 
There is evidence of a role in development for S100A8 between E 7.5 and E
14.5 but this is restricted to the maternal decidua. This role is of interest 
despite being highly unlikely to be linked to the S100A8 null phenotype. This 
role is analysed in chapter 4. There is also evidence that the S100A8 null 
phenotype is a preimplantation lethality. This could show insight to the 
function of SI00A8 in development and will be addressed in chapter 5.
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CHAPTER 4 
4 S100A8 in postimplantation development
4.1 Introduction
Having established grounds for re-examining the S100A8 null phenotype, two 
avenues of investigation were possible. One strand of questioning was whether 
S100A8 has a role in postimplantation development. There is undisputable 
evidence of S100A8 mRNA expression in maternal decidua, where the 
function is unknown. S100A8 may have a redundant role in postimplantation 
development and a non-redundant role in preimplantation development. It may 
be that any postimplantation role for S100A8 will provide evidence and 
insight into a preimplantation role for S100A8. This chapter examines the 
postimplantation role of S100A8 and seeks to answer the questions as to its 
function in maternal and embryonic tissues.
Many of the tissues and cells covered in this chapter are introduced in chapter 
1 with a summary presented here. Haematopoiesis in the developing embryo 
begins in the yolk sac at E 7.0 with the generation of primitive erythrocytes in 
the yolk sac blood islands (Moore and Metcalf 1970). By E 8.5 the primitive 
myeloerythroid precursors arise that develop into definitive erythrocytes and 
macrophages (Cumano, Dieterlen-Lievre et al. 1996). Placenta is also believed 
to be an active haematopoietic tissue at E 9.0 (Alvarez-Silva, Belo- 
Diabangouaya et al. 2003). At E 10.5 haematopoietic ES cells (HSCs) arise in 
the intra-embryonic aorta-gonad-mesonephros (AGM) region (Medvinsky, 
Samoylina et al. 1993). HSCs can also be seen at E 10.5 in the placenta and 
yolk sac although the origin and potency of these cells is unclear. 
Haematopoiesis develops through a series of migrations from initial
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haematopoietic tissues of yolk sac placenta and AGM to the foetal liver 
(Cumano and Godin 2007). Liver development begins in the definitive 
endoderm at E 8.5. Fibroblast growth factor (FGF) and bone morphogenic 
protein (BMP) signalling from nearby tissues induce hepatic gene expression 
in the ventral foregut wall (Jung, Zheng et al. 1999; Rossi, Dunn et al. 2001). 
The hepatic endodermal cells proliferate and, with the assistance of 
endothelial cells from the mesoderm, form a liver “bud”. The liver bud 
emerges from the developing gut tube and can be colonised by haematopoietic 
cells as early as E 9.5.
The colonising cells, primarily myeloerythrocyte precursors, arrive from the 
yolk sac as circulation begins. At E 11.5 HSCs can be seen in the foetal liver 
and are believed to migrate there from the AGM, yolk sac and placenta as the 
onset of circulation allows. The foetal liver is a more mature haematopoietic 
site than yolk sac with more cell types arising from the multipotent HSC 
whose population expands within the liver. Previous reports examining 
S100A8 and S100A9 in development have concentrated on myeloid cell 
differentiation in the foetal liver. It is well documented that S100A8 and 
S100A9 are expressed in myeloid cells, which first arise in the foetal liver at E
12.5 (Lagasse and Weissman 1992). At this stage S100A8 and S100A9 
positive cells resembling polymorphonuclear neutrophils can clearly be seen 
(Lagasse and Weissman 1992). This was thought to be the first expression of 
S1(X)A8 and S100A9 in development although as the studies were 
concentrated on myeloid differentiation no study had specifically looked 
earlier in development than E 12.5 before the work of Passey et al 1999.
In vitro systems using embryonic stem (ES) cells generated from embryoid 
bodies have proved a useful model for haematopoietic development especially 
in yolk sac tissues (Keller, Kennedy et al. 1993). Many of the genes and 
signalling processes involved in lineage differentiation show significant 
similarities between in vivo tissues and cultured cells (Kouskoff, Lacaud et al. 
2005). This is especially true of early haematopoietic events such as the 
generation of haemangioblasts (Kouskoff, Lacaud et al. 2005), which can be 
difficult to study in vivo. The similarity of molecular events in ES
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cell derived haematopoiesis makes it a good in vitro model to determine which 
proteins are expressed and play a role in this process in vivo.
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4.2 Results
4.2.1 Decidual cells do not seem to stain positively for S100A8 
protein
Expression of S100A8 mRNA in decidual tissue is well established in Passey 
et al 1999, Hobbs et al 2003 and this report. The data presented in this thesis 
show that the S100A8 mRNA expression is in the maternal decidual tissues. 
One issue that has not previously been addressed is whether the S100A8 
mRNA expression is translated to protein expression. It is known that S100A8 
mRNA is stable in S100A9 null myeloid cells but no S100A8 protein is 
present in these cells (Hobbs, May et al. 2003). This shows that there may be 
multiple levels of control for S100A8 protein expression. S100A8 may depend 
on a binding partner for stability as in the case of myeloid cells where S100A9 
is required (Hobbs, May et al. 2003). In maternal decidual tissue it has been 
shown that there is a population of cells that express SI00A8 mRNA but not 
S100A9 mRNA. The data suggest that if S100A8 protein is stably expressed 
in decidual tissues, it must be independent of its established heterodimeric 
partner, S100A9. The issue is critical in determining whether S100A8 has any 
role in postimplantation development. Only expression of stable S100A8 
protein in embryonic tissues could explain the S100A8 null phenotype 
postulated in Passey et al 1999. It is also possible that S100A8 protein is 
expressed in maternal tissues and could show a role for S100A8 in decidual 
tissue biology. Another possibility is that S100A8 mRNA expression is 
triggered by events in the decidua and developing placenta but that this does 
not result in translated protein and therefore no function for S100A8. It is even 
possible that there is no constitutive role for S100A8 and that S100A8 protein 
expression is controlled by a stress induced pathway. To examine these 
possibilities we probed S100A8 and S100A9 protein expression in 
postimplantation decidual and embryonic tissues using immunohistochemistry 
as shown in fig 4.1.
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Fig 4.1 Immunohistochemistry o f maternai decidual tissue. Immunohis­
tochemistry of maternai decidual tissue. Positive control tissue spleen was 
stained for S100A8 (Al) and S100A9 (A2) protein expession. Immunostain- 
ing for SI 00A8 protein is shown in decidual tissues at E 7.5,8.5,10.5,12.5 
and 14.5 (81,3,5,7 and 9) and S100A9 protein expression is shown at the 
same stages (B 2,4,6,8,10). Staining of S100A8 is with mAh 6A4 and anti-rat 
secondary Ab. Staining of SI 00A9 is with mAh 2810 and anti-rat secondary 
Ab. M-maternal, E-embryonic, white dashed line - foetal-maternal interface. 
Scale bar = 20pM.
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S100A8 and S100A9 protein expression was probed on E 8.5, 10.5 12.5 and
14.5 formalin fixed slides using mAbs 6A4 and 2B10 respectively. Relevant 
isotype control mAbs were used for these antibodies. Protein staining of 
S100A8 and S100A9 is confirmed in the positive control tissue spleen where 
myeloid cells are present and positive for both proteins. In decidual tissue 
S100A9 protein expression is restricted to a small number of cells at the 
matemal/foetal interface at all stages. This illustrates a similar pattern to 
S100A9 mRNA expression shown in fig 3.5 and is highly likely to represent a 
neutrophil population. An identical pattern of expression can be seen with 
S100A8 protein, which reinforces the myeloid cell expression pattern. In the 
wider maternal decidua S100A8 expression does not appear to occur within a 
particular cell population. This shows that the mesometrial decidual cell 
population of S100A8 mRNA expressing cells shown by in situ hybridisation 
in fig 3.5 does not stably express S100A8 protein. The general level of 
background staining is raised in decidua at E 10.5 and it was not known if this 
represented positive staining or was artefactual. It did seem clear though that 
S100A8 mRNA is not always correlated to S100A8 protein staining. These 
data show that at least at certain stages SI00A8 mRNA is expressed but 
S100A8 protein is not evident. This would be consistent with expression of 
S100A8 mRNA in S100A9 null myeloid cells where no S100A8 protein is 
found despite S100A8 mRNA expression (Hobbs, May et al. 2003).
4.2.2 A transient expression of S100A8 protein can be seen 
between E 9.0 and E 11,5 in wildtype embryonic yolk sac.
Expression of S100A8 protein could not be clearly shown in maternal decidua
at stages where high S100A8 mRNA expression can be shown. It was also of
interest whether embryonic tissues express S100A8 protein, as expression in
wildtype tissues would be key to determining the nature of any S100A8 null
lethal phenotype. This was not previously been examined in the S100A8 null
model. There has been no report of embryonic S1(X)A8 protein expression
prior to E 12.5, where it is seen in conjunction with S1(X)A9 protein in
myeloid cells of the embryonic liver. If S100A8 null embryos are lethal
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postimplantation, it should be possible to see S100A8 protein expression in 
embryo-derived tissues at a stage close to the proposed lethality. The next two 
figures show the results of embryonic tissue immunohistochemistry. Staining 
in yolk sac is as shown in fig 4.2.
S100A8 and S100A9 protein expression was probed on E 8.5, 9.5 10.5 and
11.5 on formalin fixed slides using mAbs 6A4 and 2B10 respectively. 
Relevant isotype control mAbs were used for these antibodies. Positive control 
tissue spleen shows both S100A8 and S100A9 protein expression in myeloid 
cells in the red pulp regions. Staining of E 7.0 embryos showed no S100A8 
expression as previously reported in Passey et al 1999 (not shown). Staining of 
embryonic tissue at E 8.5 -  E 11.5 shows that there is a transient expression of 
S100A8 protein at E 9.5 and E 10.5 in yolk sac blood islands. At E 8.5 and E
11.5 there is no S100A8 protein expression in blood islands showing the 
transient nature of the expression. S100A9 protein expression cannot be seen 
in the yolk sac blood islands at any stage.
4.2.3 A transient expression of S100A8 protein can be seen in 
E 11,5 foetal liver.
Expression of S100A8 and S100A9 protein in foetal liver at E 12.5 is well 
established and due to nascent myeloid cells (Lagasse and Weissman 1992). 
Expression prior to this stage of either SI00 protein has not been shown in any 
study to date. It is known that yolk sac cells can colonise the foetal liver 
starting at E 10.5. This colonisation facilitates liver development and transfers 
embryonic haematopoiesis to the foetal liver. Initially haematopoiesis in the 
liver is restricted to myeloid and erythrocyte lineages reflecting the status of 
cells migrating from the yolk sac. Monocytes and macrophage lineages can be 
seen in foetal liver as early as E 10.0 and accumulate throughout development 
(Morris, Graham et al. 1991). At E 11.5 HSCs migrate to the liver from, 
potentially, the yolk sac, the placenta and AGM region. It would be of interest 
whether S100A8 protein expression is seen prior to E 12.5 as yolk sac cells at
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Fig 4.2 Expression of S100A8 protein in embryonic yolk sac. immunohis­
tochemistry of spleen (1 -3) and yolk sac samples at E 8.5 (4-6), E 9.5 (7-9), E
10.5 (10-12), and E 11.5 (13-15). Samples are stained with either control IgG 
(1,4,7,10and 13) Ab6A4forS100A8 (2,5,8,11 and 14) orAb 2B10forS100A9 
(3,6,9,12 and 15). Scale bar = 20pM.
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E 9.5 and E 10.5 have stained positively and could be expected to migrate to 
the foetal liver prior to E 12.5. To assess this possibility, foetal liver 
expression of S100A8 and S100A9 protein was probed using 
immunohistochemistry at E 11.5 and 12.5 as shown in fig 4.3.
S100A8 and S100A9 protein expression was probed using mAbs 6A4 and 
2B10 respectively. A relevant isotype control mAb was used as a control for 
these antibodies. Expression of S100A8 protein can be seen in E 11.5 foetal 
liver. Expression of S100A9 protein cannot be seen in E 11.5 foetal liver. At E
12.5 S100A8 and S100A9 protein is expressed in a well-documented manner 
in myeloid cells. The pattern of expression between E 11.5 and E 12.5 is also 
very different. At E 11.5 many liver cells (Approximately 50%) express 
positivity for S100A8 protein with large nucleated cells staining most 
positively. The pattern did not resemble known staining patterns of 
macrophage and monocytes at this stage (Morris 91). At E 12.5 expression is 
restricted to a small and evenly distributed subset of cells, which upon close 
examination are polymorphonuclear cells. Expression of S100A8 in many E
11.5 foetal liver cells is a novel observation not previously reported in any 
study of S100A8 in development. Further attempts were made to determine 
the foetal liver cell type expressing S100A8 using markers such as c-Kit, Sca- 
1 and CD31 (data not shown) but no marker worked effectively or could 
differentiate the cells of the foetal liver.
4.2.4 Flow cytometry shows no expression of S100A8 protein 
in E 9.5 and E 10.5 yolk sac
Immunohistochemistry showed a novel expression of S100A8 protein in yolk
sac between E 9.5 and 10.5 and in foetal liver at E 11.5. This has not been
seen in previous studies of S100A8 and S100A9 in early development. To
determine whether a novel expression of S100A8 protein occurs in yolk sac
cells intracellular flow cytometry was conducted on E 9.5 and E 10.5 yolk sac
tissues. Flow cytometry, if successful, could make use of Abs for S100A8
protein in conjunction with cell marker Abs to determine which cell
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Fig 4.3 S100A8 and S100A9 protein expression in foetal liver. Immuno­
histochemistry of foetal liver at E 11.5 and E 12.5 treated with control IgG 
(A1,2) Ab 6A4-S100A8 (3,4) and Ab 2B10-S100A9 (5,6). All sections are 
treated with anti-rat secondary. Scale bar = 20pM.
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Fig 4.4 Flow cytometry of bone marrow and E 9.5 yolk sac sam ples. (A)
Flow cytometry of A) bone marrow cells and (B) E 9.5 yolk sac cells treated 
with 1) No Ab 2) Pylt-1 3) Y13 4) 6A4 (S100A8) 5) 2B10 (S100A9). All cells are 
treated with appropriate secondary antibody.
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type expresses S100A8 protein. The results are shown in fig 4.4.
Yolk sac tissues from E 9.5 and E 10.5 (not shown) were isolated and 
disrupted through a molecular cell sieve. The yolk sac cells derived were 
analysed by intracellular FACS. S100A8 protein expression was probed using 
mAb 6A4 and S100A9 protein expression was probed using mAb 2B10. A 
relevant isotype control IgG was used as a control for these antibodies. Bone 
marrow derived cells were used as a positive control for both S1 0 0 A8 and 
S100A9. Positive control bone marrow cells show a clear population of 
myeloid S100A8 and S100A9 expressing cells. The analysis in yolk sac 
samples showed a failure of S100A8 Abs to detect expression at either E 9.5 
or E 10.5 (not shown).
4.2.5 Western blot shows expression of S100A8 protein in yolk 
sac at E 9.5 and 10.5 but not E 8.5 and 11.5.
Immunohistochemistry has shown a transient expression of S100A8 protein in 
yolk sac between E 9.5 and E 10.5 and in E 11.5 foetal liver. Flow cytometry 
did not confirm this expression. It was important to determine whether 
S100A8 protein was indeed expressed by yolk sac. As another means of 
assessing the presence of S1 0 0 A8  within the yolk sac western blot analysis 
was performed. Western blotting would be able show whether S100A8 protein 
was truly present, as a western blot band with identical Mw to S100A8 is 
unequivocal. S100A9 protein expression was also analysed and the results are 
shown in fig 4.5.
Wildtype yolk sac lysates from E 8.5, 9.5, 10.5 and 11.5 were analysed for
S100A8 and S100A9 protein expression. Bone marrow lysate was used as a
positive control for both S100A8 and S100A9 protein. S100A8 protein on
western blots was probed with polyclonal antibody NH9. S100A9 is probed
using mAb 2B10, Antibodies were controlled using relevant antibodies.
Positive control bone marrow lysates stain positively for S100A8 and S100A9
protein. SI00A8 expression was seen in E 9.5 and 10.5 samples and was
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Fig 4.5 Western blot of yolk sac samples. Western blot showing S100A8 (A) 
and S100A9 B) protein expression in bone marrow lysates and yolk sac 
lysates at E 8.5,9.5,10.5 and 11.5. Staining of S100A8 is with Ab NH9 and 
anti-rabbit HRP conjugated secondary. Staining of Si 00A9 is with mAb 2B10 
and anti-rat HRP conjugated secondary.
124
Chapter 4: S100A8 in postimplantation development
not seen in E 8.5 and E 11.5 samples, S100A9 expression was not seen in any 
of the samples. The results of the western blot analysis show clear agreement 
with the immunohistochemistry results indicating a transient yolk sac 
expression of SI00A8  protein between E 9.5 and E 10,5.
4.2.6 S100A8 mRNA is not expressed in WT yolk sac blood 
islands.
It has not been previously documented that S100A8 mRNA or protein is 
expressed in yolk sac tissues at E 9.5 and E 10.5 and E 11.5 foetal liver. It was 
thought that the first expression of S100A8 was in the E 12.5 foetal liver 
where it is stably expressed by embryonic myeloid cells. Transient protein 
staining for S100A8 in E 9.5 and 10.5 yolk sac and E 11.5 foetal liver could 
indicate that S100A8 is expressed earlier in development than previously 
thought. This would also seem to correlate most closely with the report in 
Passey et al 1999 of S100A8 null lethality at E 8.5 and S100A8 null embryo 
loss by E 9.5. It would however show a very different cause of lethality than 
the one proposed in that report. Expression of S100A8 has been shown by 
immunohistochemistry and western blot but could not be confirmed by flow 
cytometry. Examination of S100A8 mRNA in foetal yolk sac should confirm 
expression of S100A8 protein in these tissues. S100A9 expression was also 
examined to further confirm whether S1 0 0 A8 expression was indeed 
independent in the tissues examined as shown in fig 4.6.
S100A8 and S100A9 mRNA expression was probed using P32 radioactively
labelled anti-sense probes for S100A8 and S100A9 mRNA. S100A8 and
S100A9 mRNA were both detected in myeloid cells in E 12.5 foetal liver
validating the probe. It can clearly be seen that no expression of S100A8
mRNA occurs in the yolk sac at any stage examined. No S100A8 mRNA
expression could be seen in the foetal liver at E 11.5 (not shown). No S100A8
mRNA expression can be seen in any foetal tissues prior to the myeloid
expression at E 12.5 in the foetal liver. This lack of expression can be
compared to the high expression levels seen in the maternal decidua
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Fig 4.6 SI 00A8 and SI 00A9 mRNA expression in embryonic yolk sac. In
situ hybridisation on foetal liver (1,2) and yolk sac tissues (3-8) with S100A8 
(1,3,5,7) and S100A9 probes (2,4,6,8) at E 8.5 (3,4), E 9.5 (5,6) and E 10.5 (7,8). 
Scale bar = 20pM.
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shown in fig 3.5. S100A9 expression is not detected at any stage in foetal 
tissues prior to myeloid cells in E 12.5 foetal liver. The evidence shows clear 
lack of any S100A8 or S100A9 mRNA expression in the foetal system prior to 
E 12.5 as has been previously reported.
4.2.7 RT-PCR of yolk sac samples show no S100A8 mRNA at 
E 8.5- E  11.5
With a lack of evidence for S100A8 mRNA by in situ hybridisation it was 
important to verify this finding with evidence of S100A8 mRNA expression 
using an alternative technique. As a second approach to answering this 
important question RT-PCR was used. Examining S100A8 and S100A9 
mRNA expression by RT-PCR should show whether the in situ hybridisation 
results were correct. This has the advantage of clearly looking at correctly 
sized specific bands for S100A8 and S100A9 mRNA expression. The results 
are as shown in fig 4.7
Yolk sac samples from E 8.5, 9.5, 10.5 and 11.5 were extracted and disrupted 
through a cell sieve. RT-PCR was conducted to analyse whether S100A8 and 
S100A9 mRNA were expressed. Bone marrow derived cells were used as a 
positive control for S100A8 mRNA. Bone marrow controls show expression 
of S100A8 and S100A9 mRNA. No stage of embryo yolk sac tissue showed 
expression of S100A8 mRNA. S100A9 mRNA expression was also absent 
from the yolk sac at these stages. These results confirm the observations from 
S100A8 mRNA in situ hybridisation in fig 4.4.
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Fig 4.7 RT-PCR of yolk sac samples. S100A8 A) and S100A9 B) mRNA 
expression In yolk sac samples at E 8.5,9.5,10.5,11.5 and E 12.5 embryo 
sample..C) Expression of S100A8 and S100A9 mRNA In S100A9 null tissue 
sample at E 12.5.
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4.2.8 ES cells diverted to erythroblast lineage express S100A8 
and S100A9 mRNA after differentiation to Yed'' 
erythroblasts.
It is known that the predominant cell types in yolk sac blood islands at E 9.5 
and E 10.5 are of erythrocyte and macrophage lineages (Haar and 
Ackerman 1971). Erythrocytes form the vast majority (95% +) of yolk sac and 
circulatory cells at these stages and so were certainly positive for S100A8 
protein in the immunohistochemistry data shown in Fig 4.4. To assess whether 
erythrocyte lineages are S100A8 mRNA and protein positive we decided to 
look at differentiated erythrocyte lineages. The advantage of using a murine 
ES cell system was that the cells are independent of maternal and foetal 
influence. If the ES cells express S100A8 mRNA and protein during 
differentiation then this will clearly show that S100A8 has a role in 
erythrocyte biology. If differentiating embryonic stem (ES) cells do not 
express S100A8 mRNA or protein it could indicate that S100A8 is not 
involved in erythrocyte biology or that S100A8 expression is caused by in 
vivo factors. With the assistance of Valerie Kouskoff (Paterson Institute, 
Manchester), whose group generated and cultured the ES cell samples we 
examined distinct stages of differentiation. At day 0 of culture the ES cells are 
undifferentiated and must undergo a process, which takes them through 
processes highly similar to haematopoiesis in vivo. By day 2-3 some of the 
cells display characteristics of haemangioblast cells. By day 4 the ES cells 
have developed into erythroid precursors. By day 6 fully differentiated 
erythrocytes can be seen (Keller, Kennedy et al. 1993). The results of RT-PCR 
on the stages of differentiation are shown in fig 4.8.
ES cells in culture were diverted to the erythrocyte lineage as described in 
Kouskoff et al 2005. Cell samples were taken at day 0, 1, 4, 5 and 6 of culture. 
RT-PCR was conducted on the samples to analyse S100A8 and S100A9 
mRNA expression. Bone marrow derived cells were used as a positive control 
for both S100A8 and SI00A9 mRNA. No S100A8 or SI00A9 mRNA
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Fig 4.8 RT-PCR of stem cell derived cell sam ples. RT-PCR of control bone 
marrow and samples derived from embryonic stem cells at Day 0 and 
differentiated through erythrocytes at day 6. RT-PCR shows expression of 
S100A9 (A)andS100A9(B).
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expression can be seen at day 0, 1, 4 or 5 samples. Day 6, fully differentiated 
erythrocyte, samples express both S100A8 and SI00A9 mRNA. This data 
shows that fully differentiated erythrocytes do express S100A8 and S100A9 
mRNA in an in vitro culture system.
4.2.9 Western Blot of ES cell samples shows no expression of 
S100A8 and S100A9 protein.
Expression of S100A8 and S100A9 mRNA in differentiated day 6 
erythrocytes cultured from murine ES cells has been shown. Analysis of the 
same stages of differentiation by western blot is necessary to reach 
conclusions from the culture experiments. In particular the day 6 sample was 
shown to express S100A8 and S100A9 mRNA so it was if interest whether 
protein was also expressed. As we have seen in earlier data S100A8 mRNA 
can be expressed without protein being detected. Analysis of S100A8 and 
S100A9 protein expression will show whether these proteins are stably 
expressed in this in vitro erythrocyte system. The samples used in this 
experiment were also derived from our collaboration with the group of Valerie 
Kouskoff. The results are shown in fig 4.9.
Cultured ES cell samples at 0,1,4,5 and 6 days were disrupted in lysis buffer 
and analysed by western blot for S100A8 and S100A9 protein expression. 
Bone marrow lysate is used as a positive control for both S100A8 and SI00A9 
protein. S100A8 on western blot is probed with rabbit polyclonal antibody 
NH9. S100A9 is probed using mAb 2B10. Antibodies were controlled using a 
relevant secondary antibody. Positive control bone marrow cells stained 
positive for both S100A8 and S100A9 protein. No expression of S100A8 or 
S100A9 expression was seen at any stage of ES cell differentiation including 
day 6 differentiated erythrocytes. These data show that S100A8 and S100A9 
mRNA is not stably translated to protein expression in ES cell derived, 
differentiated erythrocytes.
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Fig 4.9 Western Blot of bone marrow and stem cell sam ples. Staining of 
S100A8 A) and S100A9 B) protein expression in bone marrow positive 
control and Day 0,1,4,5 and 6 of culture. Staining of SI 00A8 is with Ab NH9 
and anti-rabbit HRP conjugated secondary. Staining of S100A9 is with Ab 
2810 and anti-rat HRP conjugated secondary.
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4.2.10 Maternal decidua expresses low levels of S100A8 protein 
at E 9.5
The data presented in this chapter show a clear contradiction between the 
maternal and foetal tissues for S100A8 expression. S100A8 mRNA was 
consistently expressed at high levels in maternal decidual tissues. This did not 
produce corresponding S100A8 protein staining in the cells of the maternal 
decidua. In contrast the foetal yolk sac at E 9.5 and E 10.5 and the foetal liver 
at E 11.5 expressed S100A8 protein as shown by immunohistochemistry and 
confirmed by western blot. However, they produce no detectable S100A8 
mRNA at any stage observed.
Immunohistochemistry had suggested low S100A8 protein expression 
throughout the maternal decidua at E 10.5. It was originally thought that this 
could be raised background or artefactual, but was it possible that this 
represented widespread but very low expression of S100A8 protein. It was 
decided to look at the possibility of low level S100A8 protein expression at E
9.5 and 10.5 in the maternal decidua. It would be possible to explain the 
observations if maternal decidual tissue produced S100A8 protein, which was 
secreted and crossed through the decidua to the foetal circulation. Many 
reports on the functions of S100A8 have indicated an extracellular role 
(Passey, Xu et al. 1999) and some reports have suggested a transcellular role 
(Kannan 2003). To assess this possibility western blot analysis of maternal 
decidual tissues was conducted. The decidual tissues were obtained from the 
S100A9 null mouse, as the maternal decidua will contain small populations of 
myeloid cells that are positive for S100A8 and S100A9 protein in wildtype. 
Myeloid cells would inevitably contaminate any examination of S100A8 and 
S100A9 protein expression in maternal decidua. However, S100A9 null mice 
contained myeloid cells that lack S100A8 or S1(X)A9 making it an elegant 
model to look at maternal decidual S100A8 protein expression without fear of 
contamination. E 11.5 decidua was included as a stage where no S100A8 is 
seen in the yolk sac blood islands. The results are shown in fig 4.10.
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Fig 4.2.10 Western blot o f maternal decidual tissue. Western Blot show­
ing NH9 staining of S100A8 protein expression in E 9.5 10.5 and 11.5 mater­
nal decidual samples.SI00A9 staining shown with mAb 2810.
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S100A9 null maternal decidua at E 9.5 and E 10.5 was isolated and lysed for 
analysis by western blot. Wildtype bone marrow lysate is used as a positive 
control for both S100A8 and S100A9 protein. S100A8 on western blot is 
probed with polyclonal antibody NH9. S100A9 is probed using mAb 2B10. 
Antibodies were controlled using a relevant secondary antibody. Positive 
control bone marrow stained positive for S100A8 and S100A9 protein. 
Staining of S100A8 protein was not seen in short exposures of the E 10.5 
decidual sample but longer exposures (overnight) showed staining for S100A8 
protein. Thess data show that at E 9.5 and 10.5 low levels of S100A8 protein 
expression can be detected. No expression of S100A8 was detected at e 11.5.
4.2.11 S100A8 expressing cells in maternal decidua are not 
F4/80 positive macrophages
One possible cell type responsible for the S100A8 mRNA and protein 
expressing cells in the maternal decidua is macrophages. S100A8 expression 
can be seen in macrophages under inflammatory conditions (Hu, Harrison et 
al. 1996). This makes macrophages an interesting candidate cell type for the 
maternal decidual S100A8 mRNA and protein staining. Studies in chapter 3 of 
this thesis showing 7/4 staining in the decidua have indicated that other known 
S100A8-expressing immune cells such as monocytes and neutrophils are not 
responsible for the S100A8 expression in maternal decidua so it is important 
to rule out further cell types.
This analysis is balanced with the knowledge that macrophages are excluded
from sites of implantation and development (Brandon 1993). It has been
shown that macrophages are detrimental to the delicate balance of engraftment
and rejection of the developing foetus by the maternal decidua. It was decided
to reassess macrophage distribution in our S100A8 model to determine
whether they are indeed excluded from the developing embryos or whether we
may be looking at a macrophage expression of S100A8. This will also give
reassurance that the S100A8 mRNA and protein expression we are seeing in
the maternal decidua and haematopoietic tissues is not a
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response to decidual inflammation or abnormal embryo growth. Macrophage 
distribution in the maternal decidua was probed by immunohistochemistry 
with pan macrophage marker F4/80 (Austyn and Gordon 1981) as shown in 
fig 4.11.
F4/80 protein expression was probed at E 7.5 8.5, 10.5 and 12.5 using mAb 
F4/80 (Serotech). A relevant mAb was used as a control for this antibody. 
Positive control tissue, E 12.5 foetal liver shows F4/80 expression in myeloid 
cells. Macrophages are not present in the maternal decidua at any stage 
examined. As documented they are excluded from the maternal decidual tissue 
postimplantation and cannot be the S100A8 mRNA and protein expressing 
cell type seen in maternal decidua.
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Fig 4.11 F4/80 Immunohistochemistry in maternal decidua. Macrophage 
marker F4/80 staining in positive control E 12.5 embryonic liver (1) and 
maternal decidual tissue at E 7.5 (3) E 8.5 (5) E 10.5 (7). Control tissues are 
also shown (2,4,6,8). F4/80 staining using F4/80 mAb followed by anti-rabbit 
secondary Ab. M-maternal tissue, E- embryo tissue. Scale bar = 20pM.
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4.3 Discussion
4.3.1 Postimplantation role of S100A8
This chapter presents evidence of a complex situation for S100A8 expression 
in the maternal decidua and embryonic tissues postimplantation. The data in 
chapter 3 presented a previously unknown population of S100A8 mRNA 
expressing cells in the maternal decidua. The data in this chapter showed that 
the high S100A8 mRNA in the maternal decidua was not translated to 
comparable high levels of S100A8 protein in this tissue. It has been 
demonstrated though that low amounts of SI00A8 protein were stably 
produced in the maternal decidua at E 9.5 and E 10.5. In contrast S100A8 
protein is found in E 9.5 and E 10.5 embryonic yolk sac blood island cells and 
E 11.5 foetal liver. The S100A8 protein in these cells was demonstrated by 
immunohistochemistry and western blot analysis but not by flow cytometry. 
These cells do not express S100A8 mRNA at any observed point, which was 
shown by in situ hybridisation or RT-PCR. ES cells differentiating down the 
erythroid lineage did not express SI00AS or S100A9 mRNA or protein. 
Differentiated erythrocytes from ES cells, which should represent the 
predominant cell type of foetal circulation and yolk sac blood islands, did not 
express S100A8 and S100A9 protein although they did express S100A8 and 
S100A9 mRNA at the end stage of maturation. Finally it was shown that 
macrophages were probably not the S100A8 expressing population in the 
maternal decidua, as they are not detected in the area of S100A8 expression 
during the critical period.
4.3.2 Stability of S100A8 protein in the absence of S100A9
S100A9 null myeloid cells express S100A8 mRNA but do not stably express 
S100A8 protein (Hobbs, May et al. 2003). This observation suggests that 
S100A8 protein stability in myeloid cells is dependent on S100A9 expression 
(Hunter and Chazin 1998). It also suggests that S100A8 protein
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homodimers do not occur in myeloid cells, as the conditions to produce such 
homodimers exist in S100A9 null mice. It has been proposed that in mice 
S100A8 does not have the necessary complementary dimérisation plane 
residues to form stable homodimers (Hunter and Chazin 1998). In 
development it has been shown, by studies including this one, that S100A8 
mRNA is expressed in the absence of S100A9 mRNA expression in maternal 
decidua (Passey, Williams et al. 1999; Hobbs, May et al. 2003). This study 
confirms that observation and showed further that S100A8 protein was stable 
in the absence of S100A9. This finding raises the important question of how 
S100A8 protein was stabilised in the absence of S100A9. It shows that the 
state of S100A8 in myeloid cells and in embryo development is widely 
different. Homodimerisation of S100A8 is still a possibility although this is 
not energetically favourable (Hunter and Chazin 1998). It has been proposed 
that oxidation of S100A8 stabilises homodimers (Harrison, Raftery et al. 
1999) and that this could occur in embryonic development (Passey, Williams 
et al. 1999). Another possibility is that there is an alternative binding partner 
for S100A8, in the absence of S100A9. A putative binding partner could shed 
light on the role of S100A8 in development and would be of great interest. 
Preliminary experiments to investigate a putative partner were inconclusive. 
Non-reducing western blots could show candidate bands, which might 
represent S100A8 homodimers or a heterodimeric complex. Preliminary 
experiments were undertaken to determine the nature of S100A8 in 
development but the results were not conclusive (data not shown). It is 
reasonable to conclude that S100A8 must form either homodimers or a unique 
complex with a previously unknown partner as no evidence exists for the 
stability of SI00A8 monomers.
The stability of S100A8 highlights another issue raised by the data presented. 
Different techniques gave different answers when testing for the expression of 
S100A8 protein in yolk sac cells. Immunohistochemistry and western blot 
showed expression of S100A8 protein in the yolk sac at E 9.5 and E 10.5, but 
flow cytometry of the same cells did not show S100A8 protein expression. It 
is interesting that both western blot and immunohistochemistry present a 
picture of the cells fixed in place by either lysis buffer or by fixative,
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whereas flow cytometry dilutes the cells into buffers before the fixative step. 
This may be the crucial factor in the conflicting results of these techniques 
with S100A8 protein either unstable or loosely associated with the yolk sac 
cells and hence lost in flow cytometry. Another possibility is that S100A8 was 
present in the fluid surrounding the cells and thus would have been present in 
western blot samples and was fixed with cells in immunohistochemistry but 
was lost in flow cytometry. It is also possible that the availability of S100A8 
epitopes varies between the techniques. It is unclear how S100A8 in 
development is stabilised or whether it has a binding partner. It is therefore not 
clear whether the epitopes recognised by the S100A8 Abs are available in the 
techniques used to study expression. This problem is compounded by the 
necessary use of different Abs in different techniques due to the fact that no 
one Ab worked in all the techniques used.
4.3.3 S100A8 protein in foetal and maternal decidual tissues
Expression of S100A8 protein in yolk sac at E9.5 and E10.5 and foetal liver at 
E 11.5 was initially highly surprising and difficult to reconcile with the lack of 
S100A8 mRNA in those locations at any stage studied. In addition to this the 
lack of S100A8 mRNA, a lack of protein production in the ES cell derived 
erythrocytes also confirms that S100A8 protein is not expressed in this cell 
type. The expression of S100A8 and S100A9 mRNA in ES cells at day 6 of 
differentiation could be explained by the presence of nascent myeloid cells 
within the culture. The culture conditions favour erythrocyte differentiation 
but small myeloid populations could be present (Kouskoff, Lacaud et al. 
2(X)5). There remains a slight possibility that SI00A8 mRNA expression is 
transient and S100A8 protein was produced by yolk sac and foetal liver cells 
and that this was never observed. It was far more likely that yolk sac and 
foetal liver cells do not produce the S100A8 protein and the source lies 
elsewhere. If the source does lie elsewhere it is of interest how the S100A8 
protein ends up in the yolk sac and foetal liver cells.
It was also surprising that despite high SI00A8 mRNA expression in maternal
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decidual tissue, that there was not concomitant S100A8 protein expression at 
all stages. This indicates at least 2 levels of control for S100A8 protein 
expression with mRNA induced at E 7.5 before protein is shown at E 9.5. 
However, expression of S100A8 protein in maternal decidual tissue was 
eventually shown to occur at low levels by western blot, which confirmed the 
impression that S100A8 mRNA expression is translated. The stage specific 
expression of S100A8 protein in decidual tissue suggests a mechanism for 
regulating the translation of S100A8 mRNA as it is expressed throughout 
development yet S100A8 protein is not found at most stages. Co-ordination of 
signals for transcription and translation appear to be required. The exact nature 
of the signalling events that control S100A8 mRNA and protein expression 
could give insight to the function of S100A8 and it would be desirable to 
investigate these control mechanisms.
Our data show a possible novel role for S100A8 in development at E 9.5 to E 
11.5. Combining the data from chapter 3, where we see extensive maternal 
decidual S100A8 mRNA expression throughout development, with the 
transitory expression of S100A8 protein in embryonic tissues between E 9.5 
and E 11.5 a novel mechanism of S100A8 action can be proposed. Expression 
of S100A8 protein in the maternal decidual tissues seems certain and its 
presence in the foetal yolk sac and liver strongly shows the possibility of 
S100A8 export across the placenta into foetal tissues as illustrated in fig 4.12. 
With no explanation for the embryonic expression of S I00A8 and a known 
source of S100A8 mRNA and protein nearby in the maternal decidua it is a 
strong possibility. An interesting hypothesis is that S100A8 protein could be 
exported across the placenta at E 9.5 and E 10.5 where it is picked up by foetal 
erythrocytes in the yolk sac as shown in fig 4.1. This does not occur prior to E
9.5 as the maternal decidua expresses only mRNA and not protein and it does 
not occur after E 11.5 as no protein can be detected in yolk sac. Yolk sac 
erythrocytes are known to migrate to the foetal liver at E 10.5 and S100A8 
expression is seen at E 11.5 in the foetal liver. The exact correlation of 
S100A8 protein expression in the maternal decidua and embryonic yolk sac is 
too precise in timing to be easily dismissed as coincidence.
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Trophoblast Giant cell 
Maternal decidua
Fetal decidua
Yolk sac blood island
S100A8?
Fetal blood vessel
S100A8 mRNA positive cells O  SI 00A8 protein positive cells
Fig 4.12 Separation of S100A8 m essage and protein expression at E 9.5 
and E 10.5. Representation of the divergence of S100A8 message and 
protein expression. Maternal decidual cells (purple) express high S100A8 
mRNA levels whereas SI 00A8 protein positive cells In the yolk sac and 
cIrculation.The model proposes a possible link between the two phenom ­
enon.
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In the unstudied setting of development it is not known whether S100A8 
protein could be exported, indeed it has not been conclusively shown for 
myeloid cells. In myeloid cells several lines of evidence suggest that S100A8 
protein could be exported as part of the S100A8/A9 heterodimer. Microtubule 
dependent secretion has been proposed as an S100A8 and S100A9 export 
mechanism in myeloid cells (Rammes, Roth et al. 1997). Proposed functions 
of S100A8 as chemo-attractant, antimicrobial agent and arachidonic acid 
transporter (Sohnle, Collins-Lech et al. 1991; Lackmann, Cornish et al. 1992; 
Kannan 2003) all rely on export of the protein. The combined evidence of 
myeloid cell export and developmental expression of S100A8 protein in 
S100A8 mRNA negative cells certainly suggests that the protein could be 
exported. The only other plausible possibility is that an extremely transient 
mRNA expression in embryonic yolk sac and liver may have been missed in 
our studies despite repeat samples and different techniques used. S100A8 may 
be secreted to perform a function within the maternal decidua and only seen in 
foetal cells due to their close proximity and the rapid exchange across the 
placenta.
4.3.4 Conclusions and further study
Evidence has been presented to support a model of S100A8 protein expression 
in the maternal decidua at E 9.5 and E 10.5, one stage among a continuous 
S100A8 mRNA expression from E 7.5 to E 14.5. Evidence has been presented 
that S100A8 protein is found at E 9.5 and E 10.5 in the yolk sac and at E 11.5 
in the foetal liver. No evidence was found to support S100A8 mRNA 
expression in these tissues. ES cell derived cell equivalents do not express 
S100A8 protein. The model proposed to link these events is export of S100A8 
protein from the maternal decidua to cells within the yolk sac and placenta 
before those cells migrate to the foetal liver. No evidence presented in this 
chapter supports the idea of an S100A8 null lethality at E 9.0. Studies of 
preimplantation development may be key to discovering the S100A8 null 
lethal phenotype
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CHAPTER 5 
5 Preimplantation studies of S100A8 
5.1 Introduction
Chapter 4 of this thesis examined postimplantation development and found no 
results supporting a critical role for S100A8, and instead showed evidence of a 
maternal role for the protein in the developing placenta. Data from these 
studies along with evidence from chapter 3 showing significant loss of 
S100A8 null embryos indicated a preimplantation lethal phenotype for the 
S100A8 null mouse prior to E 4.5. In order to determine the exact phenotype 
of the S100A8 null mouse model preimplantation studies were needed. This 
has been a previously unstudied area for S100A8 and there is no indication as 
to what the role of the protein might be in this context. The purpose of the 
work described in this chapter has been to attempt definition of the exact 
timing of the S100A8 null lethal phenotype and to examine the cause of 
lethality.
Oocyte maturation occurs both within the ovary and in the uterine horn. The
first round of meiosis occurs within the ovary to transform primary oocytes
with germinal vesicles into secondary oocytes. Further meiosis produces a
fully mature oocyte ready for fertilisation. After fertilisation, cell division
progresses from 1-cell to 2-cell and on to the 4-cell stage. At the 8-cell stage a
process called morulation occurs where cell-cell contacts tighten and
differentiation begins. Morulation is the first morphogenic step in
differentiation from totipotent blastomeres to the first differentiated cell types,
the trophoblast and inner cell mass (ICM) (Johnson and Ziomek 1981).
Morulae then undergo further morphogenic changes to become
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blastocysts. A liquid filled cavity called the blastocoele develops in the centre 
of the morula (Barcroft, Offenberg et al. 2003). The trophoblast cells become 
a flattened monocellular layer surrounding the blastocoele with the inner cell 
mass polarised against a section of trophectoderm. Successful blastulation 
prepares an embryo to hatch from the zona pellucida and undergo 
implantation.
In vitro culturing of preimplantation embryos first became possible after work 
in the 1950s (Whitten 1956) showed that specific buffer conditions were 
required to support growth. Further advances in culture conditions now mean 
that it is possible to culture embryos from 1 cell through to hatched blastocysts 
ready to implant. In vitro culture does have an effect on embryos and can 
cause changes in global gene expression (Khosla, Dean et al. 2001) that differ 
from in vivo development. This would be expected, as it is not yet possible to 
fully recreate the conditions of the uterus in culture.
One of the aspects that must be borne in mind when investigating 
preimplantation development is the specialised genetic nature of gametes. 
Containing only one copy of the S100A8 gene at fertilisation, sperm and 
oocytes are essentially all either S100A8 wildtype or S100A8 null. This is an 
important point as one possible cause of preimplantation lethality is a non- 
redundant S100A8 gamete function. In maintaining our breeding line of 
S 1 0 0 A8 heterozygous mice, we have backcrossed S 1 0 0 A8 heterozygous mice 
with wildtype mice. Any S100A8 heterozygous offspring from backcrossing 
must have resulted from fusion of a wildtype gamete with an S1 0 0 A8  null 
gamete. As we have used both male and female S100A8 heterozygous mice in 
backcrossing, it appears that S1 0 0A8  null sperm and oocytes are viable when 
paired with a wildtype gamete. It is evident that the combination of two 
S100A8 null gametes is necessary to cause lethality. Another aspect, which 
may influence the S100A8 null phenotype is the timing of the maternal 
zygotic transition, which in mice occurs at the 2-cell stage. This transition 
marks the first expression of the combined zygotic genome and the 
degradation of maternal oocyte transcripts and most maternal proteins. Prior to 
this stage all protein and transcripts are oocyte derived. The combination
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of two S100A8 null gametes has proven necessary for S100A8 lethality and 
this would be expected to first occur at the 2-cell stage of development. While 
we acknowledge this information, it was also important not to prejudice our 
studies of the S100A8 null lethality as unexpected results could require 
flexible analysis.
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5.2 Results
5.2.1 S100A8 protein is not expressed in testes.
Expression of S100A8 has not been previously studied in gamete 
differentiation processes. It is possible to state that logically there should not 
be a problem in gamete production or function as outlined in 5.1. In order to 
further eliminate the possibility of a role for S100A8 in gamete cells it was 
decided to probe testes for S100A8 protein expression by 
immunohistochemistry. Testes were chosen as they present the full stages of 
differentiation in spermatogenesis and it was possible to examine every step 
with one experiment. The results are shown in fig 5.1.
S100A8 and S100A9 protein expression was probed on testes in formalin 
fixed slides using mAbs 6A4 and 2B10 respectively. Relevant isotype control 
mAbs were used as controls for these antibodies. Protein staining of S100A8 
and S100A9 is confirmed in the positive control tissue, spleen, where myeloid 
cells are present and positive for both SlOO proteins. No expression of 
S100A8 or S100A9 was seen in any stage of spermatogenesis in testes. The 
data presented showed no reason to find fault with the logic that S 1 0 0 A8 null 
gametes are functional to the point of sperm differentiation in testes.
5.2.2 S100A8 null lethality occurs prior to E 2.5 of 
development.
It was shown in fig 3.2 that there is an approximate 80% loss of S100A8 null 
blastocysts at E 4.5 from S100A8 heterozygous crosses. This indicated an 
S100A8 null phenotype early in preimplantation development. To determine 
exactly when S1 0 0 A8  null lethality occurs it was decided to examine embryos 
as early as our 2-step PCR technique would allow. To this end embryos at E 
3.5 and E 2.5 were generated from S100A8 heterozygous crosses. By
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Fig 5.1 S100A8 staining in testes shown by immunohisto­
chemistry. Immunostaining in control spleen tissue sections
(1.2) and testes (3,4). Slides show 5100A8 with mAb 6A4 staining
(1.3) and control mAb staining (2,4). Scale bar = 20pm.
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examining the genotypes of the embryos, it can be determined whether earlier 
stages of embryo show loss of S100A8 null mice or whether null embryos can 
be seen in expected Mendelian ratios. To determine the stage of S100A8 null 
lethality it would be expected to see normal SI00A8 null embryos present at 
one stage of development and absent from later stages. It has been determined 
that some S100A8 null embryos do survive to form blastocysts at E 4.5. It was 
also seen in C57BL/6J and CD-I strain mice that there was a higher than 
expected number of heterozygous blastocysts and so it is of interest if this is 
also seen at earlier stages. The results are shown in fig 5.2.
S100A8 heterozygous crosses produced embryos at E 3.5 and E 2.5. These 
embryos were digested and analysed by 2-step PCR using appropriate primers. 
Embryos at both E 3.5 and E 2.5 showed reduced levels of S100A8 null 
embryos similar to the result at E 4.5. The resultant ratio of wildtype, 
heterozygous and null embryos was not the expected 1:2:1 Mendelian ratio but 
in whole numbers 1:3:0. Again we saw an increase in the numbers of 
heterozygous embryos and a significant loss of null embryos. Looking at all 
stages of embryo development analysed, there was an average approximate 
80% loss of S100A8 null embryos. This pattern was consistent across 3 days 
of preimplantation development.
5.2.3 Genotyping of S100A8 heterozygous crosses at E 1.5 is 
inconsistent.
Having determined that the SI00AS lethality occurs prior to E 2.5, it was 
decided to investigate embryos at E 1.5. This stage is comprised of embryos at 
mainly the 1, 2 and 4-cell stages and was believed to be the probable time of 
SI00AS null lethality. There was concern that the two-step PCR protocol may 
have difficulty at this level of genetic material, as it is effectively performing 
PCR on as little as 2-4 DNA strands. As the protocol had worked effectively at 
E 2.5, it was decided to analyse E 1.5 embryos. Lethality could be detected by 
normal levels of SI00AS null embryos at E 1.5 with known loss of SI00AS
null embryos at E 2.5. The results are shown in fig 5.3.
149
Embryos Controls
-KO band 
-WT band
B
Stage +/+ +/- -/- Total
E3.5* 9 31 1 41
E2.5* 10 30 3 43
Fig 5.2 Genotyping of preimplantation em bryos generated by SI 00A8 
heterozygous crosses. PCR of blastocysts from an SI 00A8 heterozygous 
crosses (A) with genotyping results shown in table format (B).#= Cross 
showed significant deviation from expected genotype ratios p < 0.01.
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B Embryos
WT HET Con
Controls
Fig 5.3 PCR analysis of E 1.5 embryos shows inconsistent results.
Repeated PCR of E 1,5 shows that the first reaction results of PCR (A) on 5 
selected blastocysts (1-5) differ from the repeat reaction (B). Controls are 
shown (C) to  validate reaction.
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S100A8 heterozygous crosses produced embryos at E 1.5. These embryos 
were digested and analysed by 2-step PCR using appropriate primers. The 
PCR results showed inconsistent genotyping for embryos with different 
genotypes shown for the same embryo in different reactions. This indicated 
that the two-step PCR protocol is not able to accurately read embryos at E 1.5 
and so no true insight can be gained into the genotypes produced by S1 0 0 A8 
heterozygous crosses at this stage. Alternative approaches must be found to 
discover the S100A8 null lethality.
5.2.4 In vitro culture of S100A8 heterozygous crosses shows no 
significant loss of embryos
To determine exactly when the S100A8 null embryo presents lethality has 
proved a difficult task by PCR methods. This could be due to the fact that the 
technique will rely on amplification of 1 DNA, which has been shown to be 
variable. Genotyping of S100A8 heterozygous crosses has shown that S100A8 
null lethality must occur early in development prior to E 2.5. It has been 
determined that logically it is difficult to conceive how S 1 0 0 A8 null lethality 
might present prior to expression of the zygotic genome at the 2 -cell stage 
although this has not been conclusively shown. In order to further analyse the 
phenomenon of SI00AS null lethality, it was decided to create a scenario 
where there would be no escape for potential SI00AS null embryos. The 
problem was that S1 0 0 A8  null embryos could be rapidly degraded in vivo and 
so not be obtained for genotyping in our experiments. Therefore it was 
decided to place embryos from S100A8 heterozygous crosses in in vitro 
culture at both 2-ceIl and 1 -cell stages. The main advantage of in vitro culture 
is that it was possible to visualise the embryos as they develop and examine 
whether their progress is normal. In an in vitro system any loss of S100A8 null 
embryos would be clearly seen and putative embryos would remain within the 
culture dish to be examined and counted.
The 2 and 1 -cell stages were chosen as they occur prior to and at the
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2-cell 4-cell Morula Blastocyst
B
Normal Odd 1 Odd 2
Morula
Blastocyst
Cross Embryos
total
Number
blastocysts
Number
failed
2-Cell S100A8 
heterozygous
42 37 5
wildtype 43 40 2
1-cellS100A8
heterozygous 35 30 5
wildtype 32 28 4
Fig 5.4 In vitro culture of embryos from SI 00A8 heterozygous crosses.
In vitro culture of embryos shows normal progression (A) along stages seen 
in culture (A1-4). Experiments show a population of abnormal embryos 
from S100A8 heterozygous crosses (B) with normal stage types shown in 
(81,4) and abnormal embryos shown in (B 2-3 & B 5-6). Results of embryo 
culture are shown in table form (C). Scale bar = 15 pM.
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zygotic genome activation, which occurs at the 2-cell stage. It was thought 
that activation of the zygotic genome could be a significant point to examine 
for S100A8 null lethality. The 2 and 1-cell stages were also the stages at 
which our 2-step PCR protocol could not provide accurate genotyping data. 
Assuming that the S100A8 heterozygous crosses produce Mendelian ratios of 
fertilised embryos 25% of embryos will be S100A8 null, 50% will be 
heterozygous and 25% will be wildtype. It could be expected that 25% of 
embryos may present a different phenotype perhaps indicating S100A8 null 
lethality. To provide a control for natural loss of embryos within in vitro 
culture C57BL/6J wildtype embryos were also cultured and examined in 
parallel. The results are shown in fig 5.4.
2  and 1-cell embryos from S1 0 0A8 heterozygous crosses along with embryos 
from wildtype, control crosses were placed in in vitro culture until they 
reached the blastocyst stage approximately 52 hours (2-cell) or 72 hours (1 
cell) later. Embryos were analysed at 10am and 5pm on each day of culture 
and photographs taken. Notes were taken as to the appearance and 
developmental stage of each embryo. The control wildtype group at both 2- 
cell and 1-cell showed low loss of embryos (2/43 and 4/32 respectively). All 
wildtype embryos that failed to progress to the blastocyst stage showed 
developmental arrest at the 2-cell stage. Having arrested they did not 
appreciably develop further and looked apoptotic at the end 52/72 hour stage. 
In both the 2 and 1 -cell S100A8 heterozygous cross group a similar low loss 
of embryos was seen (5/42 and 5/35 respectively). There was no significant 
numerical difference between the heterozygous and wildtype crosses at either 
the 2 or 1 -cell stage. The S100A8 heterozygous crosses showed a total of 10 
embryos from both 2 and 1-cell that did not reach the blastocyst stage. Nine of 
these embryos arrested at the 4-cell stage and gave a distinctly unusual 
appearance as shown in fig 5.4. They failed to develop past 4 cells but did 
undergo compaction to give the unusual shapes shown. All 10 embryos looked 
apoptotic by the end point of the experiment. The genotypes of these embryos 
were not known at that stage. There is certainly no evidence that 25% of 
embryos are lost when S100A8 heterozygous crosses are cultured in vitro
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from either 2  or 1-cell embryos, which was an expected result.
5.2.5 Genotyping of cultured embryos shows no S100A8 null 
embryos at blastocyst stage
While the phenotypes of the embryos did not show any indication of the 25% 
S100A8 null loss, the genotypes of the embryos were unknown and were of 
interest. The genotypes of the embryos that arrested were also of considerable 
interest if this could be determined. It was possible that having been cultured 
from early embryonic stages that S100A8 null embryos had survived to the 
blastocyst stage without significant changes in morphology. This would 
conflict with earlier genotyping data from E 4.5, 3.5 and 2.5 embryos 
collected in vivo, but was examined as a possibility. In vitro culture may have 
supported the S10 0A8 null embryos or they may not have been destroyed, as 
they surely would have been in vivo. In vitro culture might have maintained 
the S100A8 null phenotype and this possibility needed to be examined. In 
order to do this the embryos from the S1 0 0 A8 heterozygous cross in vitro 
culture experiment were genotyped along with embryos from the wildtype 
crosses in vitro culture as a control. The results are shown in fig 5.5.
Embryos from wildtype and S100A8 heterozygous crosses were cultured in
vitro as detailed in 5.2.4 before snap freezing at the end blastocyst stage.
Embryos were digested and genotyped using the 2-step PCR protocol and
appropriate primers. Genotyping showed that the wildtype crosses produced
1 0 0 % wildtype embryos at the blastocyst stage whether generated from 2  or 1-
cell stages. Wildtype embryos that showed arrest during in vitro culture were
wildtype by genotyping. SI OCAS heterozygous crosses produced no S100A8
null embryos, a lower than expected number of wildtype embryos and a
greatly increased number of heterozygous embryos. The ratio of S100A8
wildtype, heterozygous and null was approximately 1:7:0 from both 2 and 1-
cell cultures. Genotyping of S100A8 heterozygous cross embryos that stalled
in in vitro culture showed that all those embryos were heterozygous. The
results of this analysis were highly unexpected and differed sharply
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Blastocysts Controls
■a—  KO band 
WT band
B
Cross +/+ +/- -/- Embryos
total
2-cell S100A8 
heterozygous^
5 35 0 40
wildtype 15 0 0 15
1-cellS100A8
heterozygous*
4 31 0 35
wildtype 15 0 0 15
Fig 5.5 Genotyping o f in vitro cultured S100A8 heterozygous crosses.
PCR genotyping of embryos generated by C57BI/6J wildtype and S100A8 
heterozygous crosses that had been cultured in vitro to  blastocyst stage. 
Sample results are shown (A) and results are presented as a table (B).#= 
Cross showed significant deviation from expected genotype ratios p < 
0 .001.
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from experiments genotyping embryos at E 4.5» 3.5 and 2.5. The unusual 
result prompted careful analysis of the mice used in the S 1 0 0 A8  heterozygous 
cross.
5.2.6 Anomalous patterns of S100A8 heterozygous births
The genotyping results of cultured embryos from S100A8 heterozygous 
crosses shown in fig 5.5 were unexpected. The expected heterozygous 1:2:1 
ratio for Mendelian crosses was not seen. A ratio of 1:7:0 was seen with a 
hugely disproportionate number of heterozygous embryos. An analysis of the 
mice used was deemed necessary and all mice used in the experiments were 
analysed along with the genotypes of their littermates and their ancestry. It 
was discovered that some of the mice used to generate the S100A8 
heterozygous crosses shared littermates who had become mating pairs. Three 
breeding pairs showed unusual patterns of genotypes within their offspring. 
Breeding pairs to generate experimental mice consist of two S100A8 
heterozygous mice, which should have produced a 1 :2 :0  ratio of wildtype, 
heterozygous and null offspring, with null offspring not brought to term. The 
three pairs, (18, 17 and 15) all produced heterozygous offspring with a 
combined total of 60 mice bom which is significantly different from expected 
offspring genotypes as shown in fig 5.6. This result was curious, as all 
heterozygous offspring could only have come from crosses of S1 0 0A8 
wildtype with S100A8 null. As there was no evidence that S100A8 null mice 
reach term this is difficult to explain.
It was not, however, the first instance of all heterozygous offspring seen in the 
S100A8 null mouse breeding. In 2004 at the second stage of backcross, three 
heterozygous males were investigated because all of the offspring from 
crosses with wildtype C57BL/6J were heterozygous. At this point existence of 
an S100A8 null mouse was deemed to be the most obvious explanation and so 
investigation of the three males was undertaken. The males were crossed with 
SV129 wildtype mice, as it was considered possible that an SV129 
background might support an S100A8 null mouse to term. These crosses
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Pair Offspring
total
Number
Met
Number
WT
20 20 0
17^ 23 23 0
15^ 17 17 0
Control 23 15 8
B
Generation Offspring
total
Number
Met
Number
WT
3 males^ 17 17 0
3m alesxSV129^ 22 22 0
FI cross 88 63 25
Fig 5.6 Anomalous genotyping results of SI 00A8 heterozygous crosses.
S100A8 heterozygous crosses showed 3 pairs of S100A8 heterozygous mice 
gave anomalous results in the  ratio of wildtype (WT) and heterozygous 
(Met) offspring (A).This case is similar to  3 males crossed with SV129 wild­
type females (B). #= Cross showed significant deviation from expected 
genotype ratios p < 0.0001,
158
Chapter 5: Preimplantation studies of SI00A8
produced only S1 0 0A8 heterozygous mice and so it was decided to cross the 
FI generation to test whether the ability to produce all heterozygous offspring 
was inherited. Crosses of FI generation mice produced normal levels of 
S100A8 wildtype and heterozygous births with no null mice detected as 
shown in fig 5.6. It was never determined why the three male mice produced 
all heterozygous offspring and the investigation was terminated as no other 
mice displayed similar results and it was thought to be an isolated case. It is 
possible that the phenomenon of three males in 2004 and the three pairs 
investigated in 2007 may be linked. There could be no direct descent as all 
mice produced from the three males of 2004 were excluded from the breeding 
population although it is possible that the phenomenon could have been 
retained via relatives. There is no clear explanation as to why the phenomenon 
arises. Analysis showed that no other mice in the time between the two events 
have presented with a similar phenomenon. It is clearly not a directly inherited 
phenomenon and both the litter which produced the three males of 2004 and 
the litters that produced the 2007 pairs show normal levels of S100A8 
wildtype and heterozygous mice. This indicates that the phenomenon has 
arisen in otherwise normal crosses.
The important aspect is to determine whether this has affected the genotyping 
results presented in this thesis. The first retrospective analysis undertaken was 
to look at the genotyping results of the in vitro culture experiment, where the 
mice were used. It was found that littermates of the anomalous pairs were used 
in the S100A8 heterozygous crosses for the experiments in 5.2.4. The 
offspring of these mice in the genotyping experiment of 5.2.5 were 100% 
heterozygous. Removal of the offspring of these mice from the analysis 
removes the anomalous results. In the 2-cell stage SI00A8 heterozygous 
crosses 35 mice were genotyped. With the anomalous offspring included we 
see a 1:7:0 ratio of S100A8 wildtype, heterozygous and null. Removal of the 
offspring shows an approximate 1:3:0 ratio similar to that seen in previous 
experiments. Similar analysis at the 1-cell stage showed a similar result. The 
anomalous offspring have changed the result of the experiment.
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5.2.7 Confocal microscopy studies of developmental stages for 
S100A8 protein.
Given the difficulties experienced in determining the exact stage of S100A8 
null embryonic lethality, it was decided to approach the problem from a 
different perspective. In order to cause lethality in a null model a protein must 
be expressed prior to or at the stage of lethality, and so it would be expected 
that S100A8 protein would be expressed in early wildtype embryos. Probing 
of wildtype embryos at different developmental stages could reveal S 1 0 0 A8 
protein expression at a specific stage. This would allow us to predict the 
timing of the S100A8 null lethality and may even give insight to S100A8 
function if a distinct pattern of cellular localisation was seen. It was decided to 
examine SI00AS protein expression by Ab staining using confocal 
microscopy. The stages initially examined were morula and blastocyst, which 
were easily available and would provide multiple cells types to examine. The 
results are shown in fig 5.7.
Samples of embryos at morula and blastocyst stages were generated from 
C57BL/6J wildtype crosses and fixed in paraformaldehyde (PFA). Expression 
of S100A8 protein was analysed using Abs 6A4 (not shown) and calgranulin 
A. Control embryos were analysed using appropriate control Abs (control 
mAb for 6A4, goat serum for calgranulin A). No S100A8 expression was 
shown with Ab 6A4 (not shown) but Ab Calgranulin A showed a distinct 
pattern of expression at the morula and blastocyst stages. The expression 
pattern was distinctly granular in nature and at the blastocyst stage appears to 
be predominantly perinuclear.
5.2.8 Calgranulin A staining co-localises with golgi protein 
GM-130
Calgranulin A staining patterns in morula and blastocyst showed a granular 
perinuclear expression, which was observed to be similar to golgi proteins at
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S100A8
Hoechst
Merge
Fig 5.7 Confocal staining of Si 00A8 in morula and blastocyst. Immunos- 
taining of S100A8 with Ab calgranulin A (1,4), nuclear Hoechst stain (2,5) 
and merged images (3,6). Panels show morula (1,2,3) and blastocyst (4,5,6) 
stages. Scale bar = 15 pM.
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the same stages of development. This is an unusual pattern of expression for 
S100A8 protein, which has been shown to be cytoplasmic in myeloid cells and 
has not been demonstrated to be expressed in the golgi in any study to date. In 
order to determine whether the calgranulin A staining was indeed localised to 
the golgi, a double Ab stain was performed with calgranulin A and golgi 
protein GM-130. GM-130 is a member of the golgin family and known to be 
localised to golgi and for the purposes of our experiments is used as a marker 
of golgi expression. Co-localisation analysis would show whether calgranulin 
A is indeed staining in the golgi. The results are shown in 5.2.8.
Samples of embryos at all stages were generated from C57BL/6J wildtype 
crosses and fixed in PFA. Expression of S100A8 protein was analysed using 
Abs Calgranulin A and GM-130 with appropriate serum as controls. At all 
stages calgranulin A and GM-130 showed considerable but not complete co­
localisation. It is clear that there are granular areas with both calgranulin A 
and GM-130 staining (yellow). It is also clear that there are granules where 
calgranulin A alone (green) is expressed and others where GM-130 alone is 
expressed (red).
5.2.9 Ab NH9 staining in developmental stages shows different 
pattern to Ab calgranulin A staining
The unusual golgi staining pattern given by calgranulin A raised concerns
about whether this result truly reflected S100A8 protein staining in
preimplantation embryos. It has been reported that S100A8 and S100A9 are
seen in primary and secondary granules in myeloid cells (Stroncek, Shankar et
al. 2005) but this conflicted with work within our lab showing a cytoplasmic
distribution for the proteins (Edgeworth, Gorman et al. 1991). In order to
determine whether the Calgranulin A staining was accurate it was decided to
retry Ab 6 A4 (not shown) and also try Ab NH9, which successfully detects
S100A8 by western blot. If calgranulin A was truly showing S100A8 protein
expression the Abs should show agreement in their staining pattern. If
calgranulin A is giving a false stain then other Abs would give
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Fig 5.8 Calgranulin A and GM-130 staining in morula and blastocyst.
Immunostaining of S100A8 with Ab Calgranulin A (1,5), golgi protein 
GM-130 (2,6) nuclear Hoechst's stain (3,7) and m erged images (4,8) in 
morula (1-4) and blastocyst (5-8). Scale bar = 20pM.
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conflicting staining patterns. Blastocyst and morula stages were used to 
compare expression with established calgranulin A staining at these stages and 
the results shown in fig 5.9.
Samples of embryos at all stages were generated from C57BL/6J wildtype 
crosses and fixed in PFA. Expression of S100A8 protein was analysed using 
Abs 6A4 (not shown) and NH9 with nuclear staining using Hoechst stain 
(blue). Control embryos were probed using rabbit serum in place of NH9 Ab. 
Ab NH9 (green) gave a different pattern of expression to Ab calgranulin A. 
NH9 staining shows a diffuse cytoplasmic and strong nuclear staining pattern 
at the blastocyst and morula stage. In both stages the expression is enriched to 
circular structures within the nucleus, similar to nucleoli morphology.
5.2.10 Flow cytometry of wildtype and S100A9 null myeloid 
cells shows false positive staining from Ab calgranulin A
Abs calgranulin A and NH9 both gave distinct expression patterns in morula
and blastocyst for S100A8. However the patterns were mutually exclusive. It
was possible that either calgranulin A or NH9 was truly specific for S100A8,
neither Ab was specific or each Ab was recognising different form of S100A8.
Of these possibilities it was considered that the most likely explanations were
that one or neither Ab was S100A8 specific. NH9 was generated by the
Cancer Research UK antibody service raised against full-length recombinant
S100A8 protein. Calgranulin A is a commercial Ab (Santa Cruz) raised
against a C-terminal S100A8 peptide of 18 residues. It was decided to test
both Abs by an alternative technique to see whether either would falsely stain
for S100A8. There existed an elegant control model in the SI00A9 null
mouse. Myeloid cells from wildtype mice are positive for both S100A8 and
S100A9 protein, whereas myeloid cells from S100A9 null mice show no
expression of S100A8 or S100A9 protein (Hobbs, May et al. 2003). Tests of
the two myeloid cell types could show whether either calgranulin A or NH9
falsely stains the S100A9 null myeloid cells. As neutrophils have extensive
golgi and nuclei, both staining patterns could be examined. Flow
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Fig 5.9 NH9 immunostaining in morula and blastocyst. NH9 immunos­
taining (1,4) and Hoechst staining (2,5) with combined staining (3,6). Stain­
ing is shown in morula (1,2,3) and blastocyst (4,5,6). Scale bar = 20 |jM.
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Fig 5.10 Flow cytometry of wildtype and S100A9 myeloid cells. Flowcy- 
tometry in wildtype (A) and S100A9 null (B) myeloid cells. Cells were 
untreated (Al, 81), treated with S100A9 mAb 2810 (A2,82),S100A8 Abs NH9 
(A3,83) and calgranulin A (A4,84) and control IgG (A5,85).
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cytometry was chosen due to the similarity of the preparation process with 
confocal staining and the results are shown in fig 5.10.
Wildtype and S100A9 null myeloid cells were isolated from bone marrow 
taken from the appropriate mice. Flow cytometry was performed using mAb 
2B10 as a positive control for S100A9 protein expression. Abs NH9 and 
calgranulin A were used to investigate S100A8 protein expression along with 
appropriate serum controls. Ab NH9 did not show staining of S100A8 in 
either wildtype or S100A9 null cells, which has been previously shown. Ab 
calgranulin A showed clear S100A8 expression in wildtype myeloid cells. 
Calgranulin A also showed reduced S100A8 staining in S100A9 null myeloid 
cells. It has been established that no S100A8 protein is present in S100A9 null 
myeloid cells (Hobbs, May et al. 2003) so it is unclear what protein the 
calgranulin A Ab is detecting in this experiment. This was not an exact replica 
of the embryo confocal work but was the closest possible technique that was 
successful. Staining of neutrophils for confocal microscopy with Abs NH9 and 
calgranulin A was not successful (not shown).
5.2.11 NH9 staining across preimplantation development
S100A8 staining patterns in early development were re-assessed in light of the 
flow cytometry result for calgranulin A. NH9 has not shown non-specific 
staining and so was deemed the most likely Ab to correctly show SI00AS 
staining in preimplantation development. This does not mean that NH9 as 
assumed to show a true stain, but that it was more likely than calgranulin A to 
show the true staining pattern. Successful confocal staining would have 
answered this question, as would the identification of null embryos from 
S100A8 heterozygous crosses. As genotyping studies showed S100A8 
lethality to occur early in development a full range of preimplantation staining 
was undertaken to show unfertilised oocyte, 2-cell, 4-cell, morula and 
blastocyst stages as shown in fig 5.11. An analysis could show insight into the 
mechanism of S100A8 lethality.
167
S100A8 Hoechst Merge
Oocyte
2-cell
4-cell
Morula
Blastocyst
C
Fig 5.11 SI 00A8 expression throughout preimplantation developm ent.
S100A8 immunostaining in preimplantation developm ent stages. Immunos­
taining of S100A8 (1,4,7,10,13) nuclear Hoechst stain (2,5,8,11,14) and 
merged images (3,6,9,12,15). Stages shown are oocyte (1,2,3), 2-cell (4,5,6), 
4-cell (7,8,9), morula (10,11,12), blastocyst (13,14,15). Scale bar=  15pM.
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Samples of embryos at all stages were generated from C57BL/6J wildtype 
crosses and fixed in PFA. Ab NH9 was used to investigate S100A8 protein 
expression with nuclear Hoechst stain in blue. Control embryos were probed 
using rabbit serum in place of NH9 primary. NH9 staining across all stages 
showed a nuclear expression confirmed by co-localisation with Hoechst 
staining. In oocyte, 2-cell and 4-cell the staining showed circular areas of 
exclusion with no NH9 staining. These areas showed morphological similarity 
with the nucleolus at these stages. In oocyte the staining of NH9 shows one 
large nucleolus and was strongly correlated with the Hoechst staining of 
chromatin and is similar to acetylated histone H4 in chromatin (De La Puente, 
Viveiros et al. 2004; De La Puente 2006). This would indicate localisation 
with chromatin, which is shown most strongly at the oocyte stage. At the 2- 
cell and 4-cell stages multiple, circular structures consistent with nucleoli can 
be seen lacking NH9 staining. In the morula and blastocyst stages NH9 
staining was also nuclear but was concentrated within the cell nucleoli in a 
reversal of earlier exclusion of staining. In these stages some dividing cells 
can be seen and the chromatin stain of Hoechst is clearly co-localised with 
NH9 staining. It is not clear whether NH9 was staining in the cytoplasm at any 
stage. The pattern of expression with high staining at the cell membrane and a 
decreasing gradient within the cell is indicative of non-specific staining. 
Nuclear staining within embryonic stages is not commonly observed to be due 
to non-specific effects of Abs so there was a high degree of confidence that 
NH9 staining in the nucleus was specific.
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5 3  5.3 Discussion
5.3.1 Approaching the S100A8 null phenotype
Data have been presented in this chapter to support a preimplantation lethal 
phenotype for the S100A8 null mouse, occurring prior to E 2.5 and most likely 
to occur post fertilisation. It has been shown by embryo PCR that there is 
significant loss of S100A8 null embryos at E 4.5, 3.5 and 2.5 with an average 
80% reduction from expected numbers at each stage. The limit of the 2-step 
PCR reaction was reached at E 1.5 where genotyping became inconsistent. 
Examining gamete function S100A8 was not expressed in mouse testes at any 
stage of sperm differentiation as shown by immunohistochemistry. 
Experiments to determine the exact timing of S I00AS null embryonic lethality 
produced mixed results. In vitro culture of 2 and 1-cell embryos from SI00AS 
heterozygous crosses showed no significant loss of embryos although this 
result was tempered by irregularities in the genotyping of these embryos after 
culture. Genotyping discovered that an anomaly had arisen within the mouse 
line that resulted in some mice giving all heterozygous offspring from 
heterozygous crosses. Confocal staining showed a pattern of expression for Ab 
Calgranulin A, which was co-localised with golgi marker, GM-130. Ab NH9 
showed a different pattern of expression with nuclear localisation. The 
mutually exclusive patterns indicated that one Ab was falsely staining in 
preimplantation development. Flow cytometry of wildtype and S100A9 null 
myeloid cells showed cell staining with calgranulin A in S100A9 null myeloid 
cells where no S100A8 protein is present (Hobbs, May et al. 2003), whereas 
NH9 did not stain by flow cytometry. Examination of preimplantation stages 
with NH9 showed nuclear staining at all stages excluded from the nucleoli at 
oocyte, 2-cell and 4-cell, but concentrated in nucleoli at the morula and 
blastocyst stages.
5.3.2 Genotyping studies of S100A8 lethality
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In chapter 3 of this thesis, evidence was presented to show that no S100A8 
null embryos were found postimplantation. There was also a significant loss of 
S100A8 null embryos at the E 4.5 blastocyst stage with the null embryos that 
did survive to this point unable to progress through implantation. Data in this 
chapter show that S100A8 null lethality must occur prior to E 2.5 as 
genotyping at E 2.5 and E 3.5 showed the same significant loss of S100A8 
null embryos. At each stage a small number of SI00A8 null embryos survive 
consistently showing that it is possible for a minority to escape lethality. This 
evidence suggests that there is a tight window of S100A8 null lethality 
between fertilisation and the 8 -cell stage. This impression was reinforced by 
the lack of S1 0 0 A8  expression in testes and the logical knowledge that 
S1 0 0 A8 null gametes only cause lethality when they are combined to form a 
homozygous null zygote.
No conclusions can be drawn about the state of lethality from the in vitro 
culture experiment with S100A8 heterozygous crosses. The anomaly of all 
heterozygous offspring seen in litters from three heterozygous pairs is not 
easily explained. The cause, origin and mechanism of the anomalies in the 
mice used for this experiment are not known. The three males originally 
presenting the anomaly and the mice used with the in vitro culture 
experiments were not genetically connected and the phenomenon is not 
inherited by offspring- Analysis has shown that these anomalies did not affect 
other experiments and it should be noted that the phenomenon is rare within 
the mouse line occurring in three known mice and six suspected mice across 
many generations and hundreds of mice. It is not known whether the anomaly 
is related to the S100A8 gene or is a consequence of the mouse background. It 
would be desirable to repeat the in vitro culture experiment as it might still 
yield insight into early preimplantation stages although care must be taken to 
exclude anomalous mice from this experiment.
5.3.3 Confocal studies of S100A8 in preimplantation 
development
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Confocal staining with Abs calgranulin A and NH9 showed two very different 
patterns of expression in preimplantation development. Calgranulin A showed 
a granular stain, which co-localised with GM-130. It would be of interest what 
the staining pattern for calgranulin A in myeloid cells would be as this 
experiment was not successful. It has not been widely shown that S100A8 
occurs in golgi although one report does shows S100A8 and S100A9 in 
primary and secondary granules in myeloid cells (Stroncek, Shankar et al. 
2005). This report does conflict with work from our group, which 
demonstrates S100A8/A9 to be expressed in the cytoplasm and not in granules 
(Edgeworth, Gorman et al. 1991). This work is unfortunately misquoted in 
Stroncek et al 2005 to support a point in conflict with the data. NH9 showed 
nuclear staining from oocyte through to blastocyst stages. Nuclear staining has 
been documented in some cases for S100A8 and S100A9. Human S100A9 
was shown to stain in the nuclei of squamous epithelial cells in oesophagus, 
foetal scalp and psoriatic skin (Robinson and Hogg 2000). Confocal staining 
of myeloid cells also occasionally showed nuclear staining for S100A9 and 
S100A8 (E.McNeill -  unpublished data). While there is reason to doubt the 
result of calgranulin A staining in preimplantation development that does not 
mean that NH9 is true because it does not give false positive staining. It would 
be desirable to conduct western blot analysis on embryo stages to determine 
whether S100A8 can be seen at the correct Mw. NH9 immunostaining of 
SI00A8 in embryos generated from heterozygous crosses would also be 
desirable. It is hoped this would highlight S100A8 null embryos. It is known 
that small numbers of S 1 0 0A8 null embryos do survive to blastocyst stage and 
there might be more null embryos at 2-cell and 4-cell stages.
Expression of S100A8 in the oocyte would provide support for the theory that 
S 1 0 0A8 null lethality occurs around the maternal zygotic transition where any 
maternal transcripts or proteins are degraded. The logic of this is that oocytes 
retain maternal transcripts and proteins even after meiosis gives rise to a single 
S100A8 null allele oocyte. S100A8 protein could persist in null oocytes, 
which could also explain why a small number of S1 0 0A8 null embryos 
survive to blastocyst. This group may retain enough S100A8 transcript or 
protein to survive the maternal zygotic transition but do not
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progress past the blastocyst stage. The majority of S100A8 null zygotes may 
not retain enough maternal S1 0 0 A8 transcripts and protein after the maternal 
zygotic transition. This also raises the possibility that rescue of the S100A8 
null embryo is possible by providing transcript/protein at a targeted stage, 
which would be a desirable experiment to conduct. It would be expected that 
rescued embryos develop at least to the blastocyst stage although they may not 
progress past implantation. Expression of S100A8 in the oocyte would also 
make similar analysis of sperm desirable. Analysis of sperm differentiation in 
testes showed no S100A8 expression, but the protein may not express until 
sperm are motile and ready to fertilise. The theory that there was not an 
S100A8 function in gamete cells may be erroneous as it is possible that 
proteins retained from the heterozygous germ cell stage rescued gametes.
5.3.4 Conclusions and further study
The evidence presented in this chapter indicates a preimplantation lethality for 
S100A8 null embryos between fertilisation and the 8 -cell stage. A minority of 
embryos survive this event, possibly due to persistence of maternal S 1 0 0 A8 
transcripts and protein in the oocyte. Further study is required to strengthen 
this finding and further show the exact timing and cause of S100A8 null 
lethality
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CHAPTER 6
6 Discussion
6.1 S100A8 in development
In 1999 R.May in the Leukocyte Adhesion Laboratory produced an S100A8 
null mouse with the primary aim to examine the adult myeloid cell function of 
this protein. In the same year Passey et al 1999 showed that the S100A8 
mouse was embryonic lethal and proposed that this occurred at E 8.5-9.5, and 
was caused by a lack of S100A8 positive foetal cells infiltrating the maternal 
decidua from the ectoplacental cone region at E 7.5. The functions proposed 
for the infiltrating cells include either a role co-ordinating the maternal 
immune response, or prevention of oxidation. While characterising the 
S100A9 null mouse generated in our lab, J.Hobbs showed that S100A8 is 
expressed in maternal decidual tissue only, suggesting that our mouse model 
differed from the published report. M.Mathies showed that S100A8 null mice 
did not survive to E 8.5, reinforcing the differences between our results and 
the published report. The aims of this thesis were to re-evaluate the S100A8 
null mouse model to determine the true phenotype, to analyse the role of 
S100A8 in postimplantation development and to discover whether S100A8 
played a role in preimplantation development. The conclusion of this report is 
that the S100A8 null mouse is not lethal at E 8.5-9.5 in development. S100A8 
has a role in postimplantation maternal decidual biology, where mRNA is 
expressed through E 7.5 -  E 14.5, whereas protein is detectable only at E 9.5 
and E 10.5. We then find S100A8 protein but not mRNA in foetal yolk sac 
cells at E 9.5 and E 10.5 and foetal liver cells at E 11.5 and hypothesise that it 
is exported across the placenta. S100A8 is expressed throughout 
preimplantation development in cell nuclei and lack of expression causes
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null lethality between fertilisation and the 8-cell stage of development, most 
probably after the maternal zygotic genome transition.
6.2 Re-evaluation of the S100A8 null lethality
The first aim of this thesis was to evaluate the S I00AS null phenotype to 
reconcile differences between our findings (Hobbs 03 and unpublished data 
from J.Hobbs and M.Mathies) with the published report of Passey et al 1999. 
S100A8 null embryonic lethality was an unexpected result (Passey, Williams 
et al. 1999) and was not investigated further despite many unanswered 
questions. The S100A9 null mouse proved grossly normal (Hobbs, May et al. 
2003) and no other reports had shown a function or even expression for 
S100A8 prior to E 12.5. This was the first report of an SI00 family member 
causing lethality in a null model with the other mouse models showing largely 
predictable phenotypes given reports into their in vitro and in vivo functions. 
Evidence has been presented in this thesis that the S100A8 null lethal 
phenotype is not as reported but caused by early, preimplantation 
developmental events between fertilisation and the 8-cell stage.
This thesis has established lines of evidence to justify re-evaluation of the
S100A8 lethal phenotype. In agreement with Hobbs et al 2003 data were
shown for a maternal decidual expression of S100A8 mRNA, although across
a wider period of development than was previously investigated (Passey,
Williams et al. 1999; Hobbs, May et al. 2003). This maternal mRNA
expression is not universally translated to S100A8 protein showing at least
two levels of control for the gene. At E 9.5 and E 10.5 S100A8 is translated in
the maternal decidua, showing protein expression for the first time in this
tissue. No evidence of foetal expression of S100A8 was shown in this thesis to
support null lethality postimplantation. A major justification of
postimplantation lethality in the S100A8 null mouse was the presence of
S1(X)A8 mRNA expressing cells “infiltrating” the maternal decidua from the
embryo at E 7.5. In this thesis evidence has been presented that 7/4 positive
cells, most likely to be neutrophils, can surround the embryo at E 7.5.
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Neutrophils are attracted to this area to phagocytose apoptotic cells from the 
decidual reaction (Abrahamsohn and Zom 1993; Brandon 1993; McMaster, 
Dey et al. 1993). It is known that neutrophils and monocytes, which both 
express 7/4 antigen, are positive for S100A8 and S100A9 mRNA and protein. 
This provides a possible explanation for the “infiltrating” cells and is a 
difficult question to answer when justifying an S100A8 null lethal phenotype 
in postimplantation. The infiltrating trophoblast derived cell theory of S100A8 
null lethality is further undermined by the fact that the tetraploid aggregation 
experiment, which should have rescued a null embryo from trophoblast 
derived lethal defects, did not rescue the S100A8 null mouse.
Studies within the developing embryo showed that 8100AS protein is found in 
yolk sac cells at E 9.5-10.5 and foetal liver cells at E 11.5. This occurs without 
its myeloid cell partner, S100A9, and constitutes a novel expression for 
S100A8. No mRNA could be seen in these cells at any stage by any technique 
used, which makes it difficult to justify a foetal expression of S100A8. Even 
in foetal liver where S100A8 and S100A9 are expressed in myeloid lineages 
the expression pattern for S100A8 is earlier and more extensive than 
previously shown (Morris, Graham et al. 1991; Lichanska, Browne et al. 
1999) and certainly earlier than the proposed lethality in Passey et al 1999. 
With no data to support expression of S100A8 in foetal tissues prior to E 9.5 
and evidence that expression at that stage may not originate from the foetus, it 
is difficult to support a null lethality caused by lack of S100A8 expression. 
Two possibilities remain to support this theory. One is that despite extensive 
study, S100A8 mRNA was expressed in foetal tissues and not discovered. The 
second possibility is that fundamental differences exist between the mouse 
models of Passey et al 1999 and our group. However, crossing our mice onto 
the CD-I background used in Passey et al 1999 supported the results in our 
C57BL/6J mice.
6.3 Postimplantation role of S100A8
Having re-evaluated the role of S100A8 protein in postimplantation
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development, the conclusion was that the S100A8 null mouse did not present a 
postimplantation lethal phenotype. It became clear that S100A8 has a role in 
maternal decidual biology, which would not explain our null model but was of 
considerable interest. The expression of S100A8 mRNA across at least 7 days 
of murine development, with protein stably expressed at 2 days indicated at 
least two levels of control for the gene. It is possible that co-ordinated signals 
may be required for S100A8 protein expression, with signals deriving either 
from the maternal tissues, foetal tissues or a combination of both. The pattern 
of mRNA and protein expression could suggest a “trigger’’ mechanism for 
S100A8, with mRNA standing ready for rapid translation to protein upon a 
further signal. The expression of S100A8 at E 9.5 is possibly indicative of a 
development within the embryo, perhaps the onset of circulation and the 
connection of developing circulatory vessels, which would be required for 
exported S100A8 protein to reach the yolk sac. Further study would be 
required to discover the genetic regulation of S100A8 and whether distinct 
transcription factor binding sites related to pregnancy factors such as 
oestrogen, progesterone or decidualisation cytokines exist. Examining the 
signals involved in S100A8 decidual expression could prove fruitful in 
determining the role of the protein in postimplantation development.
The evidence for the model proposed in chapter 4, S100A8 protein export 
from decidual tissues to foetal yolk sac cells, is important in determining the 
function of SI00A8 in postimplantation development. It was not shown in this 
study whether S100A8 protein was present in the circulation of the foetus at E 
9.5 and E 10.5. This would be experimentally difficult but could be important 
to demonstrating S100A8 function. It is highly likely that foetal circulation is 
positive for S100A8 protein at E 10.5 and E 11.5. It was not possible to show 
whether S100A8 uptake by the yolk sac cells was deliberate or an inevitable 
consequence of S100A8 presence in the circulation. This is a critical point as 
the function of S100A8 could be performed in the circulation, in yolk sac cells 
or a combination of both. This hypothesis could be tested by analysis of the 
circulation fluid by techniques such as mass spectroscopy or 2D SDS-PAGE, 
which has yielded good results for proteins exported from cells (Katz-Jaffe, 
Schoolcraft et al. 2006; Hathout 2007). These approaches should
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also provide the Mw measurement matching S100A8 to provide surety of 
protein identity and perhaps even identify whether the protein is oxidised 
(Harrison, Raftery et al. 1999). These experiments would be technically 
difficult but could provide crucial information to support or refute the S100A8 
export model.
Possible functions for S100A8 must take into account localisation, timing and 
the export model. Maternal decidual expression of S100A8, which we propose 
is then exported across the placenta to foetal circulation and/or cells, implies 
both foetal and maternal interests are served by S100A8 protein. The possible 
role of SI00AS could be to co-ordinate functions across maternal and foetal 
tissues, to protect the foetus or to transport essential material across the 
placenta. Specific examples of possible S100A8 functions include protection 
from oxidative damage (Harrison, Raftery et al. 1999; Passey, Williams et al. 
1999), leukotriene function by transportation of arachidonic acid (Kannan 
2003) or regulation of the maternal immune system response to 
decidualisation (Brandon 1993; McMaster, Dey et al. 1993). An approach to 
examine the function of S100A8 in adult tissues would be to generate a 
conditional null mouse model. A SI00AS null mother would provide vital 
insight into the role of the protein in decidual biology. It would show whether 
SI00AS is required for placental development, healthy development of the 
foetus or immune regulation between maternal and foetal tissues.
6,4 Preimplantation role of S100A8
Having established a role for S100A8 in maternal decidual biology with
potential involvement in foetal yolk sac, the question of null lethality was
open for re-evaluation. In this thesis evidence has been presented to support a
preimplantation lethal phenotype for the S100A8 null mouse. SI00AS has a
non-redundant role between fertilisation and the S-cell stage, most likely to
occur after the maternal zygotic transition. SI00AS may have a role in oocyte
and sperm prior to fertilisation, which only causes lethality when two null
allele gametes combine to form a zygote incapable of expressing
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S100A8 protein. It may be that true, functional S100A8 homozygous null 
mice are only seen after the maternal zygotic transition. If this is the case then 
S100A8 may have a function in oocyte development and be continuously 
expressed throughout preimplantation development. It is, however of vital 
importance that NH9 staining is confirmed as representing S100A8 protein in 
the confocal studies presented. Efforts to use NH9 stained myeloid cells by 
confocal were unsuccessful but should not be abandoned. It is also important 
to assess S100A8 heterozygous crosses between fertilisation (where null 
gametes survive to) and the 8-cell stage (where genotyping shows null embryo 
loss) with NH9 immunostaining looking for null embryos. It could show 
S100A8 null embryos and/or the loss of oocyte S100A8 at the maternal 
zygotic transition.
It would also be desirable to conduct controlled silencing of the S100A8 gene 
in wildtype embryos to examine an exclusively null population in vitro. 
Experiments with RNA interference or morpholinos could show lethality 
caused by inhibition of S100A8 expression. Morpholinos are increasingly 
successful at early zygotic stages, as their stability is a significant advantage, 
although as with all RNA based knockdowns there are potential side effects 
and penetration can be variable (Heasman 2002), strict controls would be 
necessary. The results of synthetic silencing could be directly observed and 
would bypass any problem of embryo genotype, mouse background or 
difference in null models. Successful knockdown could be checked by NH9 
staining and western blot, which should be reduced if the S100A8 gene were 
silenced.
The expression pattern of NH9 suggests a nuclear expression of S100A8, 
excluded from nucleolus in oocyte, 2-and 4-cell embryos, but concentrated in 
the nucleoli at morula and blastocyst stages. The staining pattern of NH9 
suggests S100A8 could be associated with chromatin and gene regulation. It is 
not known why S100A8 would switch expression pattern at the morula and 
blastocyst stage and accumulate in the nucleoli, although this may indicate a 
change of function necessary to implantation. One issue that arises from this 
study is whether SI00A8 has multiple functions throughout development.
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One, non-redundant function is essential to explain the lethality of the S100A8 
null mouse but there may be several stages where S100A8 plays redundant or 
non-redundant roles. This could explain the differences between the report of 
Passey et al 1999 and the data presented in this thesis with the published 
model surviving early lethality. It has been shown that the few null embryos 
that survive to the blastocyst stage do not progress past implantation. It is not 
known whether this is because the embryos are fatally compromised despite 
surviving the early lethality or whether there is a second requirement for 
S100A8 to survive implantation. This could be determined by rescue of 
S100A8 null embryos with purified RNA injection at the critical early lethality 
stage for short-term rescue. Injection of an S100A8 vector, which will stably 
express mRNA throughout preimplantation development can examine more 
definitive rescue. Rescued embryos could survive past implantation or fail at 
the next S100A8 related hurdle. It would be of obvious interest whether 
rescued S100A8 null embryos could survive past the E 8.5-9.S period of 
development.
6.5 Conclusions
This thesis has advanced knowledge in the area of the S100A8 null lethal 
mouse. The field of the SlOO proteins is a difficult one to study with much in 
vitro data and results that differ sharply between groups. The in vivo models 
for both S100A8 and S100A9 are highly insightful to the field illustrating the 
limitations of in vitro data and more subtle complex roles for the proteins. 
This study has shown that the S100A8 null mouse is embryonic lethal between 
fertilisation and 8-cell, that S100A8 has an interesting and novel role in 
maternal decidual biology and that S100A8 can indeed be studied 
independently of its myeloid partner, S100A9.
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